cluster,term
-1,heart failure ( class l - lll )
-1,"duration of hypertension , n ( % )"
-1,type nmbr diabetes 一 no . ( % )
-1,tofacitinib nmbr mg bid [n = nmbr |
-1,high - density lipoprotein cholesterol mean ( mg / dl ± sd )
-1,temporary discontinuation of study drug
-1,"death , mi , idr , st , or any timi bleeding"
-1,race and ss at baseline
-1,high intensity
-1,"prior percutaneous coronary intervention , n ( % )"
-1,pre - randomization pci
-1,"p , subgroup *"
-1,hosji fcrhypoglycemia
-1,apixaban vs . placebo
-1,medication use — no . ( % )
-1,second prior mi
-1,subarachnoid hemorrhage
-1,total invasive cancer
-1,acute stent thrombosis
-1,alteplase ( n = nmbr )
-1,relative decrease > nmbr %
-1,nmbrth - nmbrth percentiles
-1,number of ( % ) females
-1,emphysema ( % )
-1,argentina
-1,ccq score § §
-1,vents / patients
-1,number of patients with
-1,concomitant mtx —
-1,europe / lsrael
-1,thromboaspiration — no . ( % )
-1,cardiac - biomarker status — no . / total no . ( % ) $
-1,receiving insulin therapy
-1,pulmonary embolism ± deep vein thrombosis
-1,"abdominal or perianal fistula at baseline , n ( % )"
-1,cyclosporine ( n = nmbr )
-1,geographic region - europe
-1,indian ( indian subcontinent )
-1,percutaneous coronary intervention
-1,antiplatelet or anticoagulant therapy
-1,"lesion length , mean ( sd ) , mm"
-1,non - q wave
-1,continued thienopyridine n = nmbr subjects
-1,weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ]
-1,"left ventricular ejection fraction , % af history"
-1,"single - vessel disease , n ( % )"
-1,geographic region — no . ( % )
-1,pad lower extremities
-1,bmi > nmbr kg / mnmbr ( % )
-1,"total gadolinium - enhancing lesion count , no . ( % )"
-1,fatigue
-1,nmbr to < nmbr kg / mnmbr
-1,st - elevation mi
-1,azathioprine ( n = nmbr )
-1,serum uric acid ( mg / dl )
-1,"baseline mean ( sd ) , % [mmol / mol]"
-1,"cv death , ml , or stroke"
-1,atenolol ( « = nmbr nmbr )
-1,previous antiarrhythmic treatment — no . ( % )
-1,"drugs used in diabetes , n ( % )"
-1,after pci
-1,secukinumab
-1,mean a ± sem ( % )
-1,ppi but no aspirin
-1,nmbr mg / kg ( n = nmbr )
-1,family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % )
-1,trend / het . test
-1,cv death + hf hospitalization
-1,"mepolizumab , nmbr mg ( n = nmbr )"
-1,medical therapy only ( n = nmbr )
-1,caucasian ethnicity
-1,crcl at baseline < nmbr ml / min
-1,"elevated hscrp > nmbr mg / l , n ( % )"
-1,"seizure types reported during baseline , n ( % ) a"
-1,"median total cholesterol , mmol / l"
-1,"mean ± sd bmi , kg / mnmbr"
-1,first mace
-1,disease duration nmbr to bnmbr years ( n = nmbr )
-1,history of amputation — no . ( % )
-1,lipid - lowering medication ( % )
-1,"previous hf hospitalization , n ( % )"
-1,"mean lipid values , mg / dl"
-1,prior years taking warfarin
-1,"bnp , median ( iqr ) , pg / ml"
-1,"hbanmbrca , % ( mmol / mol )"
-1,latin america hr ( nmbr % cl )
-1,current atrial fibrillation or flutter on ecg
-1,invasive
-1,estimated glomerular filtration
-1,pasi score ! * *
-1,"amiodarone , n ( % )"
-1,american indian or alaska
-1,pooled simvastatin factorial studies
-1,implantable cardioverter - defibrillator
-1,varespladib ( n = nmbr )
-1,acute coronary event
-1,ntpro - cnp ( ng / ml )
-1,useofmedical therapyathospitaldischarge
-1,"coenzyme qnmbr , ^g / ml #"
-1,"dyspnoea - mmrc grade , n ( % )"
-1,triglycerides — mmol / liter
-1,baseline ecrcl
-1,cardiovascular history
-1,with placebo ( n nmbr nmbr )
-1,cardiovascular medications
-1,after bronchodilation
-1,"mean nmbrmwd * , m ( sd )"
-1,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers
-1,medication taken alone or in combination
-1,etoricoxib dose
-1,"ischemic cerebrovascular disease , n ( % )"
-1,"bare metal stent , n ( % )"
-1,mean age ( years ) ( s . d . )
-1,"dasnmbr ( esr ) , mean ( sd )"
-1,"absolute , litres"
-1,wml load at follow - up mri
-1,"clopidogrel ( n = nmbr , nmbr )"
-1,ancestry ( % ) f
-1,no p - blocker intake at randomisation ( n = nmbr )
-1,"valsartan / hctz , n / n ( % )"
-1,> nmbr oral agents
-1,"total chol , mg / dl"
-1,"calcium channel blockers , n ( % )"
-1,"bsa > nmbr % , n ( % ) t"
-1,benralizumab nmbr mg qnmbrw ( n = nmbr )
-1,"blood pressure , mean ( sd ) [range] , mm hg"
-1,atenolol n = nmbr
-1,type of mi ( % )
-1,mtx + non - mtx
-1,"concomitant corticosteroid use , n ( % )"
-1,"estimated glomerular filtration rate ( mdrd ) , ml / min / nmbr . nmbrmnmbr"
-1,mild impairment ( nmbr to < nmbr )
-1,years since menopause
-1,major cvd /
-1,medical therapy ( n = nmbr )
-1,no . of tnfi among non - tnfi naive
-1,use of ace inhibitor
-1,haemorrhagic
-1,stroke ( vs tia )
-1,"detemir / insulin glargine , %"
-1,"screening prebronchodilator fevnmbr , l"
-1,stent plus placebo
-1,coronary revascularization nmbr days after randomization
-1,sacubitril / valsartan
-1,no . of prior bdmards
-1,"mean prebronchodilator fevnmbr ( sd ) , % predicted"
-1,paracetamol
-1,"aspirin / other antiplatelet agents , n ( % )"
-1,randomized to receive beta carotene
-1,"bsa , % *"
-1,erosion score
-1,"peripheral arterial disease , n ( % )"
-1,"primary end point , no . of events / total no . ( % )"
-1,lvdd ( mm )
-1,"draining cutaneous fistula at baseline , n ( % )"
-1,"tg < nmbr , hdl > nmbr ( n = nmbr )"
-1,comorbidities other than diabetes
-1,toast classification of qualifying stroke
-1,"rasagiline , nmbr mg / day"
-1,"metabolic syndromenmbr baseline lipids , mg / dl"
-1,"crude analysis , n ( % )"
-1,bypass surgery
-1,missing — number / n ( % )
-1,"cholesterol , ( . nmbr . nmbr mmol / l ) , n ( % )"
-1,right coronary
-1,health habits
-1,blood pressure
-1,"homa . % b , median ( ql , qnmbr ) , %"
-1,"severity of copd , ( gold nmbr ) , %"
-1,prior myocardial infarction
-1,both ptca and cabg
-1,major cerebrovascular
-1,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )"
-1,diastolic blood pressure ( mm hg ) medications
-1,iglar dose at randomization ( u / day )
-1,prior cv event at randomization !
-1,"mean ± sd waist circumference , cm"
-1,risk of bleeding
-1,"cv medication , % of patients"
-1,"total updrs score ( range , nmbr - nmbr ) 卞"
-1,"atrial fibrillation , duration — no . ( % )"
-1,"known duration of diabetes , yr"
-1,nmbr % < hbanmbrc < = nmbr %
-1,dactylitis count
-1,previous disease :
-1,"previous dmards use , n ( % )"
-1,gly nmbr . nmbr gg b . i . d n / n ( % )
-1,previous percutaneous coronary intervention
-1,unfractionated heparin before randomisation
-1,oad plus insulin
-1,diabetes with target organ disease *
-1,unknown type
-1,beta - blocker — no . ( % )
-1,cognitive functioning
-1,( % ) nmbr - nmbr
-1,history of hyperlipidemia ( % )
-1,"evenls per nmbr , nmbr palienl - years"
-1,fasting free fatty acids ( ^mol / liter )
-1,treatment after admission
-1,rarertd antocagibtcn before andorrtzafon
-1,"intestinal area involved , n ( % ) $"
-1,ethnicity ( % )
-1,all cardiovascular
-1,smoking in the past year
-1,"diskus only , n"
-1,"jsn score , mean nmbr sd"
-1,number omega - nmbr number placeb fatty acid
-1,high - intensity statin vs medium - or low - intensity statin at randomization
-1,score on nih stroke scale — median ( iqr )
-1,initiation of insulin
-1,nmbrnd > nmbr . nmbr / < nmbr . nmbr
-1,cad and abi < nmbr - nmbr §
-1,pioglitazone events / n ( % )
-1,"acecoumarol , no . ( % )"
-1,cigarette users
-1,gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr )
-1,bmi ( kg / mnmbr ) cardiac parameters
-1,ace inhibitor or arb at last follow - up
-1,blood urea nitrogen ( mg / dl )
-1,grip strength ( kg )
-1,current smoker — no . of patients ( % )
-1,one - third radius
-1,psychosocial risk factors
-1,bursitis
-1,non - hdl - c in nmbr classes
-1,family history ol diabetes ?
-1,age ( years ) : nmbr - < nmbr
-1,"digital clubbing , n ( % )"
-1,death or myocardial infarction
-1,"risk reduction , %"
-1,"a mini - mental state examination , omega - nmbr fatty acids vs placebo"
-1,"pain vas , nmbr - nmbr mm"
-1,smoking : ex - smoker
-1,statin treatment
-1,pre - bronchodilator fevnmbr / fvc ratio *
-1,prior stroke or transient ischemic attack
-1,czp nmbr mg ( n nmbr nmbr )
-1,microvascular eye diseased
-1,"extent of disease , %"
-1,mean ( nmbr % ci ) difference vs saxa + dapa + met
-1,urgent coronary revascularization
-1,caucasian simva
-1,full analysis set
-1,serious ae
-1,smoking history ( ever )
-1,uncodable
-1,no pah therapy
-1,standard ( n = nmbr )
-1,patent foramen ovale
-1,laboratory values
-1,"years , mean ( sd )"
-1,hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr )
-1,physician ' s judgment that vka
-1,calcium - channel blocker ( ratelowering )
-1,left ventricular hypertrophy ( % )
-1,randomized to aspirin use
-1,"antihypertensive , antianginal , and other cardiovascular medications"
-1,glp - nmbr receptor agonist ( other than study drug )
-1,primary renal endpoint or death
-1,"metabolic syndrome characteristics , n ( % )"
-1,"mean duration of disease , years"
-1,other oral hypoglycemic drug ( s )
-1,> nmbr additional cv risk factorsnmbr
-1,pancolitis
-1,death from any cause
-1,"high - density lipoprotein cholesterol , mg / l"
-1,diabetes mellitus status
-1,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % )
-1,stool frequency subscore
-1,psap - b ( ng / ml )
-1,no use of nmbr - asa compounds
-1,visit nmbr ldl cholesterol strata
-1,endothelin nmbr ( pg / ml )
-1,normal ( egfr > nmbr )
-1,py = nmbr . nmbr )
-1,fibrinogen
-1,"total haq , nmbr - nmbr"
-1,"mean baseline ibdq score ( sd ) § crp concentration , mg / l"
-1,dipyridamole
-1,aspirin and other antiplatelet
-1,positive
-1,age [years] ( interaction : p = nmbr . nmbr )
-1,decreased appetite
-1,beta - blocker ( except sotalol )
-1,geometric mean crp concentration ( mg / l )
-1,duration of morning
-1,hr ( enl vs lcz ) ( nmbr % cl )
-1,rf positive — number ( % )
-1,selected medications — no . ( % )
-1,"no peripheral revascularization ( n = nmbr , nmbr )"
-1,white / european
-1,at least nmbr flare
-1,"time to admission , min"
-1,octave sustain
-1,lm bifurcation not treated
-1,radial access
-1,history of peripheral artery disease
-1,"baseline fev , ( l )"
-1,combined trials
-1,negative
-1,severe dysfunction
-1,"fasting c - peptide , ng / ml"
-1,aggressive ( n = nmbr )
-1,"aldosterone blocker , %"
-1,management of event — no . ( % )
-1,> nmbrmg / dl chd status
-1,"serum albumin , g nmbr nmbr"
-1,intraperitoneal
-1,headache
-1,left main artery
-1,"> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a"
-1,established
-1,gender ( % ) male / female
-1,chondroitin sulfate ( n = nmbr )
-1,unstable angina ( biomarker negative )
-1,american indian or native alaskan
-1,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !
-1,age ( years ) [median ( nmbrth to nmbrth percentile ) ]
-1,formoterol nmbr gg bid
-1,race or ethnic group ( % )
-1,dihydropyridine
-1,canakinumab
-1,"lev status , n ( % )"
-1,steroids § §
-1,normal / mild ckd
-1,number of stent = nmbr
-1,"previous medications , n ( % )"
-1,nyha class nmbr - nmbr : no { n = llll )
-1,tofacitinib nmbr mg twice daily n = nmbr
-1,verapamil sr n = nmbr no . ( % )
-1,no prior ml or stroke
-1,"stent length per lesion , mm"
-1,chf history
-1,anti - ccp antibody positive
-1,oral medications
-1,no antidiabetic drug
-1,tofacitinib nmbr mg two times a day
-1,no . of nmbr - mg acetaminophen tablets / day
-1,"acpa positive , %"
-1,timi major / minor
-1,"severity of airflow limitation ( gold nmbr - nmbr ) , n ( % )"
-1,pooled simva
-1,timi risk score — no . ( % ) : t
-1,"baseline dyspnea index , mean total score"
-1,number ( % ) of patients with event
-1,atrial fibrillation onset
-1,infarct characteristics
-1,caucasian simva ( „ = nmbr }
-1,ticagrelor nmbr mg nmbr yr km %
-1,galectin - nmbr ( ng / ml )
-1,"hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index , t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients ."
-1,nmbr mg clopidogrel load
-1,intravenous dobutamine
-1,family history of diabetes — no . ( % )
-1,primary prevention subgroup
-1,"telmisartan ( n = nmbr , nmbr )"
-1,ppi use ( p = nmbr - nmbrt )
-1,large mi
-1,never / rarely
-1,medication adherence
-1,no concomitant cortcosteroid use
-1,severity of hypertensionb
-1,"clopidogrel , %"
-1,fevnmbr percent predicted ( sd )
-1,antidiabetic medication | |
-1,gad positive — no . ( % ) ^
-1,intravenous vasodilators ( % )
-1,european trial
-1,systemic corticosteroid use
-1,"weight , median ( interquartile range ) , kg"
-1,indacaterol nmbr ug versus placebo
-1,crohn ’ s disease related surgery
-1,peripheral arterial disease — no . ( % ) §
-1,"mases ( nmbr - nmbr ) , mean ( sd )"
-1,duration of coronary artery disease — yr
-1,"hbanmbrc , mean ( sd ) , % [mmol / mol]"
-1,total cholesterol ( week nmbr )
-1,at least nmbr severe flare
-1,baseline / concomitant therapies
-1,chd eze / simva ( n = nmbr]
-1,heart failure criteria met
-1,left atrial diameter
-1,"pulmonary function tests , % of predicted"
-1,other nsaids
-1,rheumatic heart disease
-1,coronary angiography and intervention
-1,time of qualifying ecg to balloon inflation ( hrs )
-1,time from symptoms to treatment
-1,ratio fp / sal : sal ( nmbr % ci )
-1,coexisting conditions — no . ( % )
-1,"clopidogrel , ticlopidine , or prasugrel"
-1,crp ( mg / dl ) < nmbr . nmbr
-1,"mean ± s . d . duration of diabetes , years"
-1,russia / georgia ( n = nmbr )
-1,fatal and nonfatal ml
-1,hypertension ( n 二 nmbr )
-1,"cv event , years"
-1,oxidative stress
-1,age ( yrs ) < nmbr
-1,no . of previous anti - tnf drugs — no . ( % )
-1,< nmbr . nmbr mmol / liter apob : apoa - l ratio
-1,"former smoker , n ( % )"
-1,less than nmbr %
-1,hispanic ( n = nmbr )
-1,ischemic tvr
-1,any albuminuria — no . ( % )
-1,"baseline ics use , n ( % )"
-1,bosentan ( n = nmbr )
-1,nitrates ( oral or topical )
-1,left - sided disease only
-1,"third heart sound , n ( % )"
-1,other antiarrhythmics^
-1,"psa duration , years"
-1,low molecular weight ( lmw ) heparin before randomisation
-1,interval study drug to pci
-1,"atrial fibrillation / atrial flutter , %"
-1,anmbr + ez n = nmbr
-1,initial aspirin — no . ( % )
-1,symbol digit score
-1,time from qualifying event to randomization
-1,"serum hdl cholesterol ( mmol / l ) , mean ( sd )"
-1,"pav , mean ( nmbr % ci )"
-1,events treatment ( nmbr )
-1,annt or bnnh ( nmbr % ci )
-1,"geographic region , %"
-1,drug - related teaesnmbr
-1,atorvastatin dose
-1,"ldl - cihdl - c , mean ( sd )"
-1,prior biologic therapy ( including anti - tnfs )
-1,left ventricular ejection fraction within previous nmbr mo |
-1,cabg or pci
-1,ace inhibitor monotherapy
-1,treated with cabg — no . / total no . ( % )
-1,psoriatic arthritis pain]
-1,erythrocyte sedimentation rate — mm / hr | |
-1,dose of aspirin
-1,p - val . ( nmbr )
-1,small - artery occlusion ( lacune )
-1,"atorvastatin , n ( % )"
-1,baseline heart rate
-1,apo b ( mg / dl ) - mean ± sd
-1,peak procedural act — sec
-1,"extended - duration enoxaparin , n / n ( % )"
-1,total stent length
-1,"triglycerides , median ( range )"
-1,efficacy
-1,non - stemi
-1,mri substudy ( n = nmbr )
-1,lv mass index ( g / mnmbr - nmbr )
-1,"all with coenzyme qnmbr ( n = nmbr , nmbr )"
-1,"serum total cholesterol , mmol / l ( sd )"
-1,visits nmbrenmbr
-1,week nmbr ( itt population )
-1,puerperium
-1,gold group d — no . ( % ) | |
-1,atv nmbr mg study protocol
-1,aml / val nmbr / nmbr mg
-1,median albumin / creatinine ratio ( g / mg )
-1,smoking ( a )
-1,tirofiban ( n = nmbr )
-1,"time from acs to randomization ( median , iqr )"
-1,smoking pack - years
-1,"serum creatinine > nmbr mmol / l , n ( % )"
-1,nonaspirin antiplatelet agent
-1,use of concomitant lipid - modifying therapy
-1,"% stenosis , as assessed by investigator"
-1,parenteral anticoagulalion before randomization
-1,lesions bnmbr / c
-1,median fasting insulin ( iqr ) — pu per milliliter
-1,death or stent thrombosis
-1,measured at home with automated device
-1,atenolol *
-1,neuropilin ( ng / ml )
-1,"individuals with diabetes , n = nmbr"
-1,basal insulin analogue : insulin
-1,"mean pulse pressure , mmhg ( s . d . ) “"
-1,oral hypoglycemic drug
-1,antihypertensive treatment
-1,patients with > nmbr exacerbations resulting in hospital admission
-1,"ranolazine ( n = nmbr , nmbr )"
-1,final timi flow grade post - ppci
-1,"duration of disease , median"
-1,ace inhibitor or arb at enrollment
-1,"psoriasis duration , yrs *"
-1,nmbr to < nmbr . nmbr %
-1,"simvastatin monotherapy ( n = nmbr , nmbr * )"
-1,timi major bleeding
-1,small - artery occlusion
-1,left ventricular hypertrophy — no . ( % )
-1,laboratory findings
-1,"crp , nmol / l , median ( range )"
-1,bivariate frailty model ( statin users vs non - users )
-1,"resection performed , %"
-1,liraglutide nmbr . nmbr mg ls means ( n )
-1,ada ifg
-1,"median change , %"
-1,sita nmbr + pio nmbr
-1,combined estimated gfr and albuminuria status
-1,neoplasia
-1,venous graft
-1,"mean age , y , median ( range )"
-1,body - mass index ( kg / mj ) previous diagnosis
-1,antihyperglycemic
-1,"duration of ra ( time from symptom onset ) , years"
-1,grouped region
-1,nitrate — no . ( % )
-1,"shs , mean nmbr sd"
-1,"oral antidiabetes monotherapya , n ( % )"
-1,"patients without ra , as , or psa ( n = nmbr , nmbr )"
-1,treatmentofpulmonary embolismpriorto randomization
-1,renin - angiotensin inhibitors
-1,"fevnmbr , litres ( post - salbutamol ) , mean ( sd )"
-1,upper respiratory tract infection nmbr ( nmbr . nmbr )
-1,"age at diagnosis , y"
-1,change in mtss ( mean )
-1,aliskiren ( n = nmbr )
-1,"number of exacerbations in last nmbr months ,"
-1,"p , all vs all"
-1,fasting plasma insulin — mu / liter
-1,baseline albumin / creatinine ratio in nmbr classes
-1,cvd risk factors ( age > nmbr )
-1,former smoker ( n = nmbr )
-1,"prior use of biologics , n ( % )"
-1,amlodipine nmbrmg / v = nmbr
-1,moderate or less airflow limitation
-1,ethnic group — no . ( % ) '
-1,any event
-1,pain in extremity
-1,"hospitalized for asthma , n ( % ) *"
-1,sex : male ( n = nmbr )
-1,apolipoprotein b^
-1,abnormal angiogram
-1,three or more drugs
-1,data missing
-1,heart failure nyha ii - iii
-1,"cerebrovascular disease , n ( % )"
-1,western europe hr ( nmbr % cl )
-1,biologic agents
-1,ls mean difference ± seb
-1,factor xa inhibitor
-1,"mean bmi , kg / mnmbr ( s . d . )"
-1,anti - ischaemia agents *
-1,exposure
-1,mycophenolate mofetil
-1,age when diabetes first diagnosed — yr
-1,randomization to placebo or telmisartan
-1,aspirin nmbr clopidogrel
-1,"chd risk equivalents , n ( % )"
-1,systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr )
-1,clinical history
-1,ezetimibe + simvastatin ( n = nmbr * )
-1,"duration of psoriasis , years"
-1,procedures for index event
-1,killip class at admission — no . / total no . ( % )
-1,other lipid parameters
-1,tc / hdl - c ratio
-1,ct or mr scan of the brain *
-1,peri - or postmenopausal
-1,indeterminate or unknown
-1,ratet ( nmbr % cl )
-1,"> nmbr % stenosis of coronary , carotid , or lower extremity arteries"
-1,"atrial fibrillation / flutter , n ( % )"
-1,hypertension — no . ( % ) hypercholesterolemia — no . ( % )
-1,pulmonary disease
-1,"region of enrollment , n ( % ) +"
-1,"baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr"
-1,"statin + ezetimibe , n ( % )"
-1,ldl - c ( calculated ) *
-1,"evaluable for acrnmbr at week nmbr , n"
-1,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr
-1,ez / simva n = nmbr n ( % )
-1,"event rates , %"
-1,"baseline nmbr - h ppg ,"
-1,nontrial ppi
-1,cardiac resynchronization therapy
-1,nyha class iii or iv ( n = nmbr )
-1,oral agents use
-1,recurrent ischemia - urgent revascularization
-1,"rheumatoid factor positive § , n ( % )"
-1,serum pnmbrnp ( ^g / liter )
-1,investigator - reported hypoglycaemia *
-1,diuretic — no . / total no . ( % )
-1,interleukin - nmbr ( ng / l )
-1,non - caucasian eze / simva ( „ = nmbr }
-1,median ( qnmbr : qnmbr ) tgs
-1,indacaterol nmbr ug versus indacaterol nmbr ug
-1,score of > nmbr . nmbr — %
-1,"weight , median ( nmbrth — nmbrth percentiles ) , kg"
-1,"nmbr - nmbr ( n = nmbr , nmbr )"
-1,anti - cholinergics ( short - acting ) a
-1,north america n z nmbr
-1,diabetes durationa < median
-1,discontinuations
-1,available baseline blood specimen n
-1,quicki
-1,ratio of women to men — %
-1,randomization to arterial sheath insertion
-1,p value versus placebo
-1,history of cardiac arrhythmia
-1,n analysed
-1,"body mass , kg"
-1,mean cdai score
-1,placebo plus aspirin
-1,ii - iv ( % )
-1,previous bowel resection performed — no . of patients ( % )
-1,"left anterior descending , n ( % )"
-1,postmenopausal hormone use
-1,femoral neck
-1,standard control ( n = nmbr ) no . of patients ( percent )
-1,other asian
-1,measurements
-1,antithrombotic / coagulant
-1,myocardial infarction within the previous nmbr yr
-1,receiving concomitant nsaids and / or cox - nmbr inhibitors
-1,"b digit symbol substitution , omega - nmbr fatty acids vs placebo"
-1,post - bronchodilator ratio of fevnmbr to fvc — %
-1,statin with niacin
-1,neither glucocorticoids nor immunosuppressive agents
-1,anti - inflammatory drugs
-1,i & ii : fevnmbr > nmbr % predicted
-1,interval clopidogrel to pci
-1,procedure
-1,electrophysiological study — no . ( % ) weight — ibj
-1,montelukast ( n = nmbr )
-1,nmbr - h pmg ( mg / dl )
-1,phenytoin
-1,enact - nmbr trial rerandomization to natalizumab ( n = nmbr )
-1,"nmbr bmi , kg / m"
-1,baseline ldl cholesterol
-1,iglar ( insulin glargine lnmbr u )
-1,llv wlalil nmbr statin
-1,"number of prior csdmards , n ( % )"
-1,efficacy and safety : net adverse clinical events *
-1,glucocorticoids and immunosuppressants
-1,heart disease risk factors
-1,statin use at baseline
-1,current smoker : ex - smoker ( % )
-1,aspirin but no ppi
-1,nsaid use — no . / total no . ( % )
-1,"dx at presentation , n ( % )"
-1,recent surgery or trauma
-1,left anterior descending
-1,"ezetimibe nmbr mg + statin ( n = nmbr , nmbr )"
-1,coumadin
-1,device group
-1,glargine
-1,"safety population , n ( % )"
-1,"pef , post - bronchodilator , % predicted normal"
-1,all randomized patients ( range )
-1,permanent
-1,tocilizumab
-1,nmbr = help needed ; still independent
-1,non - metsyn
-1,"hemoglobin , g nmbr nmbr"
-1,level of renal impairment
-1,soe or sue
-1,previous stroke ortransient ischaemic attack ( % )
-1,clopidogrel / ticlopidine
-1,selexipag
-1,mi type unknown ( % )
-1,crohn ' s disease
-1,high - sensitivity crp — mg / liter | |
-1,prior coronary revascularization
-1,severe teaes
-1,any statin + other llt
-1,arb at last follow - up
-1,ml without st - segment elevation !
-1,hydralazine
-1,multivessel pci
-1,oral anticoagulant — no . / total no . ( % )
-1,notable abnormalities
-1,contrast nephropathy risk score
-1,aspirin at last follow - up
-1,physical component
-1,indacaterol nmbr gg qd
-1,elderly ( > nmbr years )
-1,odds ratio versus placebo ( nmbr % ci )
-1,geographic region - north america
-1,all patients with fistulas ( n = nmbr )
-1,fevnmbr / fvc ( post - albuterol )
-1,prior medications
-1,location of ml
-1,use of hormone replacement therapy ( a )
-1,versus tiotropium nmbr . nmbr pg
-1,"prior coronary revascularization , n ( % )"
-1,duration of infusion — hr
-1,beta - blocker at last follow - up |
-1,rentrop score
-1,randomisation visit ( baseline )
-1,gastrointestinal area involved — no . / total no . ( % )
-1,"baseline pulmonary medication , n ( % )"
-1,"median serum periostin , ng / mla"
-1,multiple tnfi *
-1,diet + pravastatin ( n = nmbr )
-1,prior coronary artery bypass graft surgery
-1,"c - peptide , median ( ql , qnmbr ) , nmol / l"
-1,enoxaparin
-1,vorapaxar placebo nmbr - yr %
-1,missing data
-1,risk reduction ( % ; nmbr % ci )
-1,fastest third
-1,gemfibrozil
-1,chanmbrdsnmbr - vasc
-1,ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr )
-1,( nmbr % ci] nmbr
-1,triglycerides mean ( mg / dl ± sd )
-1,incidence rate
-1,"urinary albumin / creatinine ratio , median mg / g ( range )"
-1,minimum stent diameter
-1,nt - probnp pg / mla ( iqr )
-1,"body mass index ( bmi ) , kg / mnmbr"
-1,diet plus pravastatin group ( n = nmbr )
-1,duration of clopidogrel pretreatment 一 hr median
-1,family history of coronary artery disease
-1,"sex , n ( % ) male"
-1,cv risk factor - no . ( % )
-1,valvular disease ( % )
-1,"no corticosteroid + no imm , n"
-1,antimalarials only
-1,"tnl ultrapositive > nmbr . nmbr pg / l , nmbr = nmbr"
-1,"dactylitis count ( nmbr - nmbr ) , mean ( sd )"
-1,nasal polyps
-1,verapamil sr n = nmbr
-1,continued thienopyridine n ( % )
-1,disease - progression composite outcome !
-1,"egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr , n ( % )"
-1,diarrhea
-1,uric acid ( mg / dl )
-1,"pasi score , mean ± sd"
-1,theophylline compound
-1,heterogeneity / trend test
-1,disease
-1,hispanic / latin american
-1,isolated pulmonary embolism
-1,"middle tertile ( range , nmbr . nmbr - nmbr . nmbr mg / dl ; mean ± sd , nmbr . nmbr ± nmbr . nmbr mg / dl )"
-1,"total cholesterol ( mg / dl ) , mean + sd , available for nmbr patients"
-1,geometric mean of baseline
-1,"baseline fvc , l"
-1,csf nmbrs - hydroxy -
-1,mean annualized exacerbation rate
-1,placebo no . / total ( % )
-1,not reported / unknown
-1,"prior therapy with tnf antagonist , n ( % )"
-1,difference from baselinea
-1,age at randomization ( years )
-1,never used lev
-1,single vessel coronary artery disease *
-1,non - sulfonylurea secretagogues
-1,index event asymptomatic or unconfirmed
-1,baseline medical therapy
-1,prior corticosteroid failure only
-1,"one or more blood pressure medications , n ( % )"
-1,evomab ( n = nmbr )
-1,"baseline post - bronchodilator % predicted fev , < nmbr %"
-1,cardiovascular hospitalization
-1,crohn ' s disease activity index score]
-1,prior use of biologic agents
-1,relative risk reduction ( nmbr % cl )
-1,hbanmbrc distribution
-1,diuretic agent
-1,patients treated with insulin
-1,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |
-1,nmbr - aminosalicylic compounds — no . ( % )
-1,iwqol - lite physical score ( arbitrary units )
-1,bdi total score ( baseline )
-1,"estimated * creatinine clearance < nmbr mlvmin , %"
-1,"low - density lipoprotein cholesterol , %"
-1,"education , high school or higher"
-1,partial mayo clinic scored
-1,prior lipid - modifying therapy
-1,cv risk factor
-1,mets w / o tnmbrdm
-1,other countries
-1,smoking history — no . ( % )
-1,other vascular disease — no . ( % )
-1,mean — g / dl
-1,outcome
-1,"ccbs , ( % )"
-1,sfc nmbr / nmbr | ig bid n = nmbr
-1,"cangrelor , %"
-1,losartan n = nmbr
-1,laba + ics
-1,short - acting anticholinergics
-1,> nmbr vessels with > nmbr % stenosis
-1,"concomitant antihyperglycaemic drugs , n ( % )"
-1,losmapimod
-1,history of myocardial infarction ( % )
-1,nmbr - nmbr with cv disease ( n = nmbr )
-1,severely impaired
-1,estimated creatinine clearance < nmbr ml / min *
-1,"anticyclic citrullinated peptide positive^ , n ( % )"
-1,wrist fracture
-1,mtx exposure ( mg / week )
-1,"ischaemic , n ( % )"
-1,atenolol n = nmbr no . ( % )
-1,vascular disordersb
-1,"adjusted mean change from baseline ( nmbr % ci ) , % [mmol / mol]"
-1,< nmbr . nmbr mmol / liter triglyceride level
-1,previous myocardial infarction — no . ( % )
-1,"time since diagnosis of diabetesa , n ( % )"
-1,"fevnmbr / fvc , % , mean ( sd ) nmbr"
-1,> nmbr . nmbrmmol / l ( n = nmbr )
-1,"serum albumin , g / dl"
-1,"classification of af , no . ( % )"
-1,age at screening
-1,change in sbp ( nmbr months )
-1,bronchitis
-1,"left ventricular ef , mean ( sd ) , %"
-1,pdenmbr inhibitor monotherapy
-1,"ischemic heart disease , %"
-1,neither pbo + statin eze + statin
-1,impaired fasting glucose level ( n = nmbr )
-1,cancer ( n = nmbr )
-1,"selected clinical characteristics , n ( % )"
-1,lumbar spine
-1,reversibility of fevnmbr ( % )
-1,missing data — no . / total no . ( % )
-1,insulin ( pmol / l ) t vital signs
-1,glucose - lowering therapies
-1,baseline heart failure severity nyha class i
-1,selected baseline medications
-1,endovascular — no . ( % )
-1,"aspirin - erdp ( n = nmbr , nmbr )"
-1,previous treatment with tnf antagonist — no . ( % ) §
-1,zotarolimus - eluting
-1,change in nt - probnp at nmbr months ( log - transformed )
-1,low - molecular - weight
-1,"heart rate ( b . p . m . ) , mean ± sd"
-1,vorapaxar group ( n = nmbr )
-1,glucose test
-1,"number of concomitant aeds , n ( % )"
-1,mean number of exacerbations ( per patient - year [nmbr % ci] )
-1,use nmbr - asa compounds
-1,glycemic drugs
-1,balloon angioplasty — no . ( % )
-1,"prior history of cardiovascular disease , n ( % )"
-1,"accp bleeding risk at inclusion , no . ( % ) f"
-1,angina pectoris — no . ( % )
-1,history of systemic hypertension
-1,angiography — no . ( % )
-1,prasugrel
-1,cardiovascular disease
-1,prior congestive heart failure
-1,post - bronchodilator reversibility fevnmbr ( % ) mean ( sd )
-1,"diabetes therapy , n ( % )"
-1,low - dose aspirin use at baseline yes
-1,medication at enrollment — no . ( % )
-1,"age , yrs , median ( nmbrth , nmbrth )"
-1,no . of predictors of cardiovascular risk
-1,"mean ( s . d . ) free pcsknmbr , ng / ml"
-1,enrollment in lmwh
-1,coronary angiography during the index hospital stay
-1,primary pci ( n = nmbr )
-1,versus tiotropium + olodaterol nmbr . nmbr / nmbr pg
-1,long - acting or short - acting nitrates
-1,cardiovascular and respiratory
-1,hispanic ethnic group — no . ( % ) f
-1,"placebo , n ( rate )"
-1,"calcium antagonists , n ( % )"
-1,"egfr , ml / min / mnmbr"
-1,lipid lowering medication use
-1,"opg , ( ng / ml )"
-1,final timi flow
-1,"patient ' s global assessment of disease activity , mean ( sd )"
-1,with revascularisation
-1,antihypertensive medication or
-1,level nmbr immobility § | |
-1,"serum creatinine , limo nmbr nmbr"
-1,central / eastern europe / russia
-1,role physical
-1,"hbanmbrc category , n ( % )"
-1,not reported in ecrf
-1,"beta - blockers ( all ) , n ( % )"
-1,laba users
-1,creatinine clearance at admission ( ml / min )
-1,"egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )"
-1,other anticoagulant
-1,severe impairment ( < nmbr )
-1,pre - bronchodilator fevnmbr ( % predicted normal )
-1,insulin + oad
-1,clopidogrel ( n = nmbr )
-1,first - generation stentt
-1,"crp , mg / l : median ( range )"
-1,least square mean ( se )
-1,preoperative heart rate ( beats per minute )
-1,angiography during index hospitalization
-1,allhat - llt
-1,prior cardiovascular event — no . ( % ) - j -
-1,baseline killip class
-1,score on modified rankin scale — no . ( % ) §
-1,energy / fatigue
-1,atrial flutter
-1,subjects randomized
-1,active a
-1,rec . ischemia leading to hasp
-1,"history of cabg surgery , n ( % )"
-1,western europe and other
-1,qualifying mi type
-1,potassium - sparing at last follow - up
-1,"congestive heart failure , n ( % )"
-1,score distribution : < nmbr
-1,candesartan nmbr / nmbr
-1,planned treatment strategy
-1,/ ’ - valuenmbr ’
-1,parental history of myocardial infarction before nmbr yr of age ( % )
-1,"hbanmbrc distribution at baseline , n ( % )"
-1,change in haq - di ( mean ) t
-1,normoalbuminuria at baseline ( nmbr % of patients treated )
-1,previous deep - vein thrombosis or pulmonary embolism
-1,placebo mean ( n )
-1,previous coronary revascularization — no . ( % )
-1,medical history and risk factors — no . ( % )
-1,rankin grade
-1,previous heart failure
-1,ptca or pci
-1,inflammatory disease
-1,exacerbations
-1,statin ( open )
-1,glyburide ( n = nmbr )
-1,history of cardiovascular disease — no . ( % ) ^ |
-1,heart failure — no . ( % )
-1,normoglycemicnmbr
-1,"fevi , % predicted , mean ( sd ) nmbr"
-1,"cardiac failure , n ( % )"
-1,previous vascular disease
-1,"ethnic origin , n ( % )"
-1,abatacept monotherapy ( n = nmbr )
-1,"calcium channel antagonists , n ( % )"
-1,high potencyc
-1,ra symptom duration — year
-1,previous myocardial infarction ( % )
-1,post - bronchodilator fvc ( l ) a
-1,moderate risk
-1,< nmbr . nmbr mm hg diastolic blood pressure
-1,nmbr mg cohort
-1,"exercise times per week , ( minimum"
-1,other ( nmbr . nmbr % ) t
-1,"medical conditions , no . ( % )"
-1,"smoking status at screening , n ( % )"
-1,low - dose rivaroxaban + aspirin ( n / n )
-1,revascularization
-1,"hoehn and yahr stage ( range , nmbr - nmbr )"
-1,blood leukocyte count ( nmbr cells per l )
-1,low risk and fewer symptoms ( group a )
-1,alt and / or ast > nmbr times uln consecutive #
-1,nmbr yr km % ( n )
-1,history of symptomatic
-1,time of symptom onset to balloon inflation ( hrs )
-1,"statin potency stratum , n ( % )"
-1,no dysglycaemia or mets
-1,"weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n"
-1,race or ethnic group
-1,moderate impairment ( nmbr to < nmbr )
-1,ascvd including tia
-1,receiving concomitant corticosteroids
-1,laba + ics ( free or fixed - dose combination )
-1,"fc - ldl - c , friedewald - calculated"
-1,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % )
-1,"receptor blockers , n ( % ) baseline lipid and apolipoprotein levels"
-1,hyperkalemia ( > nmbr . nmbr meq / l )
-1,"region of enrollment , no . ( % )"
-1,mean score on haq - di §
-1,medications at randomization
-1,"nmbr , nmbr / nmbr , nmbr ( nmbr . nmbr )"
-1,history of cardiovascular disease
-1,> nmbr yr warfarin experience
-1,intervention in complex lesions
-1,"peak creatine kinase - mb , u / l"
-1,secondary ( change in total updrs score from baseline to final visit in phase nmbr )
-1,leflunomide ( mean dose : nmbr . nmbr mg / day )
-1,"antithrombotic agents , n ( % )"
-1,leisure
-1,angiotensin receptor blocker and / or ace
-1,"type of treatment , n ( % )"
-1,pancreatic cancer
-1,mean iglar dose ± sd ( u / day )
-1,int . p *
-1,hawaiian / pacific
-1,aspirin at any dose
-1,"baseline fpg ,"
-1,crp ( mg / l ) : < nmbr
-1,large - artery atherosclerosis
-1,antihyperglycemic medication usage
-1,carotid
-1,"western european includinq australia , israel , and south africa"
-1,"low density lipoprotein cholesterol , mg / dl * *"
-1,blood eosinophil count ( nmbr cells per l )
-1,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd )
-1,placebo n = nmbr subjects
-1,treatment with candesartan
-1,hbanmbrc nmbr - < = nmbr %
-1,eze / simva nmbr / nmbr mg ( n = nmbr )
-1,pulmonary rales
-1,loop at last follow - up
-1,modified rankin scale score
-1,qualifying event — no . ( % )
-1,claudication ( fontaine class > nmbr )
-1,"steroid use at baseline , n ( % )"
-1,metabolic syndrome ( > nmbr of nmbr characteristics )
-1,killip class
-1,respiratory medication ( % )
-1,"concomitant lipid - lowering therapy , n ( % )"
-1,duration of tnmbrdm
-1,"egfr , ml min nmbr nmbr . nmbr m nmbr"
-1,smoking status ( % )
-1,bare - metal stent — no . ( % )
-1,rate / nmbr patient - years
-1,> nmbr servings / wk ( n = nmbr )
-1,key secondary end point : st
-1,no . of risk factors ( % ) | |
-1,"prior antihypertensive medication , n ( % )"
-1,mean yearly decline
-1,standard therapy
-1,"phosphorus , mmol nmbr nmbr"
-1,lipid levels — mg / dl
-1,"smoking habit , n ( % )"
-1,open triple ( n = nmbr )
-1,"no prior hf hospitalization ( n = nmbr , nmbr )"
-1,glyburide
-1,"mean ( sd ) extent of exposure , days"
-1,"triple therapy use at screening , n ( % )"
-1,europe nmbr ( n = nmbr )
-1,ankle - brachial index < nmbr . nmbr — no . ( % )
-1,number of subjects
-1,fasting insulin
-1,ace - i or arb use
-1,pfo closure group ( n = nmbr )
-1,"median ( qnmbr : qnmbr ) duration of insulin use , years"
-1,control group ( n = nmbr )
-1,normal troponin
-1,ind / glynmbr / nmbr pg o . d . n = nmbr
-1,traditional chinese medicine for respiratory disease — no . ( % )
-1,"baseline copd exacerbation history , * n ( % )"
-1,european union
-1,blood pressure - lowering treatment
-1,ezetimibe
-1,fish oil
-1,cardiovascular inclusion criteriat
-1,median duration of study - drug administration
-1,psoriasis body surface area > nmbr %
-1,exenatide
-1,cardiovascular risk factors — no . / total no . ( % )
-1,( nmbr % ci ) p value
-1,time from symptom onset to randomization
-1,percentage difference ( nmbr % cl )
-1,"fpg ( mmol / l ) , mean ( sd ) 、"
-1,apo anmbr ( g / l )
-1,fibrinolysis ( n = nmbr )
-1,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci )
-1,combined n = nmbr
-1,simplified disease activity index
-1,ratio of ldl to hdl
-1,st ( arc definite only )
-1,"duration of diabetes mellitus , y"
-1,"sex , male / female , %"
-1,"total study population ( n = nmbr , nmbr )"
-1,sita / pio nmbr / nmbr
-1,blood eosinophils count
-1,who / idf ifg
-1,cardiovascular history 一 no . ( % )
-1,ace inhibitor at last follow - up
-1,"prior cardiac surgery , n ( % )"
-1,"ischemic aetiology , n ( % )"
-1,placebo nmbr year km ( % )
-1,vorapaxar n = nmbr
-1,"postmenopausal , never or past hormone therapy use"
-1,"difference vs placebo , % [nmbr % cl] , p"
-1,urinary albumin - to - creatinine ratio^
-1,percent change
-1,standard care ( n = nmbr )
-1,"cerebrovascular disorders , n ( % )"
-1,ace inhibitor — no . ( % )
-1,location of treatment center
-1,indacaterol nmbr ug ( n = nmbr )
-1,history of peripheral arterial disease ( % )
-1,"creatinine , mean ( sd ) , mg / dl"
-1,sfnmbr - pcs
-1,randomization groups nmbr and nmbr
-1,"presence of honeycombing , nmbr n ( % )"
-1,very severe n z nmbr
-1,years since pah diagnosis
-1,partial mayo score $ | |
-1,rosuvastain + fenofibric acid nmbr = nmbr
-1,severity n ( % )
-1,history of hypercholesterolemia
-1,> nmbr years education
-1,"angiographic complications , site - reported — no . / total no . ( % )"
-1,acute coronary syndrome nmbr
-1,"asastoppedat randomization , n"
-1,"mean blood pressure , mmhg ( s . d . j"
-1,baseline lipids ; mean ± sd ( mmol / l )
-1,philippines
-1,"active cancer at randomization , n ( % )"
-1,"current ( , nmbr cigs / day )"
-1,aspirin and ppi
-1,screening % reversibility fevnmbr
-1,prior pci or cabg surgery
-1,lower - limb arterial — no . ( % )
-1,baseline disease and quality - of - life scores
-1,"index event , %"
-1,endoscopy subscore
-1,intended clopidogrel dose nmbr mg
-1,placebo + mtx
-1,celecoxib ( n = nmbr )
-1,oral hypoglycemic agent
-1,"death , mi , idr , or st"
-1,unacceptable adverse events
-1,tolal choleslerol - lo - hdl choleslerol ralio
-1,median ( days )
-1,ldl particle size ( week nmbr )
-1,gold nmbr groups
-1,parameter
-1,vascular intervention
-1,anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr )
-1,amlodipine / vaisartan ( n = nmbr )
-1,ldl cholesterol — mg / dl | |
-1,"week nmbr ( geometric mean , cv )"
-1,triglycerides ( week nmbr ) a
-1,cause of heart failure
-1,copd or asthma
-1,latin and north america
-1,comorbid diseasesa diabetesb
-1,cardiac rhythm
-1,proactive intervention ( n = nmbra )
-1,nmbr = minor symptoms ; no limitations
-1,"patients ' characteristics age ( years ) , mean + sd"
-1,"history of hypercholesterolemia , n ( % )"
-1,"acc / aha lesion class bnmbr or c , n ( % )"
-1,enact - nmbr trial
-1,fasting insulin — / tiu / ml §
-1,"biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl ) , na"
-1,"age , mean years , [sd]"
-1,lipoprotein ( a ) ( mg / dl )
-1,any pulmonary medication
-1,non - study ppi use
-1,> nmbr : obese class iii
-1,acute dvt study
-1,high subgroup
-1,"mean ( sd ) body mass index , kg / mnmbr"
-1,diuretic drugs
-1,gallbladder - related aes
-1,rivastigmine ( n = nmbr )
-1,vitamin e
-1,jvp > nmbrcm
-1,family history of venous thromboembolism ( % )
-1,post - bronchodilator fevnmbr ( % predicted * )
-1,creatinine clearance by c - g ( ml / min )
-1,associated with hiv infection
-1,muscle spasms
-1,copd severity ( gold stage )
-1,rivaroxaban nmbr mg
-1,baseline cardiac biomarkers elevated
-1,mental component score ( mcs )
-1,combined end points
-1,"death , large mi"
-1,"race , white , n ( % )"
-1,elevated tg
-1,"baseline scales , median ( range )"
-1,"formal education , years"
-1,tiotropium nmbr gg qd
-1,thrombocytopenia
-1,presence of mets
-1,treatment at randomization — no . ( % )
-1,other biologic agent
-1,hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women
-1,baseline systolic bp
-1,angina class iii or iv prior myocardial infarction
-1,mucolytic agent
-1,acenocoumaroi
-1,multiple
-1,emotional well - being
-1,nmbr ( fevnmbr < nmbr % pred )
-1,rec . ischemia due worsening angina
-1,current ( nmbr + cigs / day )
-1,prior surgery : no
-1,carotid stenosis
-1,"smoking history , pack - years , mean ( sd )"
-1,ever smoked ( current / former )
-1,"estimated gfr , ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a"
-1,"isolated systolic hypertension , n ( % ) “"
-1,feno placebo ( lsm )
-1,no . of prior tnfi
-1,non - fatal myocardial infarction
-1,"involved intestinal area , n ( % )"
-1,normal fasting glucose level ( n = nmbr )
-1,saxa + dapa + met n = nmbr
-1,joint damage outcomes ( mitt population )
-1,discontinuations teaes
-1,aldosterone inhibitor
-1,adverse outcome
-1,etoricoxib nmbr mg n = nmbr n ( % )
-1,asia - pacific hr ( nmbr % cl )
-1,left bundle - branch block
-1,any prior anti - tnf treatment failure
-1,pioglitazone pts / n ( % )
-1,central / eastern europe and russia hr ( nmbr % cl )
-1,copd - rosuvastatin ( n = nmbr )
-1,abatacept / open - label abatacept
-1,nonblack race — no . ( % ) - j -
-1,prior ischemic stroke
-1,"ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )"
-1,baseline nihss score ( % ) #
-1,free fatty acids ( mmol / l )
-1,laba or lama ’ versus ind / gly lsm difference ( nmbr % cl )
-1,change from baseline in hbanmbrc ( % )
-1,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years )
-1,angiogenin ( ng / ml )
-1,weight ; mean ± sd ( kg )
-1,"race / ethnicity , %"
-1,etanercept ( n = nmbr )
-1,serum creatinine — pmol / liter
-1,prior carotid intervention
-1,abx - facil . pci
-1,antiplatelet — no . / total no . ( % )
-1,"other lipid - modifying drug use at study entry , n ( % )"
-1,without dm ( n = nmbrinmbr * )
-1,potassium
-1,difference ( tiotropium - placebo ) ml ( nmbr % ci )
-1,any relevant infarct
-1,"baricitinib , nmbr mg daily ( n = nmbr )"
-1,ls mean % change from baseline _ se
-1,established ascvd or > nmbr cv risk factors
-1,"fasting plasma glucose , mg / dl , mean ( sd ) b"
-1,enmbr + anmbr -
-1,filtration rate nmbr - nmbr
-1,placebo secukinumab nmbr mg
-1,sf - nmbr physical component summaryjj
-1,angiographic data
-1,community hospital ( % )
-1,death or absolute fvc decrease > nmbr %
-1,indacaterol nmbr mg[n z nmbr]
-1,other statin
-1,"median ( iqr ) age , years"
-1,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §
-1,"homa_ % b tx difference vs pbo , median change from baseline ( se ) nmbr"
-1,tim nmbr nsk score
-1,indication for pci
-1,"percutaneous coronary intervention or coronary artery bypass graft surgery , n ( % )"
-1,"nmbr - aminosalicylates ’ i "" i ‘"
-1,native latin
-1,"left atrial diameter , mm ( sd )"
-1,patient history of disease
-1,copd severity : severe / very severe
-1,"mean platelet volume , fl"
-1,"in ibdq total score at week nmbr , mean [se]"
-1,baseline ezetimibe usec
-1,"ics use at screening , n ( % )"
-1,"mdi / hfa , n"
-1,moderate or severe exacerbations in the previous year ( range )
-1,mixed chronic bronchitis and emphysema
-1,"triple - vessel disease , n ( % )"
-1,"mean ( sd ) crp , mg / l *"
-1,epa / aa ratio
-1,one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr
-1,"health state index score , uk algorithm"
-1,"time from onset of pain to randomization , median ( iqr ) , h"
-1,"homajr tx difference vs pbo , median change from baseline ( se ) nmbr lipid parameters"
-1,"ticagrelor , nmbr mg ( n = nmbr )"
-1,dpp - nmbr inhibitor therapy
-1,median cardiac troponin t ( iqr ) — pg / ml
-1,> nmbr ( ml ) additional angiography
-1,sbp < nmbr mmhg and dbp < nmbr mmhg
-1,insulin and oral hypoglycemic drugs
-1,other antiplatelet
-1,use of ics
-1,"mean hscrp , mg / l ( sd )"
-1,carotid revascularization
-1,"time from onset to randomization , h , mean ± sd"
-1,beta - adrenergic blocker
-1,class l / ll heart failure
-1,rerandomization to placebo ( n = nmbr ) f
-1,triglycerides > nmbr mg / dl
-1,history of cabg surgery
-1,vomiting
-1,thoracic cage fractures
-1,baseline sgrq score
-1,usa and canada
-1,obesity ( body mass index > nmbr kg / mnmbr )
-1,clopidogrel plus aspirin ( n = nmbr )
-1,"intent of early invasive strategy , %"
-1,"mean fevnmbr , l ( sd )"
-1,heavy calcification
-1,"cardiovascular medications , %"
-1,only peripheral artery disease
-1,inhaled anticholinergic §
-1,nmbr - h plasma glucose during ogtt ( mmol / l )
-1,"uacra , mg / g , n ( % )"
-1,western europe and israel
-1,sglt - nmbr inhibitors^
-1,myocardial infarction — no . ( % )
-1,united states
-1,"number of antidiabetes drugs at screening , n ( % )"
-1,"any type , according to daily dose * *"
-1,glucocorticoids plus immunosuppressive agents
-1,"left anterior descending artery , n ( % )"
-1,"albuterol reversibility , %"
-1,rivaroxaban + aspirin
-1,anyantianginal agent
-1,patients with diabetic nephropathy
-1,"hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se )"
-1,health - related quality of life
-1,"risk factors , %"
-1,"concomitant therapy , no . ( % )"
-1,"any cardiovascular disease history , n ( % )"
-1,"cardiac history , %"
-1,subgroup by treatment interaction p - value
-1,anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr )
-1,"dpi ( other than diskus ) , n"
-1,"previous copd treatment , n ( % ) *"
-1,body mass index ( kg / mnmbr ) - mean ± sd
-1,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f
-1,"psoriasis duration , mean ± sd , years"
-1,"fevi , l *"
-1,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening
-1,black race
-1,"lp ( a ) , mean ( sd )"
-1,previous transient ischaemic attack / ischaemic stroke previous warfarin use
-1,calculated ldl - c in nmbr classes
-1,rosiglitazone
-1,without revascularsation
-1,odds ratio
-1,"body mass index , kg / mnmbr , median ( qnmbr , qnmbr )"
-1,exenatide n = nmbr
-1,total score on the sgrq - c ; i ;
-1,elevated creatinine ( > nmbr pmol / l )
-1,valsartan / hctz
-1,baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l
-1,"history of currently treated hypertension , n ( % )"
-1,"tg , mmol / l [mg / dl]"
-1,terminal ileum
-1,dasnmbr - esr lda
-1,"prior tnfi , n ( % )"
-1,liraglutide nmbr . nmbr mg / day ( n = nmbr )
-1,established ascvd
-1,depressed and low perceived social support
-1,limb ( sd )
-1,emergent / urgent surgery
-1,laboratory measurements
-1,simva n = nmbr n ( % )
-1,"czp nmbr mg , % ( n / n )"
-1,fibrinogen ( pmol / l ) c
-1,frailty status
-1,basal insulin dose at run - in ( u / day )
-1,worsening angina
-1,use of parenteral antithrombotic
-1,cvd or mi
-1,screening bmi ( kg / mnmbr )
-1,"atherosclerosis^ , n ( % )"
-1,none ( cdmard - naive or past use at baseline )
-1,tender joint count ( nmbr - nmbr )
-1,"hbanmbrc , % , n ( % ) b"
-1,ldl - c < nmbr . nmbr mmol / l
-1,duration of last qualifying episode of atrial fibrillation > nmbr days
-1,"saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )"
-1,years [range]
-1,potassium - sparing at enrollment
-1,"body mass index > nmbr kg / mnmbr , n ( % )"
-1,modmy al randcnxzaton
-1,additional investigations
-1,peri - op amiodarone : no ( n = nmbr )
-1,"ejection fraction , % nyha class , n ( % )"
-1,class i or iii aad use in nmbr months before enrollment
-1,intravenous anticoagulant during hospitalization
-1,"high density lipoprotein cholesterol , mg / dl^"
-1,functional assessment of chronic illness
-1,hormonal status
-1,"postmenopausal , current hormone"
-1,spironolactone ( n = nmbr )
-1,any disease
-1,endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors
-1,bolus administered — no . ( % )
-1,"tofacitinib , nmbr mg ( n = nmbr )"
-1,medical history — no . / total no . ( % )
-1,tobacco use ( % )
-1,infliximab - naive ( n = nmbr )
-1,week nmbr mean 士 sd
-1,hr ( nmbr % ci ) p value for interaction *
-1,history of congestive heart failure
-1,"events , no ."
-1,event / total
-1,serum cholesterol — mmol / liter
-1,pooled empagliflozin ( n = nmbr )
-1,statin monotherapy
-1,"total comparators , patients with events / total patients"
-1,( % ) control ( nmbr )
-1,hypertension : no ( n = nmbr )
-1,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker
-1,bdmard - ir
-1,estimated glomerular filtration rate
-1,periprocedural medications — no . / total no . ( % )
-1,"proportion of predicted normal fevnmbr value ; , §"
-1,mellitus
-1,amiodarone
-1,permanently stopped study drug because of adverse events
-1,median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol
-1,apolipoproiein anmbr ( tng / nmbr )
-1,"metformin dose , mg"
-1,placebo no . of events / total no . ( % )
-1,hbanmbrc nmbr % - < nmbr % ( n - nmbr )
-1,hypoglycaemic agents
-1,apremilast nmbr mg bid n = nmbr
-1,"duration , mean ( sd ) , years"
-1,patient global assessment of disease activity ( vas nmbr - nmbr mm )
-1,intermittent claudication
-1,myocardial ischaemia
-1,arb at enrollment
-1,rosuvastatin of patients ( rate )
-1,recent cardioversion ( within nmbr days before randomization ) —
-1,denosumab ( n = nmbr )
-1,genotyping
-1,"remission , n ( % )"
-1,radius fracture
-1,clopidogrel dose on / before pci
-1,enoxaparin / vka
-1,sf - nmbr score
-1,seropositivity
-1,interval pain onset to admission
-1,metrex modified intention - to - treat population with an eosinophilic phenotypey
-1,number of previous anti - tnf treatments for psoriatic arthritis
-1,"serum creatinine , mean ( sd ) , pmol / l"
-1,coronary heart disease ( % )
-1,bmi ( kg / mnmbr ) < nmbr
-1,abdominal aortic — no . ( % )
-1,"mean weight , kg ( sd )"
-1,severe hyperkalemiac
-1,"history of bone disease ( predefined ) , n ( % )"
-1,abrupt vessel closure
-1,/ j - valuc ! l
-1,> nmbr days warfarin
-1,"non - hdl - c ( mmol / l , mean )"
-1,"yes , non - insulin - treated"
-1,nmbr - nmbr . nmbr kg / mnmbr
-1,baseline lp ( a ) in nmbr classes
-1,primary + gusto moderate or severe bleeding
-1,dyspepsia
-1,south asian
-1,claudication
-1,anticoagulant therapy
-1,"dactylitis , n ( % )"
-1,prior immunnosupressive failure but no anti - tnf failure
-1,"sf - nmbrvnmbr domain scores , mean [sd]"
-1,"reversibility ( bnmbr - agonist ) , % , mean ( sd ) nmbr"
-1,icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl )
-1,"fev , at baseline"
-1,"low - density lipoprotein cholesterol , mg / dl"
-1,qualifying type of atherosclerosis — no . ( % )
-1,white : black : other
-1,placebo estimated mean
-1,salmeterol - fluticasone group
-1,impaired glucose tolerance or impaired fasting glucose — no . ( % )
-1,duration of tnmbrdm ( % )
-1,"therapy ( asa nmbr , nmbr / placebo nmbr )"
-1,antihyperglycemic oral agent therapy
-1,"gender , % of patients"
-1,planned thienopyridine at baseline
-1,medical history
-1,medium - or low - intensity statin
-1,current / past
-1,rosuvastatin n = nmbr
-1,pulse rate ( bpm )
-1,anti - cholinergics ( long - acting )
-1,primary + gusto severe bleeding
-1,"mean age , years ( nmbr % ci )"
-1,vertebrobasilar infarct
-1,alathosterol ( % )
-1,"blood oxygenation , mean ± sd"
-1,"rf positive , %"
-1,sf - nmbr ( health transition score )
-1,time since diagnosis of osteoarthritis — yr
-1,no . of days to homa - ir testing — median ( iqr )
-1,certolizumab group ( n = nmbr )
-1,nmbr - nmbr / week
-1,pnmbrynmbr inhibitor
-1,previous cardiovascular disease !
-1,acute and delayed reaction
-1,atenolol strategy
-1,nationality
-1,bl updrs : high
-1,"history of paroxysmal atrial fibrillation , n ( % )"
-1,biomarker status
-1,nicotine pack - years
-1,congestive heart failure — no . ( % ) | |
-1,fibrin - specific
-1,≥ nmbr . nmbr to < nmbr . nmbr years
-1,duration of hypertension ( years )
-1,therapy ( asa nmbr / placebo nmbr )
-1,nmbr prolonged antithrombotic pretreatment ( n = nmbr )
-1,isolated igt
-1,pasi < nmbr *
-1,nmbr locf )
-1,uacr ( mgg - nmbr )
-1,vorapaxar placebo nmbr - yr . km % rate
-1,"change from baseline , adjusted mean ( nmbr % ci ) , %"
-1,paclitaxel - eluting
-1,distal anastomosis ( % )
-1,< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % )
-1,"atrial fibrillation , n ( % )"
-1,"uacr , mg / mmol ( interquartile range ) b"
-1,"fasting glucose , mmol / l , mean ± sd"
-1,coronary artery bypass surgery
-1,prior cardiovascular event — no . ( % )
-1,"concomitant atorvastatin dose , mg"
-1,n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo )
-1,etanercept
-1,"aortic stenosis , n ( % )"
-1,pretreatment / concomitant treatment
-1,circumflex
-1,"diuretic drugs , n ( % )"
-1,baseline median ( iq range )
-1,serum sodium — meq / liter
-1,pacific islander
-1,hbalc > = nmbr % ( n - nmbr )
-1,hbanmbrc ( % ) all countries
-1,prior diabetes
-1,number of events / patients
-1,coronary heart disease
-1,mean sgrq total score ( sd )
-1,managed medically — no . / total no . ( % )
-1,postoperative glucocorticoid use
-1,losartan + placebo
-1,geographical region ( % )
-1,"serum haemoglobin anmbrc concentration ( % ) , mean ( sd )"
-1,creatinine ≥ nmbr . nmbr mg / dl
-1,"previous balloon angioplasty , n ( % )"
-1,thrombolytic treatment before randomization
-1,apixaban
-1,urgent cor revasc
-1,diabetic treatments !
-1,primary ep ( cvd / mi / ri )
-1,cv death / mi / stroke
-1,ticlopidine ( n = nmbr )
-1,"alt , ast , or both > nmbrx uln"
-1,"qualifying nstemi , n ( % )"
-1,"baseline nihss score , median ( range )"
-1,"scr , gmol / l"
-1,"baseline cardiovascular medication , c n ( % )"
-1,thienopyridine drug at start of open - label period
-1,egfr ( mumin / nmbr . nmbr mnmbr )
-1,"median ( sd ) , mg / mmol"
-1,"double - vessel disease , n ( % )"
-1,lipid profile
-1,chronic obstructive pulmonary disease
-1,"treatment difference , ml"
-1,"homa - ir , median ( qnmbr , qnmbr )"
-1,nmbr placebo n = nmbr
-1,"concomitant mtx use , n ( % )"
-1,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr )
-1,dmard | |
-1,calculated ldl cholesterol ( week nmbr )
-1,median ( qnmbr : qnmbr ) total daily insulin dosenmbr
-1,hematologic
-1,physician global assessment ( nmbr - nmbr mm vas )
-1,ipf - related
-1,history of major bleeding
-1,"fpg , mean ( sd ) , mmol / l"
-1,ldl - c ( bq ) ( mg / dl ) - mean ± sd
-1,body - mass index ; ! ; waist - to - hip ratio
-1,"hba , % nmbrc"
-1,"current tobacco abuse , n ( % )"
-1,hormone therapy
-1,total group ( n = nmbr )
-1,smoking pack year ( years ) fl
-1,"( nmbr % ell ' ll , * non - hdl - c"
-1,"terol ; hdl - c , high - density lipoprotein cholesterol ;"
-1,"age at first seizure , years , mean ( sd )"
-1,glomerular
-1,"median blood eosinophil count , cells per pla"
-1,cv death or first hhf
-1,balloon angioplasty plus abciximab
-1,"lipoprotein ( a ) , median ( ql , qnmbr ) , nmol / l"
-1,osteoporosis
-1,acute rheumatic disorders
-1,intensive control
-1,"treatment duration , days"
-1,warfarin ( n = nmbr )
-1,reported hypertension *
-1,before bronchodilation
-1,ccv history / condition at baseline
-1,ivabradine ( n = nmbr )
-1,bmi ( nmbr . nmbr ; nmbr . nmbr )
-1,"physical function ( nmbr - nmbr , short form - nmbr subscale )"
-1,prior cerebrovascular disease
-1,reason for enrollment in active a — no . ( % )
-1,medical characteristics
-1,medication use at baseline — no . ( % )
-1,age < nmbr years — no . ( % )
-1,"planned valve surgery , n ( % )"
-1,"time from randomization to pci ( st - elevation mi ) , min"
-1,haq - di score ( nmbr - nmbr )
-1,mean ( sd ) dasnmbr - nmbr ( esr ) *
-1,randomised treatment
-1,"v alsartan / hctz , n ( % )"
-1,nmbr year or more
-1,"crcb - ( ml / min ) , mean ( s . e . )"
-1,three - vessel disease
-1,"st - segment depression > nmbr . nmbr mv on admission , %"
-1,"planned treatment duration , n ( % )"
-1,z\tonastaiin
-1,"inadequate response / intolerance to prior therapy , %"
-1,"change from baseline in dasnmbr - esr , meannmbr sd"
-1,cause of heart failure — no . ( % )
-1,predominant type of heparin
-1,western europe / australia / israel
-1,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria
-1,"glucose , mmol / l"
-1,aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr
-1,retinopathy — %
-1,pulmonary embolism
-1,mild or moderate copd
-1,prior ml ( before index acs )
-1,"diabetes duration ( known ) , % of patients"
-1,"creatinine clearance ， : : nmbr ml / min , %"
-1,baseline hb < nmbr g nmbr nmbr n = nmbr
-1,joint swelling
-1,nmbrmwd decrease > nmbr m
-1,profound thrombocytopenia ( < nmbrxnmbr / l )
-1,"body mass index , median , ( nmbrth — nmbrth percentiles ) , kg / mnmbr"
-1,associated with connective tissue disease
-1,postbronchodilator lung function at screening
-1,non – small - cell lung cancer
-1,prior anti - tnf therapy — no . ( % )
-1,all rosuva
-1,peripheral edema
-1,insulin - na ' ive
-1,"gender , women n , % )"
-1,mean ( sd ) swollen joint count *
-1,diuretic drugs ( excluding antialdosterone )
-1,"hfpef ( ef n nmbr ) , ( % )"
-1,"extent of disease , n ( % )"
-1,tendonitis
-1,previous hypertension
-1,oral contraceptives
-1,syncope — no . ( % )
-1,anatomic complexity characteristics
-1,conventional treatment
-1,left circumflex
-1,amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl )
-1,number of pack - years
-1,baseline cardiac biomarkers
-1,"type nmbr diabetes duration , mean ( sd ) , years"
-1,oral study drug administered — no . / total no . ( % )
-1,diltiazem or verapamil
-1,major bleeding ( statin use vs non - use )
-1,placebo secukinumab pooled
-1,bilateral disease ( % ) ' j ' ' j '
-1,pathological q waves
-1,"leukocytes , nmbr / nl"
-1,lipid - lowering agents ( % )
-1,history of second prior mi
-1,study medication — no . ( % )
-1,"laboratory data , mean ( sd )"
-1,p value ( men versus women )
-1,former n z nmbr
-1,insulin : glucose ratio
-1,tnmbrdm duration ( years )
-1,serum creatinine > nmbr pmol / l . n ( % ) |
-1,kellgren and lawrence radiographic reading grade nmbr — no . ( % )
-1,data missing or no drug given
-1,gpiib / iiia receptor inhibitor
-1,ethnic origin
-1,supine after nmbr minutes change from baseline
-1,omega - nmbr fatty acid ( n = nmbr )
-1,"pulmonary rales , n ( % )"
-1,"< nmbr months , n ( % )"
-1,"fibrinogen , g / l"
-1,right ventriculardysfunction atinclusion
-1,nace ( primary endpoint )
-1,"micro - / macro - albuminuria , ckd and / or retinopathy"
-1,interaction : treatment by psoriasis p valuenmbr
-1,"score > nmbr % , % of patients"
-1,"any aes , n ( % )"
-1,ace inhibitors or angiotensin ii
-1,des ( % previous stenting )
-1,comparison with placebo ( mean
-1,"mean ( s . d . ) hbalc , %"
-1,exercise
-1,vascular territory # nmbr
-1,native hawaiian or other pacific islander
-1,control baseline ( n - nmbr )
-1,rando . in na * *
-1,"estimated glomerular filtration rate - ml / min , median ( iqr ) '"
-1,nyha class within past month — no . / total no . ( % )
-1,aspirin group
-1,non - hdl - c ( mg / dl ) - mean ± sd
-1,fibrinolytic for qualifying event
-1,nmbr degree of ica stenosis 丰
-1,calcium - channel blockers ( % )
-1,duration of ra ( years )
-1,"min , max"
-1,"estimated gfr , < nmbr ml min - nmbr nmbr . nmbr m - nmbr , n ( % ) a"
-1,"ctn - l , ng / ml"
-1,chd + cerebral infarction
-1,fenofibric acid + moderate - dose statin
-1,highest tg tertile
-1,days of study - drug administration ( % ) * * nmbr day
-1,emotional role
-1,antithrombotic therapy
-1,periprocedural medications — no . / total no .
-1,kim nmbr ( pg / ml )
-1,mi or cad
-1,d - dimer levelsatinclusion
-1,any immunosuppressive agent
-1,"tender joint count , of nmbr"
-1,increased waist circumference
-1,cross - damp time : < l : llhrs : min ( n = nmbr )
-1,"aspirin only ( n = nmbr , nmbr )"
-1,high risk with atherosclerotic vascular disease *
-1,metrex overall modified intention - to - treat population ? :
-1,"basmi ( linear ) , mean ( sd )"
-1,cor revasc
-1,"high ( > nmbr ) ( n = nmbr , nmbr ; nmbr % )"
-1,"adl subscale ( range , nmbr - nmbr ) *"
-1,baseline statin usec
-1,unbound pcsknmbr ( nmol / l )
-1,months from mi — median ( iqr )
-1,enthesitis count
-1,enalapril
-1,history of alcohol use
-1,"initiation of dialysis , renal transplantation , or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l )"
-1,female race / ethnicity
-1,"bsa affected , mean ± sd , %"
-1,timing of clopidogrel loading dose
-1,"week nmbr fpg , mean ( s . e . )"
-1,"crohn ' s disease - related medication at baseline , n ( % )"
-1,post - menopausal ( a )
-1,saxagliptin nmbrmg ( n z nmbr )
-1,weight ( range ) ( kg )
-1,monotherapy
-1,small vessel
-1,history of microvascular disease — no . ( % )
-1,baseline sitosterol
-1,hypertension and left ventricular hypertrophy
-1,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr
-1,severe n z nmbr
-1,arthritis
-1,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff
-1,extensive
-1,baseline corticosteroids *
-1,"lv hypertrophy , n ( % )"
-1,sex ( interaction : p = nmbr . nmbr )
-1,native hawaiian / other
-1,pain ( nmbr - nmbr mm vas )
-1,randomized
-1,nmbrbaseline mean
-1,"fc - ldl - c , mg / dl"
-1,patients with previous loss of response to and intolerance of infliximab *
-1,other glp - nmbr receptor agonist
-1,"baseline hematocrit , median ( iqr )"
-1,"placebo event rate ( n = nmbr ) , %"
-1,history of amputation
-1,low - dose rivaroxaban + aspirin group
-1,documented asymptomatic cardiac ischemiac
-1,seropositive ( rf + ve and / or acpa + ve ) subgroup
-1,"| ? ) - blocker , %"
-1,metabolizer phenotype ( % ) §
-1,disease location / type : terminal ileum
-1,selexipag ( n = nmbr )
-1,clinical presentation
-1,patients not receiving corticosteroids at baseline
-1,alteplase group ( n = nmbr )
-1,"obesity , % *"
-1,cardiovascular history — no . / total no . ( % )
-1,"cardiac therapy , n ( % ) d"
-1,femoral access — no . / total no . ( % )
-1,laboratory data
-1,other drugs
-1,apob : apoa - nmbr ratio
-1,"length of stay ( randomization to discharge , h )"
-1,nmbr - aminosalicylates | | | |
-1,peripheral - artery disease ( % )
-1,"severity of the disease ( gold nmbr ) , n ( % )"
-1,"apixaban , nmbr . nmbr mg"
-1,coronary bypass graft
-1,vascular disease indicator no ( n = nmbr )
-1,laboratory values at randomization ( median and iqr )
-1,"acr , mg / mmol"
-1,tc / hdl - c
-1,"hbanmbrc at baseline , %"
-1,indication for stent
-1,history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %
-1,"months since ra was first diagnosed , mean ( sd )"
-1,hemorrhagic stroke ( n = nmbr )
-1,mini - mental state examination
-1,number of stents implanted
-1,risk score category ( points )
-1,"microvascular complications , n ( % ) ’"
-1,"erosion score , median ( min , max )"
-1,fevnmbr / fvc ( post salbutamol )
-1,type nmbr diabetes
-1,"% predicted pre - bronchodilator fevnmbr , % *"
-1,patients receiving corticosteroids at baseline
-1,odds ratio adj ( nmbr % cl )
-1,no statin vs statin alone vs any statin plus other llt
-1,general and lumbar epidural
-1,rf and acpa negativenmbr
-1,hispanic
-1,"onsetofaf , no . ( % )"
-1,percentage with disease duration < nmbr years
-1,doubling of creatinine †
-1,"diameter stenosis , mean ( sd ) , %"
-1,biologic naive
-1,"systemic corticosteroids , n ( % ) a"
-1,europe ( non - eu )
-1,fasting blood glucose ( mg / dl )
-1,"fevnmbr reversibilityz ( pre / post ipratropium ) , %"
-1,"mean eosinophil count , per ml"
-1,"men , total ( n 二 nmbr )"
-1,"rhabdomyolysis , myopathy , or myalgia with ck elevation > nmbrx uln"
-1,"rf positive , n ( % )"
-1,without insulin or insulin - modifying therapy
-1,hospitalized for heart failure during that time period
-1,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr )
-1,clinical and laboratory measurements
-1,current medication — no . ( % )
-1,infliximab nmbr mg / kg
-1,randomization - to -
-1,low hdl cholesterol
-1,history of chronic hf
-1,"race - non - white ( n = nmbr , nmbr )"
-1,moderate teaes
-1,sfc nmbr / nmbr mg twice daily ( n = nmbr )
-1,time since diagnosis of type nmbr diabetes
-1,riva roxa ban n / n { % ) nmbr ( nmbr . nmbr )
-1,disease and quality - of - life scores
-1,"laba / ics use at screening , n ( % )"
-1,mean change in radiographic end points
-1,screening % predicted fevnmbr
-1,lntensityd
-1,steroid use at baseline
-1,angina class at baseline
-1,emotional status
-1,albuminuria ( g / g )
-1,concomitant therapy
-1,thrombophilia
-1,mean — mg / dl level — no . ( % )
-1,urine albumin - to - creatinine ratio - no . ( % ) § §
-1,mean a ± sd ( mmhg )
-1,hdl cholesterol ( week nmbr ) a
-1,low - dose rivaroxaban plus aspirin ( n = nmbr )
-1,clinical criterianmbr
-1,abatacept ( n = nmbr * )
-1,ind nmbr gg q . d . n / n ( % )
-1,"lvef ( % ) , mean ± sd"
-1,menopausal status and use of hrt ( % ) y
-1,renin inhibitor ( e . g . aliskerin )
-1,urine albumin - to - creatinine ratio
-1,total n = nmbr n ( % )
-1,chronic heart failure
-1,type nmbr diabetes mellitus ’
-1,mean score on dasnmbr - nmbr ( crp ) ^
-1,orthostatic hypotension
-1,"previous oral glucose - lowering agents , % of patients"
-1,aortic stenosis
-1,no . of patients / total no . ( % )
-1,any dose reduction
-1,hazard ratio for event ( nmbr % ci )
-1,"prior implantable cardiodefibrillator , n ( % )"
-1,"crp ( mg / l ) , median ( min , max )"
-1,"gold nmbr groups , n ( % )"
-1,enalapril + aliskiren dm = nmbr non - dm = nmbr
-1,"ics , mg / day"
-1,"psoriasis covering > nmbr % bsa , n ( % ) §"
-1,"antihypertensive drug , %"
-1,"mean ( sd ) post - bronchodilator fevnmbr reversibility , %"
-1,nmbr - nmbr ( severe )
-1,"stroke or pvd , ( % )"
-1,cabg > nmbr month ago
-1,history of percutaneous coronary intervention
-1,current or previous atrial fibrillation
-1,ace - inhibitor use
-1,anemia — no . ( % ) | |
-1,low - dose corticosteroid user
-1,upper gastrointestinal
-1,"cad history and risk factors , n ( % )"
-1,"das - nmbr ( crp ) < nmbr . nmbr , n ( % )"
-1,repaired chd
-1,gusto - defined bleeding
-1,peripheral vasodilators
-1,"mean ( sd ) number of albuterol per day , puff"
-1,"liraglutide ( n = nmbr , nmbr )"
-1,angiotensin - converting enzyme or angiotensin receptor blocker
-1,perianal or anus
-1,framingham nmbr - year cv risk score
-1,native coronary - artery lesions
-1,current drinker
-1,placebo ls means ( n )
-1,"( % , nmbr % cl )"
-1,"duration of disease , years"
-1,musculoskeletal
-1,severe ( gold nmbr )
-1,moderate thrombocytopenia ( < nmbrxnmbr / l )
-1,st change > nmbr mm
-1,received an oral aha within nmbr weeks prior to screening
-1,stiffness subscale
-1,"egfr < nmbr , n ( % )"
-1,rec . ischemia requiring revasc
-1,type of concomitant statin
-1,bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ]
-1,moderate ( nmbr risk factor )
-1,timi risk score nmbr - nmbr
-1,"chronic obstructive pulmonary disease , n ( % )"
-1,glycopyrronium nmbr mg ( n = nmbr )
-1,"history of microvascular eye disease 本 , n ( % )"
-1,oral aminosalicylates
-1,bmi kg - m - nmbr
-1,"mean ± sd triglycerides , mg / dl"
-1,type of des
-1,"white , n ( % )"
-1,aspirin / antiplatelet
-1,any peripheral arterial disease
-1,ldl cholesterol mean ( mg / dl ± sd )
-1,index event — no . ( % )
-1,hospital factor # nmbr
-1,baseline tobacco use
-1,persistent anemia bsl hb < nmbrg i - nmbr ; yr nmbr < nmbrg i nmbr
-1,"previously taken tnfi , %"
-1,troponin t
-1,exacerbations in the previous year
-1,omega - nmbr fatty acid
-1,stroke risk score
-1,"daily insulin dose , mean ( sd ) , iu"
-1,former or never
-1,"type nmbr diabetes duration , years"
-1,ccv history / condition
-1,microalbuminuria or proteinuria
-1,"absolute risk difference ( ci ) , % *"
-1,elevated at wk nmbr — no . ( % ) nmbr
-1,proctosigmoiditis
-1,mean age ( years ) race
-1,cat total score
-1,nmbr no . of events
-1,intervention group ( n = nmbr )
-1,( nmbr % cl ) interaction
-1,"apoa - nmbr , g / l"
-1,"yes , insulin - treated"
-1,epa treatment ( n = nmbr )
-1,responders of three - item end point at nmbr weeks *
-1,systemic glucocorticoid use at randomisation
-1,"duration of tnmbrdm , y"
-1,ace inhibitors or angiotensin ii blockers
-1,physician ' s global assessment of dis -
-1,clopidogrel no . of patients % )
-1,duration of crohn ' s disease ( yrs )
-1,"multivessel intervention , n ( % )"
-1,tertile nmbr
-1,cabg surgery
-1,"crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l ) , n ( % )"
-1,fatal and nonfatal stroke
-1,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §
-1,"ace - i / arb , ( % )"
-1,gliclazide ( modified release ) 一 no . ( % ) ^
-1,conventional treatment ( n = nmbr )
-1,currentother ( notpredefined ) medical conditions
-1,history of coronary revascularization
-1,concomitant conventional dmard use
-1,dual antiplatelet
-1,digitalis
-1,active or previous cancer
-1,therapy at discharge
-1,north america hr ( nmbr % cl )
-1,"intermediate ( nmbr ) ( n = nmbr , nmbr ; nmbr % )"
-1,male sex — no . ( % ) race — no . ( % ) ) :
-1,"primary end point kaplan - meier rate , %"
-1,all ~ cause mort / hf hosp .
-1,haemodynamics and lv function
-1,duration of study - drug infusion
-1,salmeterol nmbr gg bid
-1,p value for adjusted hr
-1,vitamin k antagonist ( e . g . warfarin / coumarol )
-1,a / v ( n = nmbr )
-1,unknown
-1,ff / vi nmbr / nmbr pg od
-1,ivabradine group
-1,comparison with baseline ( mean
-1,irofiban
-1,laba / lama
-1,< nmbr years eze / simva
-1,placebo ( dm - vs . dm + )
-1,o total randomized
-1,cabgorptca
-1,total patients n = nmbr
-1,left circumflex artery
-1,lebrikizumab ( n = nmbr )
-1,"disease duration , median ( range ) years"
-1,bl updrs : low
-1,fevnmbr % reversibility
-1,"lipoprotein ( a ) tx difference vs pbo , ls mean % change from baseline ( se )"
-1,( $ nmbr mg / dl [nmbr . nmbr mmol / l] )
-1,very high risk
-1,"location of crohn ' s disease , %"
-1,baseline diabetes
-1,number of vessels disease
-1,patient history of disease n ( % )
-1,tocilizumab ( n = nmbr )
-1,"mean ( sd ) duration of smoking , pack years"
-1,difference ( a ) vs placebo ( nmbr % cl )
-1,nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr
-1,demographic characteristics
-1,ezetimibe use
-1,subset of patients on metformin
-1,nmbr vessels or left main
-1,congenital shunts
-1,eze / simva gender
-1,methotrexate dose at baseline
-1,"neoplasia , n ( % )"
-1,mesothelin ( ng / ml )
-1,"non - smoker ( n = nmbr , nmbr )"
-1,amlodipine / valsartan nmbr / nmbr mg / v = nmbr
-1,> nmbr . nmbr hdl cholesterol level
-1,past or current angina pectoris
-1,history of peripheral vascular disease
-1,group — no . ( % )
-1,number of treated vessels ( per patient )
-1,"ranolazine , n = inmbrinmbr"
-1,prior failure of anti - tnf therapy — no . ( % )
-1,concomitant medications for ulcerative colitis — no . ( % )
-1,lipid - lowering therapy
-1,"dlqi , nmbr - nmbr *"
-1,patients treated for > nmbr weeks ( % )
-1,immunomodulatory agents
-1,endothelin - receptor antagonists
-1,"nt - probnp , median ( iqr ) , pg / ml"
-1,hosp . for hf
-1,alcohol use ( > nmbr drink / wk )
-1,st - segment elevation mi
-1,history of dyspepsia
-1,"ncep risk category at study entry , n ( % )"
-1,treated hypertension :
-1,"presence of dactylitis , n ( % )"
-1,placebo every nmbr weeks ( n = nmbr )
-1,"heart rate , mean ± sd ( b . p . m . )"
-1,"post - bronchodilator fevnmbr , reversibility percentage of baseline value"
-1,intense physical activity
-1,concomitant drugs
-1,cholesterol absorption inhibitor ( ezetimibe )
-1,"chanmbrdsnmbr - vasc score ( median , iqr )"
-1,serum potassium — mmol / liter
-1,nadroparin vs control
-1,type of event — no . ( % )
-1,stroke or tia — no . ( % )
-1,previous major bleeding
-1,coexisting conditions
-1,characteristics of pulmonary embolism at inclusion
-1,time of symptom onset to randomization ( hrs )
-1,recurrent heart failure
-1,all completers ( n nmbr nmbr )
-1,qualifying hbanmbrc ( % )
-1,medically important infectionsa
-1,three arm
-1,after nmbr h
-1,fevnmbr % pred
-1,copd assessment test ( cat ) score
-1,aspirin use ( > nmbr mg )
-1,moderate ( gold nmbr )
-1,"no ascvd + additional cv risk factors , n ( % )"
-1,arb / ace
-1,hypertension serum lipid values
-1,measured at clinic visit with usual device
-1,average maximum cimt ( mm )
-1,"thrombophilia , no . ( % ) e"
-1,health assessment questionnaire - disability index
-1,"median ( qnmbr : qnmbr ) lp ( a ) , mg / dl"
-1,any clinical ae
-1,"mean ( sd ) feno , ppb"
-1,cdai score §
-1,unfractionated
-1,physical and cognitive examination : ! :
-1,syst . bp ( mmhg )
-1,"medications at discharge or day nmbr , if earlier ( % )"
-1,drug discontinuation not due to death
-1,congestive heart failure ( < nmbr wk )
-1,aliskiren
-1,physician global assessment of disease activity ( vas nmbr - nmbr mm )
-1,baseline dlco . mmol kpa - ’ -
-1,role emotional
-1,"baseline ( geometric mean , cv )"
-1,pah classification
-1,"days without albuterol use , * %"
-1,simva ( % )
-1,treatment with open - label perindopril
-1,new diabetes — no . ( % )
-1,adjusted change from baseline mean ( s . e . )
-1,"$ nmbrand , nmbr years"
-1,fpg ( range ) ( mmol / l )
-1,arterial graft
-1,any established coronary artery disease
-1,time to treatment ( min ) t
-1,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr )
-1,hemoglobin concentration — g / liter
-1,clopidogrel + aspirin ( n = nmbr )
-1,"previous metformin use , %"
-1,current ( % )
-1,ecg findings at baseline — no . ( % )
-1,concomitant therapies n ( % )
-1,baseline therapy
-1,hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol )
-1,history of recurrent venous thromboembolism
-1,magnetic resonance angiography
-1,free fatty acids — mmol / liter
-1,"baseline post - bronchodilator % predicted fev , > nmbr % and no concurrent tiotropium"
-1,id genotype
-1,major coronary
-1,cardiac rhythm disorders
-1,"previous ischemic stroke , n ( % )"
-1,"apolipoprotein b tx difference vs pbo , ls mean % change from baseline ( se )"
-1,"history of macroalbuminuriat , n ( % )"
-1,high ( > nmbr risk factor )
-1,psoriasis affecting > nmbr % of body - surface
-1,"asthma duration ( sd ) , years"
-1,glucose metabolism
-1,"glycated hemoglobin , median ( iqr )"
-1,"blood pressure , mean ± sd mm hg"
-1,"fpi , mean ( sd ) , pu / mlt"
-1,secondary # nmbr
-1,nmbr . nmbr - nmbr . nmbr kg / mnmbr
-1,primary pci no .
-1,rectum and sigmoid colon only
-1,radial access — no . / total no . ( % )
-1,oral blood glucose - lowering
-1,age nmbr + yrs
-1,> nmbr . nmbr pmol / liter hscrp level
-1,other ischaemic heart disease ( non - infarction )
-1,calcium supplements
-1,"a mini - mental state examination , insulin glargine vs standard care"
-1,country : argentina ( n = nmbr )
-1,estimated gfr — no . ( % ) nmbr
-1,"received > nmbr prior anti - tnf therapies , n"
-1,nmbr placebo ( n = nmbr nmbr )
-1,standard care n ( % )
-1,"interval from clopidogrel loading , h"
-1,"severity of copd * , n ( % )"
-1,acr deciles
-1,change at week nmbr
-1,"europe , israel , or australia"
-1,low density lipoprotein cholesterol - mg / dltt
-1,other dmard use
-1,duration of hypercholesterolemia ( yr )
-1,personal relationships
-1,heart failure or lvef < nmbr % associated with index acs event
-1,previous venous thromboembolism — no . ( % )
-1,prior biologic exposure
-1,need for urgent coronary - artery bypass grafting
-1,egfr ( ml / min / nmbr - nmbr mz )
-1,"egfr ( mdrd ) , ml / min / nmbr . nmbr mnmbr"
-1,"previous stroke , n ( % )"
-1,alpha nmbr blockers
-1,moderate dysfunction
-1,tnf - rnmbra ( ng / ml )
-1,jejunum
-1,neither ace - i nor arb use
-1,history of vte * *
-1,"d - dimer level , mean ( sd ) , ng / mld"
-1,gfr ( ml / min per nmbr . nmbr nr )
-1,diastolic fmmhff ' )
-1,"diabetes duration , median ( iqr ) , years"
-1,nmbr . nmbr ( nmbr nmbr . nmbr )
-1,plaque score ( nmbr - nmbr )
-1,prior disease
-1,"mean sd fpg , mg / dl"
-1,serum ctx ( ng / ml )
-1,baseline triglycerides in nmbr classes
-1,ff / vi nmbr mg / nmbr mg ( n = nmbr )
-1,"previous anti - tnf therapy , n [ % ]"
-1,dronedarone ( n = nmbr )
-1,standard ( nmbr )
-1,"age , median ( interquartile range ) , y"
-1,one or more copd exacerbations ( n / n [ % ] )
-1,peripheral embolism
-1,"arterial blood pressure , mm hg"
-1,"co - morbidities , a n ( % )"
-1,oral hypoglycemic drugs only
-1,p value ( on vs off omt )
-1,mucocutaneous
-1,any new anti - hyperglycemic rx
-1,metsyn with ldl > nmbr . nmbr mg / dl
-1,severe or worse airflow limitation
-1,periprocedural anticoagulant
-1,lsms difference ( nmbr % ci ) nmbr
-1,"age , y sex , no . ( % )"
-1,blood eosinophil
-1,pah classification — no . ( % )
-1,short - acting bnmbr - agonists
-1,"fevnmbr reversibility , pre - / post - albuterol , %"
-1,"ischemia on cecg ( n = nmbr , nmbr )"
-1,ularitide n / n ( % )
-1,three of seven risk factors
-1,moderately high risk without atherosclerotic vascular disease *
-1,randomised to canakinumab nmbr mg
-1,ff nmbr pgod
-1,"fevnmbr post - bronchodilator , % predicted normal"
-1,migraine — no . ( % ) $
-1,hypertension — no . / total no . ( % )
-1,randomized to active yitamin e
-1,low risk and more symptoms ( group b )
-1,high risk
-1,carotid artery diseaset
-1,cholesterol — mmol / liter
-1,fasting plasma glucose
-1,daily activities
-1,extended - duration enoxaparin ( n = nmbr )
-1,dasnmbr - nmbr ( esr )
-1,associated with corrected - congenital shunts
-1,traditional nsaid use
-1,baseline albumin : < nmbr
-1,"high - risk cvd , n ( % )"
-1,pro / pro homozygotes
-1,sulfasalazine ( mean dose : nmbr . nmbr g / day )
-1,> nmbr years eze / simva baseline ldl - c
-1,"< nmbr % predicted arr ( n = nmbr , nmbr )"
-1,pe associated with dvt at diagnosis
-1,baseline hbanmbrc
-1,"renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr"
-1,"blood eosinophil concentration , nmbr cells per l"
-1,less severenmbr
-1,cardiovascular risk
-1,prehospital ticagrelor ( n = nmbr )
-1,symptoms of atrial fibrillation in the nmbr months before randomiza -
-1,perindopril
-1,tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr )
-1,symptom onset to hospital admission
-1,ldl - c ( measured ) *
-1,rerapamil - sr strategy ( n = nmbr )
-1,"erosion score , mean nmbr sd"
-1,"valve surgery , n ( % )"
-1,ticagrelor nmbr mg nmbr year km ( % )
-1,north america ( plus australia and new zealand )
-1,calcium antagonist — no . ( % )
-1,"penetrating disease , %"
-1,non - drug - eluting stent
-1,number of exacerbations in the past nmbr months
-1,potassium supplement
-1,age group
-1,congestive heart failure ( chf ) ( in past nmbr weeks )
-1,"platelet count , x nmbr mmnmbr"
-1,other supraventricular tachycardia
-1,egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] )
-1,"mean bmi , kg / mnmbr"
-1,* * * unstable angina
-1,rate ratio
-1,recurrent vte ( statin use vs non - use )
-1,"saxagliptin nmbr mg ( n = nmbr , nmbr )"
-1,irregular or ulcerated ica p ) laque : [ :
-1,extreme tortuosity
-1,angina status — no . ( % )
-1,p value nmbr . nmbr
-1,nonaspirin antiplatelet
-1,"antihyperglycemictherapies , %"
-1,geographic distribution - no . ( % )
-1,conventional synthetic dmard use at baseline
-1,statins 一 no . ( % )
-1,at six weeks
-1,angiographic data and treatment :
-1,"clinical indication at the index procedure , n ( % )"
-1,mean bdi focal score ( sd )
-1,cabg during index hospitalization
-1,pci for index event
-1,concomitant drug treatment
-1,"third primary ( change in updrs score / wk , wk nmbr - nmbr )"
-1,implanted pacemaker
-1,"concomitant asthma medications , n ( % )"
-1,hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol )
-1,uacr not available
-1,ret / abx - facil . pci
-1,"severity of copd , airflow limitation , n ( % )"
-1,claudication only
-1,mean % predicted dlco * ( sd )
-1,titre ( u / ml ) t
-1,treatment before admission ( % )
-1,overall quality of life
-1,no baseline corticosteroids
-1,high on - treatment platelet reactivity *
-1,"potassium ( meql ) , mean + sd , available for nmbr patients"
-1,all patients with opg n - nmbr
-1,"urinary albumin : creatinine ratio ( pg / mg ) , median ( iqr )"
-1,cardiac rhythm disorder at baseline yes
-1,islander
-1,left circumflex coronary artery
-1,risk category ( points )
-1,"nihss at randomization , nmbr - nmbr"
-1,cilostazol
-1,"creatinine clearance category , ml / min , no . ( % ) b"
-1,"tg > nmbr mg / dl , n ( ° / o )"
-1,chf on losartan ( % )
-1,"comorbidities , %"
-1,prior lipid - lowering agent use
-1,iwqol - lite total score ( arbitrary units ) #
-1,absolute change
-1,gusto moderate / severe
-1,ls mean difference ( se ) vs placebo
-1,stent implanted — no . ( % )
-1,eze / simva ( „ = nmbr }
-1,"low eosinophil subgroup ( , nmbr / ml ) ( n = nmbr )"
-1,alaska native
-1,| interactior nmbr p
-1,number ( s ) of features present
-1,extent of disease — no . / total no . ( % ) § ^ |
-1,eze / simva nmbr / nmbr mg n = nmbr
-1,bivalirudin
-1,two arm
-1,metreo modified intention - to - treat population §
-1,any blood pressure medications ( % )
-1,"p , net difference"
-1,statin users ( n = nmbr )
-1,simplified disease activity index score ( nmbr - nmbr )
-1,calcium channel
-1,level — no . ( % )
-1,no regular consumption
-1,"nmbr / nmbr , nmbr ( nmbr . nmbr )"
-1,"time from randomization to pci ( non - st - elevation mi ) , h"
-1,"nmbre < nmbr % , n ( % )"
-1,"prior pacemaker , n ( % )"
-1,"non - detectable / unknown , n ( % )"
-1,"individuals without diabetes , n = nmbr , nmbr"
-1,post - fibrinolysis angioplasty ( n = nmbr )
-1,aerobic activity
-1,pulse pressure
-1,laboratory measures
-1,deep - vein thrombosis ( % )
-1,cardiovascu lar subg roup
-1,greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr
-1,"statin , n ( % )"
-1,location of infarction
-1,infliximab - experienced ( n = nmbr )
-1,time since first copd diagnosis ( years )
-1,potassium — mmol / liter
-1,rivaroxaban ( n = nmbr )
-1,investigator - determined myocardial infarction
-1,time from first eval
-1,diagnosis of heterozygous familial hypercholester
-1,baseline crp ( mg / dl )
-1,average of maximum far wall cimt ( mm )
-1,hispanic ethnicity
-1,other vasodilator
-1,maintenance dose
-1,thienopyridine type
-1,perfusion defectsatinclusion
-1,dasnmbr - esr remission
-1,no . of panents . total no . nmbr % )
-1,disease activity outcomes ( itt population ) week nmbr
-1,fluticasone furoate and vilanterol ( n = nmbr )
-1,any infarct
-1,apolipoprotein a - i *
-1,current smoking — no . / total no . ( % )
-1,miami k antagonist received
-1,rivastigmine
-1,europa ( n = nmbrlnmbr )
-1,"lung function , mean"
-1,"physician ' s global assessment of disease activity ( nmbr - nmbr mm vas ) , mean ( sd )"
-1,nmbr - nmbr ( very severe )
-1,high - risk clinical features
-1,second primary composite outcome
-1,baseline % predicted fevnmbr
-1,treatment characteristics
-1,digoxin at last follow - up
-1,both impaired glucose tolerance and impaired fasting glucose tolerance — no .
-1,ez / simva < % >
-1,"sbp indicates systolic blood pressure ; dbp , diastolic blood pressure ; aa , arachidonic acid ; epa , eicosapentaenoic acid . values for age , bmi , total cholesterol , ldl cholesterol , hdl cholesterol , sbp , dbp , aa , epa , and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups ."
-1,# of prior bdmards
-1,acute reaction
-1,ulcers / gangrene
-1,fasting plasma glucose ( mmol / l )
-1,other teaes
-1,alcohol intake
-1,change from baseline ( % )
-1,ileum only
-1,anti - tnf - ir patients
-1,north america plus australia and new zealand
-1,medial - distal - diag
-1,"bw at nmbr weeks , kg +"
-1,haemoglobin ( mmol / l )
-1,"severity ofcopd ( goldnmbr ) , n ( % )"
-1,prior stroke — no . ( % )
-1,adalimumab ( n = nmbr )
-1,aliskiren dm = nmbr non - dm = nmbr
-1,previous cabg ( before index acs ) *
-1,number of patients ( % ) or mean 士 sd
-1,"severity of copd , n ( % ) ( gold nmbr ) : moderate"
-1,western friroce
-1,baseline lipids ; mean ± sd ( mmol / nmbr )
-1,baseline calcium yes
-1,cardiac mediations
-1,large vessel
-1,no . of treated vessels
-1,sinus rhythm at baseline
-1,ipah / hpah
-1,ccs class §
-1,antithrombotic and anticoagulant medications
-1,"ixeqnmbrw , n = nmbr"
-1,warfarin group ( n = nmbr )
-1,white - cell count — xnmbr_nmbr / liter
-1,mean % predicted fvc ( sd )
-1,only cerebrovascular disease
-1,three or more agents
-1,"msfc timed nmbr - foot walk test , median seconds"
-1,mean ( sd ) baseline scores
-1,patients with > nmbr % ■ nmbr ml increase in fevnmbr post - bronchodilator ( % )
-1,meglitinide
-1,"prior tobacco use , n ( % )"
-1,graft occlusionsa
-1,ascot - lla
-1,cortical only
-1,"key : tc = triglyceride ; hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose ; ncep atp * this category did not include ar to have > _ nmbr of the indicated char least - square means , except tc an note : all treatment by subgroup"
-1,prior disease - modifying drugs resulting in inadequate response — mean no . / patient
-1,extent of disease
-1,candesartan group ( n = nmbr )
-1,rivaroxaban alone ( n = nmbr )
-1,"body mass index , mean ( sd ) [range]a"
-1,"baseline antihyperglycemic medications , n ( % )"
-1,"fasting lipid levels , mmol / l"
-1,proximal gastrointestinal tract
-1,diabetes mellitus ( type nmbr or nmbr )
-1,"heart failure ( hf ) , ( % )"
-1,"platelet , nmbr / l"
-1,hbanmbrc < nmbr % ( n - nmbr )
-1,"spironolactone , n ( % )"
-1,"b digit symbol substitution , insulin glargine vs standard care"
-1,proteinurianmbr ( g / day )
-1,elevated blood pressure
-1,ldl - c ( mg / dl ) < nmbr
-1,laser or vitrectomy
-1,total study population ( n = nmbr )
-1,presenting diagnosis
-1,duration of type nmbr diabetes ( years )
-1,alt ( units / l )
-1,severity of airflow limitation
-1,patient ' s global assessment of disease
-1,daily dose nmbr - nmbr mg n = nmbr
-1,in - stent restenosis of des
-1,"baseline hbanmbrc , mean ( s . e . )"
-1,predicted normal ( % )
-1,killip class — no . ( % ) i
-1,prior ml or abnormal angiogram
-1,placebo + mtx ( n = nmbr )
-1,baseline corticosteroid use ( mg )
-1,"ind / gly nmbr / nmbr mg once daily ( n = nmbr , nmbr )"
-1,patients who received positive results on test for antibodies to infliximabt
-1,ptca < nmbr h
-1,verapamil - sr ( « = nmbr nmbr )
-1,simvastatin ( nmbr / nmbr mg / d )
-1,insulin 一 no . ( % )
-1,duration of type nmbr diabetes mellitus ( years )
-1,central america and south america
-1,hip circumference — cm
-1,rnmbr + ezio ( n = nmbr )
-1,male sex — no . of patients ( % )
-1,"stents per lesion , n"
-1,infliximab ( n = nmbr )
-1,dose of rosuvastatin
-1,"lvef < nmbr % , n = nmbr nmbr ) “"
-1,"n - terminal pro - brain natriuretic peptide , pg / ml"
-1,bmi — mean ( sd ) ( kg / mnmbr )
-1,"vorapaxar event rate ( n = nmbr ) , %"
-1,death or nmbrmwd decrease > nmbr m
-1,associated with transient or reversible risk factor
-1,europe and australia
-1,all countries
-1,urinary protein : creatinine ratioa ( mg / mg )
-1,"serum cholesterol , median ( iqr ) , mg / dl"
-1,intermediate risk ( ri = nmbr )
-1,cangrelor
-1,"baseline cdai score , mean ( s . d . )"
-1,major bleeding events *
-1,"baseline , mm hg"
-1,white / caucasian
-1,body mass index ; mean ± sd ( kg / mnmbr )
-1,recurrent ischemia
-1,index event not confirmed
-1,non - hdl cholesterol ( mg / dl )
-1,comparison with placebo
-1,current use of an ace inhibitor
-1,"mean total serum ige ( sd ) , iu / ml"
-1,af or atrial flutter 卞
-1,pain subscale
-1,ejection fraction based on local reading
-1,cardiac and echocardiography parameters
-1,"albuterol use ( sd ) , puffs / day"
-1,white race — number ( % )
-1,"stable angina ( n - nmbr , nmbr )"
-1,"weight , kg , median ( nmbrth , nmbrth )"
-1,long - term aspirin
-1,moderately impaired
-1,left side only
-1,past or never
-1,gastroesophageal reflux disease
-1,anticoagulant — no . ( % )
-1,"region , asia / paafic"
-1,arteriosclerosis
-1,fasting plasma glucose nmbr medan
-1,age mean ( yrs ± sd )
-1,chronic renal failure
-1,peripheral artery
-1,neither tnmbrdm nor mets
-1,"time since first af diagnosis , yrs"
-1,anti - hypertensive therapy - no . ( % )
-1,pacemaker
-1,infarct ion w ithin previous nmbr day s
-1,cardiac death
-1,interval between clinical evaluation and initiation oftreatment — no . ( % )
-1,"apolipoprotein b , mean ( sd ) , g / l"
-1,no . of participants with events ( % )
-1,"mean a ± sd , mg / dl ( mmol / nmbr )"
-1,homa - ir ( mu / l^mmol / l )
-1,"> nmbr months ( n = nmbr , nmbr )"
-1,"elevated troponin ( > nmbr . nmbr mg / l ) , %"
-1,"mean weight ( sd ) , kg"
-1,europe ( zone nmbr )
-1,cox bsl onlyc
-1,number resulting in ed visit
-1,left ventricular systolic or diastolic dysfunction
-1,any other llts ( other than statin )
-1,other blood - pressure drug
-1,both ace inhibitor and arb
-1,"tg , median ( sdy rng / cjl"
-1,statin at last follow - up
-1,p - value ( lnteraction )
-1,mild dysfunction or normal
-1,recurrent infections ( > nmbr per year )
-1,estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr
-1,"median ( qnmbr : qnmbr ) duration of diabetes , years"
-1,nmbrlnmbrmmhg
-1,chronic non - steroidal antiinflammatory drugs
-1,european subcategories
-1,placebo + nmbr mg / d of simvastatin ( n = nmbr )
-1,median c - reactive protein — mg / dl^
-1,use of other medications — no . ( % )
-1,total - c : hdl - c
-1,pre - bronchodilator fevnmbr / fvc ( % )
-1,reversibility ( % predicted fevnmbr ) *
-1,conversion to sinus rhythm in < nmbr days
-1,stent implanted
-1,"median weight , kg ( iqr )"
-1,saxagliptin ( % )
-1,salmeterol - fluticasone group ( n = nmbr )
-1,abciximab
-1,vein bypass graft stented
-1,"mean age ( sd ) , years"
-1,prior treatment
-1,bivalirudin used during pci
-1,"mean ( s . d . ) ldl particle number , nmol / l"
-1,pad symptoms ( % )
-1,number of treated lesions
-1,"infliximab ( combined nmbr mg / kg and nmbr mg / kg ) , n ( % )"
-1,"high dose statin ( n = nmbr , nmbr )"
-1,any recurrent stroke
-1,distal one - third of radius
-1,mean mayo score ( sd )
-1,diagnosis at presentation
-1,median disease duration — yr
-1,events / control group
-1,lowest tg tertile
-1,"other antihyperglycemic agents , not listed"
-1,index stroke > nmbr days before randomization — no . ( % )
-1,renal fmclicn : creatntoe clearance
-1,"prior mi ( n - nmbr , nmbr )"
-1,losartan plus placebo ( n = nmbr )
-1,"anti - ccp positive ( > nmbr u / ml ) , n ( % )"
-1,"total occlusion , n ( % )"
-1,male sex — no . ( % ) risk factors
-1,multiple tnfi and other bdmards §
-1,stiffness ( min )
-1,rosuvastatin nmbr - nmbr mg ( n = nmbr )
-1,randomization to angiography
-1,thienopyridine n = nmbr
-1,treatment difference
-1,"absolute reversibility in fevnmbr , ml *"
-1,time to treatment
-1,"duration of initial anticoagulation , mean ( sd ) , mo"
-1,undetermined etiology
-1,ace inhibitors through hospital discharge or day nmbr — %
-1,patient ' s global assessment ( vas )
-1,"triglycerides ( mg / dl ) , mean + sd , available for nmbr patients"
-1,"qualifying type of atherosclerosis , n ( % )"
-1,"patient ' s preference not to take vka , only reason"
-1,probable
-1,at least two cardiovascular risk factors
-1,surgical technique post - randomisation characteristic * *
-1,"age group , no . ( % ) , y"
-1,disease location ( % ) *
-1,previous oad ( % )
-1,hdl cholesterol — mg / dl triglycerides — mg / dl
-1,< nmbr months in - nmbr kill
-1,antialdosterone agents
-1,"risk factors bmi ( kg / mnmbr ) , mean + sd"
-1,ex - smoker / current
-1,at goal
-1,history of heart failure — no . ( % )
-1,diabetes duration subgroups
-1,western europe ( including south africa )
-1,randomization stratum
-1,"death , mi , idr , st or gusto severe bleeding"
-1,clopidogrel / total no . of patients % %
-1,corticosteroid ( without imm )
-1,creatinine ratio nmbr - nmbr
-1,overall pad
-1,steroids ( other )
-1,"mean ± s . d . weight , kg"
-1,amlodipine ( n = nmbr )
-1,previous infliximab therapy — no . of patients ( % ) * *
-1,"anti - tnf - naive , n ( % )"
-1,previous acute hypersensitivity reaction to infliximab — no . of patients ( % )
-1,non - elderly ( < nmbr years )
-1,pravastatin ( n = nmbr >
-1,"week nmbr ( mean , sd )"
-1,factor v leiden ( % )
-1,tender joint count ( nmbr - nmbr possible joints )
-1,male sex — no . / total no . ( % )
-1,insulin glargine n ( x )
-1,time since randomization
-1,post - bronchodilator fevnmbr ( % predicted normal ) a
-1,"vessel size , mean ( sd ) , mm"
-1,"hs - crp ( median , iqr ) , mg / l"
-1,insulin - requiring
-1,"homa . ir , median ( ql , qnmbr ) , % / nmbr"
-1,baseline short - acting anticholinergics
-1,multivitamin use ( current )
-1,apob : apoal
-1,cardiac stretch
-1,hospitalization for heart failure within nmbr mo
-1,"lv ejection fraction , mean ( sd ) [range] , %"
-1,"pasi score , nmbr - nmbr *"
-1,patients with event / patients analyzed
-1,"mean ( sd ) periostin , ng / ml"
-1,any blood transfusion
-1,low molecular weight heparin
-1,yes ( stopped for trial )
-1,previous chronic use of antiplatelet drugs
-1,aspirin - erdp clopidogrel no . of patients / total no .
-1,denosumab
-1,patients randomized
-1,days with asthma symptoms / week
-1,statin with fibrate
-1,delayed - start group ( n = nmbr )
-1,fevnmbr % predicted ( post salbutamol )
-1,intended durat - sm of antccagubficn
-1,"baseline dmard use , n ( % )"
-1,creatinine — mg / dl urinary albumin - to - creatinine ratio §
-1,companion : wake - up stroke
-1,placebo events / n ( % )
-1,cdai score < nmbr
-1,"baseline ibdq total score , mean"
-1,"positive for rheumatoid factor , anti - cyclic citrullinated peptide antibodies , or both — % ff"
-1,"current alcohol use , n ( % )"
-1,"cardiac medications at discharge , %"
-1,medical management only
-1,shoulder pain
-1,"hbalc , mean ( s . d . )"
-1,nmbr . nmbr mg bid
-1,pci during index hospitalization
-1,history of cv disease
-1,complex lesions^
-1,level nmbr immobility^
-1,asia / pacific / other
-1,"calcium , mmol nmbr nmbr"
-1,"race , % caucasian"
-1,mtss cfb mean ± sd
-1,study end concentration
-1,"potassium , mean ( sd ) , meq / l"
-1,naive to antihyperglycemic agent therapy
-1,"swollen joint count , of nmbr"
-1,hemispheric tia n = nmbr
-1,"c - peptide tx difference vs pbo , median change from baseline ( se ) nmbr"
-1,"severity of airflow limitation ( gold nmbr ) , n ( % )"
-1,other atherosclerotic event
-1,retinopathy ( stage nmbr / nmbr / nmbr / nmbr )
-1,mean — ml / min / nmbr . nmbrmnmbr
-1,fevnmbr ( % predicted normal )
-1,baseline total cholesterol
-1,"egfr category , n ( % )"
-1,rhabdomyolysis
-1,any other antihyperglycaemic drugs
-1,any risk factor for stent thrombosis
-1,copd severity : mild / moderate
-1,medications taken at time of randomization statins
-1,"neither n = nmbr , nmbr"
-1,exercise at least weekly ( a )
-1,patients with previous intolerance of infliximab
-1,mayo clinic score §
-1,nob systolic blood pressure ( mm hg )
-1,geographic region - other
-1,"months since first ra symptom , mean ( sd ) f"
-1,continuation ( n = nmbr )
-1,timi - defined bleeding
-1,"glycosylated hemoglobin , %"
-1,omeprazole
-1,in - hospital ticagrelor ( n = nmbr )
-1,mean bmi ( nmbr % ci )
-1,physiological measures
-1,atrial fibrillation pattern
-1,corticosteroid + imm
-1,thiazide at enrollment
-1,nasopharyngitis
-1,established atherosclerotic
-1,overall effect
-1,omega - nmbr fa
-1,ejection fraction : < nmbr % ( n = nmbr )
-1,< nmbr mm hg heart rate
-1,lv ejection fraction ( % )
-1,cangrelor clopidogrel no . of events / total no . ( % )
-1,killip at baseline
-1,time since asthma diagnosis ( years )
-1,nmbr placebo
-1,carbamazepine
-1,"postmenopausal , current hormone therapy use"
-1,known duration of type nmbr diabetes ( years )
-1,beta - blocker at enrollment
-1,number of exacerbations nmbr months before randomisation
-1,"week nmbr hbanmbrc , mean ( s . e . )"
-1,tertile nmbr ( n = nmbr )
-1,"mean ( sd ) duration of copd , years"
-1,ci - aki risk score
-1,"risk factors for stroke , no . ( % )"
-1,"esr ( mm / h ) , median ( min , max )"
-1,"units per week , mean ( sd )"
-1,c - reactive protein — mg / literj
-1,non - u . s .
-1,acuity - defined bleeding
-1,vedolizumab
-1,other / multiracial
-1,time since qualifying event
-1,> nmbr vessels treated
-1,"statin use , n ( % )"
-1,previous coronary - artery bypass grafting
-1,"median ( min , max )"
-1,intensive control ( n = nmbr ) no . of patients ( percent )
-1,"arterial hypertension , n ( % )"
-1,ranolazine ( n = nmbr ) placebo ( n = nmbr )
-1,large shunt
-1,"history of hypertension , n ( % )"
-1,"age y , median ( range )"
-1,companion : nmbr - nmbr hours
-1,nt - pro bnp
-1,lipid difference ( mg / dl )
-1,other determined etiology
-1,baseline pasi score
-1,mean ( sd ) total asthma symptom scores
-1,time since pah diagnosisc ( years )
-1,alpha receptor antagonist
-1,esrd on losartan ( % )
-1,stroke at entry ( vs transient ischemic attack )
-1,medical history and risk factors ( % )
-1,placebo monthly ( n = nmbr )
-1,intravenous inotropes or vasopressors ( % )
-1,overall a phase population
-1,symptom onset to first medical contact : ambulance or emergency department
-1,any glucocorticoid *
-1,mean ( sd ) post - bronchodilator fevnmbr percentage predicted
-1,insulin ( mu / ml )
-1,creatinine clearance < nmbr ml / min
-1,nihss at randomization
-1,"elevated serum potassium , > nmbr . nmbr mmol / l"
-1,concordant stress test abnormalities
-1,"eos serum k + , meq / l"
-1,duration of diabetes
-1,arterial revascularization
-1,endpoint rate
-1,"highest tertile ( range , nmbr . nmbr - nmbr . nmbr mg / dl ; mean ± sd , nmbr . nmbr ± nmbr . nmbr mg / dl )"
-1,p interaction women vs men
-1,malaysia
-1,populations :
-1,"serum creatinine , 弘 mol 儿 | |"
-1,index pci performed
-1,retinopathy
-1,history of nicotine use
-1,insulin glargine n ( % ) / nmbrpy
-1,no chd simva ( n = nmbr]
-1,treated with insulin
-1,previous ischemic stroke ortia
-1,iglarlixi
-1,previous cabg surgery
-1,statin alone
-1,study drug loading days ( actual ) : nmbr ( n = nmbr )
-1,lumbar epidural
-1,periprocedural medications
-1,"mean age , y , mean = sd"
-1,group dif . ( nmbr )
-1,"prior cardiac resynchronization therapy , n ( % )"
-1,cardiac risk
-1,albuterol use
-1,no . of events / total
-1,no . of participants per nmbr patient - yr
-1,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr — no . / total no . ( % ) §
-1,established atherosclerotic disease
-1,ukraine
-1,negative for helicobacter pylori — no . / total no . ( % )
-1,other medical history — no . / total no . ( % )
-1,left atrial anteroposterior diameter — mm
-1,any established peripheral arterial disease
-1,serum k + level and drug treatment
-1,chronic inflammatory disease
-1,randomization to arrival in catheterization laboratory
-1,rituximab
-1,hemoglobin
-1,high risk ( receiving treatment for ) :
-1,"c - reactive protein , median ( iqr ) , mg / l"
-1,anti - tnf - naive patients
-1,"lipids , mean ( sd ) , mg / dlt"
-1,high - dose statin use at screening *
-1,second primary ( estimated change in total updrs score from baseline to wk nmbr )
-1,abciximab no . / total ( % )
-1,no . of non - tnfi
-1,"current cvd / diabetes , n ( % )"
-1,cv mortality
-1,"duration of dementia symptoms , months"
-1,no pad baseline
-1,pre ' rtous eptscde ( s } d dvt / pe
-1,prior coronary artery bypass surgery
-1,interaction p - valuenmbr
-1,"ipah , hpah , hiv , drug or toxin induced"
-1,< nmbr mg / dl simva ( n = nmbr]
-1,"location of disease , n ( % )"
-1,mtx ( mean dose : nmbr . nmbr mg / wk )
-1,labs at the index acs event
-1,black race ( n = nmbr vs nmbr )
-1,treatment with any bp lowering drugs
-1,placebo nmbr / nmbr
-1,"diagnosed , y"
-1,peri - op statins : no ( n = nmbr )
-1,"region , europe"
-1,copd disease severity
-1,baseline dyslipidemia
-1,difference in ls means ( nmbr % ci ) nmbr
-1,"male gender , n ( % )"
-1,( nmbr - nmbr - cm vas )
-1,"screening absolute reversibility fevnmbr , ml"
-1,k - m %
-1,type of surgery
-1,hosp . worsening hf
-1,rest of the world
-1,placebo no . / total no .
-1,azathioprine / nmbr - mercaptopurine
-1,"duration of diabetes , mean ( sd ) , y"
-1,cox - nmbr selective nsaid
-1,"total ( n = nmbr , nmbr ) - -"
-1,laboratory variables
-1,baseline anti - hyperglycemic medications
-1,ivabradine group ( n = nmbr )
-1,undergoing major vascular surgery
-1,< nmbr baseline killip class
-1,statin intensitynmbr * nmbr
-1,multivitamin use
-1,baseline body weight quartile
-1,"baseline fpg , mean ( s . e . )"
-1,primary pci n = nmbr
-1,prior tnfi treatment
-1,multiple ( > nmbr ) chd risk factors that confer a nmbr - year risk of chd > nmbr %
-1,pctindopnl - indapamide ( n = nmbr )
-1,history of impaired renal function
-1,stroke of any etiology
-1,fasting insulin ( pmol / l )
-1,total body ( without head )
-1,fatty acid composition
-1,cerebral hemorrhage
-1,pasinmbr response }
-1,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg
-1,duration of diabetes ( months )
-1,alpha - glucosidase inhibitors
-1,anthropometry : mean ( sd )
-1,white ethnicity
-1,"vascular history , %"
-1,time from qualifying myocardial infarction
-1,nmbr — nmbr nlmw
-1,postoperative glucocorticoid use post - randomisation characteristic * *
-1,sinus rhythm
-1,united states or canada
-1,"heparin , ‘ ondaparinux or brvalirudin use between rxjex event"
-1,"community hospital , n ( % )"
-1,patient - reported outcome measures
-1,> nmbr . nmbr mg / liter antiplatelet agents
-1,ara functional class — no . ( % )
-1,left ventricular ejection fraction
-1,restenotic vessel
-1,mean nmbr - year cvd risk *
-1,^median > median
-1,ace inhibitors / sartans
-1,"duration of hypertension , y"
-1,history of pci — no . / total no . ( % ) : t
-1,current cigarette smoker or within past year
-1,time to randomization from symptom onset
-1,motor weakness
-1,"hospitalization for hf previous year , ( % )"
-1,"st - segment depression < nmbr . nmbr mv , %"
-1,ab / ff nmbr / nmbr pg ( n = nmbr )
-1,severity of airflow obstruction
-1,tender - joint count ( of nmbr joints )
-1,tenecteplase
-1,"median duration of symptoms ( range ) , yr"
-1,history of pci / ptca
-1,only dvt
-1,glucose - lowering drug
-1,age group ( years )
-1,renal events
-1,blood leucocyte concentration ( nmbr cells per l )
-1,baricitinib nmbr mg
-1,etd ( % ) [nmbr % ci]
-1,ranolazine ( n = nmbr )
-1,below - knee popliteal
-1,uacr ( mg / g )
-1,geographic location
-1,albuminuria
-1,"angina , n ( % )"
-1,acrnmbr response
-1,dyslipidemianmbr
-1,past or current
-1,interval from randomization to angiography
-1,enthesitis
-1,previous treatment
-1,non - tnf inhibitors
-1,any blood - pressure - lowering drug 一 no . ( % )
-1,previous stroke — no . ( % )
-1,proximal to the splenic flexure
-1,high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr )
-1,"patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr , n"
-1,slo days
-1,cardiovascular mortality
-1,mnmbr subgroup
-1,valsartan ( n = nmbr )
-1,japan n = nmbr
-1,modified se - adl scale
-1,corticosteroids only
-1,p - value interaction
-1,"undetermined , other , or cardioembolism"
-1,percentage patients reaching target
-1,"hispanic , n ( % )"
-1,modified has - bled
-1,insulin alone
-1,"statin only , n ( % )"
-1,body - mass index categories — no . ( % ) : c
-1,"monocytes , nmbr / nl"
-1,"criteria for subcortical vad ( by mri ) , %"
-1,crp mean ( mg / dl ± sd )
-1,angiographic features
-1,> nmbr years to < nmbr years ( n = nmbr )
-1,"pathologic q waves , n ( % )"
-1,duration of metformin therapy ( months )
-1,"baseline bmi > nmbr kg / mnmbr , n = nmbr change from baseline to nmbr weeks"
-1,lesion location
-1,patients treated with statins ( n = nmbr )
-1,copd exacerbations during the previous year
-1,biasp nmbr
-1,insulin — iu
-1,subject characteristics
-1,primary composite outcome
-1,category nmbr and nmbr
-1,race or ethnic background — no . ( % ) f
-1,renal function subgroups
-1,percent of patients
-1,placebo / simvastatin
-1,% of predicted normal value *
-1,"body - mass index ( kg / mnmbr ) , mean ( sd )"
-1,rolofylline dose
-1,canagliflozin dose
-1,pbo + statin nmbr
-1,orthopaedic
-1,geographic region — number ( % )
-1,black race — no . / total no . ( % ) f
-1,versus olodaterol nmbr pg
-1,"antihypertensive agents , n ( % )"
-1,baseline cardiovascular medication
-1,alpha - blocker
-1,modified total sharp score * *
-1,beta - blocker use at baseline
-1,all - cause
-1,class nmbr or no symptoms
-1,laboratory variables at baseline
-1,pneumonia in past year
-1,"apixaban , nmbr mg ( n = nmbr )"
-1,chd men
-1,calcium antagonist strategy ( cas ) ( events / n )
-1,muscle twitching
-1,other medication usage
-1,qvanmbr nmbr / nmbr | ig od n = nmbr
-1,female sex — number ( % )
-1,"heart rate , beats / min , mean ± sd"
-1,"mitral insufficiency , n ( % )"
-1,from baseline ( nmbr % ci )
-1,compression stockings
-1,baseline triglycerides < nmbr mg / dl
-1,apo b / apo a - l
-1,"beta - carotene ( n = nmbr , nmbr )"
-1,> nmbr years baseline ldl - c
-1,prevalence of each metabolic syndrome criterion
-1,"sex , men / women , %"
-1,"high - dose statin use , n ( % ) e"
-1,fasting glucose ( mmol / l )
-1,"fistula at baseline , n ( % )"
-1,dizziness
-1,coronary angiography — no . ( % )
-1,presenting signs and symptoms
-1,moderate copdb [n z nmbr]
-1,planned conservative therapy subgroup
-1,sonti amenca
-1,"clopidogrel , nmbr mg *"
-1,methotrexate
-1,"hs - crp ( mg / l , median )"
-1,"previously taken dmards other than methotrexate , %"
-1,non - ischaemic ( n = nmbronmbr )
-1,progestins
-1,"fasting serum glucose ( mg / dl ) , median ( iqr )"
-1,normalized
-1,"time from hospital admission to pci , h , median ( qnmbr , qnmbr )"
-1,known t ' rc - iitoji cccndilon
-1,ii or iii
-1,left ventricular ejection
-1,left ventricular ejection fraction — no . / total no . ( % )
-1,"previous loss of response to and intolerance of infliximab , n ( % ) *"
-1,reported diabetes mellitus
-1,other / missing
-1,severe or moderate
-1,"coronary bypass , n ( % )"
-1,new zealand
-1,cox - nmbr selective nsaid use
-1,heart failure cause
-1,sbp ( mmhg ) < nmbr
-1,"past smoker , n ( % )"
-1,previous stroke — no . ( % ) concomitant treatment — no . ( % )
-1,mean ( s . d . ) hdl cholesterol
-1,amiodarone ( n = nmbr )
-1,previous disease — no . ( % ) f
-1,esrd on placebo ( % )
-1,acute respiratory insufficiency
-1,> nmbr % predicted arr ( n = nmbr )
-1,associated with drug or toxin exposure
-1,ls mean change ± sea
-1,reversible ( % )
-1,"left atrial dimension , cm"
-1,aspirin alone ( n = nmbr ) nmbr . nmbr
-1,diuretics ( % )
-1,ldl cholesterohhdl cholesterol ratio
-1,renal insufficiencynmbr
-1,> nmbr : nmbr hrs : min ( n = nmbr )
-1,sr ii b nmbr - cjl nmbr
-1,csdmards + mtx ( n = nmbr )
-1,"uc duration , y , mean ( range )"
-1,ejection fraction category
-1,high - probability ventilation / perfusion lung scanning
-1,mmse nmbr - nmbr
-1,use oforal glucose - lowering agent — no . ( % )
-1,baseline sgrq total score
-1,min - max age
-1,"baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr , n ( % )"
-1,ischemic stroke
-1,medications at discharge
-1,"multiracial , n ( % )"
-1,qnmbr : nmbr . nmbr to < nmbr . nmbr kg ( n = nmbr vs nmbr )
-1,heart rate
-1,"self - reported disease severity , nmbr - nmbr scale *"
-1,concomitant aedsa
-1,"immunosuppressant use , %"
-1,moderately high risk
-1,"triglycerides , median ( ql , qnmbr ) , mmol / l"
-1,nmbr = some restrictions ; no help needed
-1,nmbr or nmbr high - risk categories
-1,calcium antagonist strategy ( n = nmbr nmbr )
-1,"time to balloon / needle , min *"
-1,no - diuretics group ( n = nmbr )
-1,"egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )"
-1,patients with any clinical
-1,squamous cell carcinoma
-1,( pg / mg )
-1,phosphodiesterase type nmbr inhibitors
-1,history of stroke ( % )
-1,"age ^nmbr yrs , n ( % )"
-1,cangrelor ( n = nmbr )
-1,previous cabg ( % total )
-1,baseline composite mayo clinic score
-1,ticlopidine after completion of study drug
-1,"admission for hf in previous year , n ( % )"
-1,time since diagnosis — mo
-1,left main coronary artery
-1,other llt at randomization
-1,other anti - hypertensives
-1,a ngina > nmbr day s previously *
-1,% predicted
-1,use of antihypertensive drugs
-1,"total cholesterol ( median , iqr ) , mg / dl"
-1,hr ( nmbr % ci ) p   value
-1,loop or thiazide diuretic : ! :
-1,monitoring group ( n = nmbr )
-1,ischemic coronary artery disease
-1,blood eosinophil count > nmbr / mmnmbr at screening — no . ( % )
-1,no known frtrontxtfufoc cond aon
-1,mssbp / msdbp
-1,devices for heart failure at screening visit
-1,interleukin nmbr ( pg / ml )
-1,"priorvascular disease , %"
-1,planned thienopyridine at enrollment
-1,background csdmard category
-1,relative risk ( nmbr % ci ) ofprimary end point
-1,history of gi bleeding or ulcer — no . / total no . ( % )
-1,non - fibrin - specific
-1,gly nmbr . nmbr mg b . i . d . n = nmbr
-1,"previous coronary angioplasty , n ( % )"
-1,"mean ± sd egfr , ml / min / nmbr . nmbr mnmbr"
-1,octave induction nmbr and nmbr
-1,single vessel coronary artery diseasenmbr
-1,greater than or equal to nmbr %
-1,baseline nih stroke scale — no . ( % ) ^
-1,history of stroke or tia — no . ( % )
-1,chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr )
-1,albumin ( mg / dl )
-1,lp ( a ) ( pmol / l )
-1,st - segment depression
-1,statin — no . / total no . ( % )
-1,> nmbr episodes of atrial fibrillation in previous nmbr mo
-1,ascvd as per protocol
-1,"oral antidiabetes combination therapy without insulina , n ( % )"
-1,interquartile range — yr
-1,beta - blockers through hospital discharge or day nmbr — %
-1,"korea , republic of"
-1,"corticosteroid ( without imm ) , n"
-1,index event subtype
-1,"residual perfusion defect > nmbr % on lung scan , no . ( % )"
-1,antiplatelet agent or anticoagulant
-1,atorvastatin monotherapy ( n = nmbr * )
-1,glycoprotein ilb / iiia inhibitor before pci]
-1,extensive disease other
-1,catheter access site
-1,number of individuals
-1,congenital heart disease
-1,"ff nmbr gg ( n = nmbr , nmbr )"
-1,time from event to randomization — days
-1,clinical
-1,presence of mets ( % ) a
-1,parental history of mii
-1,"fasting serum glucose , mg / dl"
-1,treatment at randomization
-1,"glomerular filtration rate ( ml / min / nmbr . nmbrma ,"
-1,"qrs duration > nmbr ms , n ( % )"
-1,median time to first exacerbation ( months [nmbr % ci] )
-1,fasting c - peptide ( nmol / l ) c
-1,tender joint count ( nmbr joints )
-1,all - cause hospitalization
-1,duration of full - dose warfarin therapy before enrollment ( mo )
-1,severe or very severe copd
-1,nmbrmg vs placebo
-1,"nmbrmwd , m"
-1,"proportion ( nmbr % ci ) adjusted for baseline hbanmbrc , %"
-1,waist ( cm )
-1,qualifying diagnosis
-1,"mean disease duration , y ( sd )"
-1,daily activities / social functioning
-1,saxa nmbr . nmbr mg
-1,rosuva nmbr mg n = nmbr
-1,bmi group — no . ( % )
-1,lv mass
-1,"hours from clopidogrel loading , mean ( sd )"
-1,non - ischaemic
-1,omega nmbr allocation
-1,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl )
-1,n - nmbr pufa
-1,combined ( n = nmbr )
-1,lamotrigine
-1,maximal diameter stenosis
-1,"hispanic ethnic group , n ( % )"
-1,multivessel coronary artery disease — no . / total no . ( % )
-1,history
-1,"patient ' s global assessment of disease activity ( nmbr - nmbr mm vas ) , mean ( sd )"
-1,"prior cardiovascular event "" ' """
-1,no . with event / total no . { % )
-1,ras - aldosterone inhibitor^
-1,"mean ( sd ) post - bronchodilator fevnmbr / fvc , %"
-1,non - hispanic white
-1,ethacrynic acid
-1,aqlq ( s ) score
-1,patients who received negative results on test for antibodies to infliximabt
-1,non - hdl ( mg / dl ) < nmbr
-1,all completers
-1,mean difference = seb
-1,"> nmbr , n ( % ) gender , n ( % )"
-1,prior use of $ nmbr systemic therapies
-1,health assessment questionnaire ( nmbr - nmbr range )
-1,low - molecular - weight heparin
-1,non - hdl cholesterol ( mmol / l )
-1,previous medication for respiratory disease — no . ( % )
-1,characteristics of the index ml
-1,history of heart failure
-1,prior cardiovascular history
-1,metabolic syndromenmbr *
-1,consistency of effect
-1,fondaparinux
-1,other lipid - modifying drug 一 no . ( % )
-1,initial timi flow
-1,overall nmbr
-1,absolute decrease > nmbr %
-1,recurrent hf hospitalization
-1,intrathoracic or intraperitoneal surgery
-1,former or never diabetes
-1,"geographic site , %"
-1,history of high cholesterol ( a ) nmbr
-1,"history of heart failure , n ( % )"
-1,sco . ’ ita ' rojs dvt . ' pe
-1,"general health vas , nmbr - nmbr mm"
-1,placebo / open - label abatacept
-1,prior known stenosis > nmbr %
-1,"ras antagonist , %"
-1,cancer medications
-1,current other ( predefined ) medical conditions
-1,center location
-1,time from qualifying stroke to randomization
-1,"geographical region , n ( % )"
-1,priorbone disease
-1,laba - inhaled glucocorticoid use at screening
-1,"main concomitant treatments , no . ( % )"
-1,use of rescue medication
-1,p vs placebo
-1,cardiac troponin t level > nmbr . nmbr pg / l
-1,aspirin < nmbr day
-1,native coronary
-1,arthralgia
-1,"other bdmards ( no tnfi taken ) t , n ( % )"
-1,hmgcoa rl
-1,"egfrmdrd , ml - min - nmbr - nmbr . nmbr m - nmbr"
-1,prior angioplasty
-1,anti - ccp antibody ( u /
-1,mean baseline ldl - c ( mmol / l )
-1,composite events
-1,foot fracture
-1,non - caucasian simva ( „ = nmbr }
-1,"tc , mean ( sd ) , rrig / dl"
-1,high risk and fewer symptoms ( group c )
-1,"type nmbr diabetes history , n ( % )"
-1,total cholesterol / hdl - c
-1,hypertension absent
-1,warfarin
-1,"moderate , n ( % ) a"
-1,urine acr ( mg / g )
-1,baseline systolic blood pressure
-1,hrnmbr and nmbr % cl
-1,ventricular tachyarrhythmias
-1,sulfonylurea based
-1,medication use — no . ( % ) ^ |
-1,bivalirudin ( n = nmbr )
-1,"p - blockers , n ( % )"
-1,acarbose 一 no . ( % )
-1,unfractionated heparin
-1,all patients n = nmbr
-1,sitagliptin no . / total no .
-1,% anti - ccp + ( > nmbr units )
-1,septal anomaly — no . ( % )
-1,intensified ( n 二 nmbr )
-1,long - acting bnmbr - agonists
-1,bodily pain
-1,mmrc grade
-1,alcohol consumption > once weekly
-1,p - value for trend *
-1,blood eosinophil count > nmbr / mmnmbr in nmbr months before screening — no . ( % )
-1,at entry
-1,tiotropium group ( n = nmbr )
-1,nmbr - nmbr months ( n = nmbr )
-1,dapagliflozin nmbr mg group ( n = nmbr )
-1,p value ( aged > nmbr vs . < nmbr years )
-1,valvular disease
-1,prior angina
-1,japan and south korea
-1,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *
-1,all randomized patients
-1,"pack - years , mean ( sd )"
-1,epa hr events ( % )
-1,type of myocardial infarction — no . ( % )
-1,pciperformed for qualifying event
-1,nonsustained ventricular tachycardia — no . ( % ) - j -
-1,ventricular tachycardia or fibrillation
-1,percutaneous intervention
-1,"hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )"
-1,"hypercholesterolemia , n ( % )"
-1,diclofenac
-1,nmbr week to nmbr month
-1,gp llb / llla inhibitors
-1,"current , n ( % )"
-1,"syndesmophyte present , n ( % )"
-1,angiographic findings | |
-1,"apixaban , nmbr mg"
-1,bypass graft
-1,bmnmbr ( kg / mnmbr )
-1,nmbr = no symptoms
-1,prior brachytherapy
-1,time since cessation of full - dose warfarin therapy
-1,"history of or current cardiac disorders , %"
-1,impaired glucose tolerance or impaired fasting glucose
-1,"severe , n ( % ) b"
-1,hospitalization for heart failure within previous nmbr mo — no . ( % )
-1,"diuretics , n ( % )"
-1,mmse ( points )
-1,apixaban ( n = nmbr )
-1,corticosteroid ( with or without immunosuppressants )
-1,congestive heart failure
-1,chf on placebo ( % )
-1,overall hr ( nmbr % cl )
-1,hyperlipidemia — no . ( % )
-1,p value for trend across tertiles
-1,nmbr - nmbr drinks / wk
-1,> nmbr mg / dl — %
-1,diagnosis of allergic rhinitis
-1,refractory to such therapy — no . ( % )
-1,"lymphocytes , nmbr / + il"
-1,adjusted * or ( nmbr % ci ) p value
-1,"fevnmbr % pred . ( post - albuterol ) , %"
-1,known thrombophilia — no . ( % )
-1,nmbr - nmbr ( mild )
-1,"simvastatin , n ( % )"
-1,"age , mean ( sd ) [range] , y"
-1,"copd exacerbation history , n ( % )"
-1,atio - pla
-1,"cardiac troponin t level , median ( iqr ) , pg / l"
-1,"estimated glomerular filtration rate , ml / min per nmbr . nmbr mnmbr"
-1,toast classification of qualifying stroke ( % )
-1,duration of diabetes by tertiles
-1,on drug treatment ( % )
-1,triglyceride ( median ; mg / dl ) - nmbr [nmbr - nmbr percentile |
-1,pre - specified hr ( nmbr % cl )
-1,cardiac medications during indexhospitalization and / or discharge
-1,neither corticosteroid nor immunosuppressant
-1,"albumin / creatinine ratio , n ( % )"
-1,score on modified rankin scale — median ( iqr )
-1,placebo group
-1,discontinuations due to ae
-1,"creatinine clearance , n ( % )"
-1,multi vessel ( or left main )
-1,infarct location
-1,elevated hscrp
-1,laba + ics n = nmbr
-1,"renal function , severe"
-1,"high - density lipoprotein cholesterol , median , ( nmbrth — nmbrth percentiles ) , mg / dl"
-1,"mean ± sd fasting insulin , uu / ml"
-1,at least nmbr / mo
-1,atrial fibrillation — no . / total no . ( % )
-1,ls - mean between - group difference ( nmbr % ci )
-1,"all others , n ( % )"
-1,"joint swelling , effusion , or both on clinical examination — no . ( % )"
-1,"median age ( nmbr % , nmbr % ) , y"
-1,history of cerebrovascular disease
-1,laba or lama ’
-1,metformin ( n = nmbr )
-1,prior cabg ( before index acs )
-1,anti - tnf - experienced patients
-1,digoxin / digitalis glycoside
-1,body mass index ( range ) ( kg / mnmbr )
-1,patients with previous loss of response to infliximab
-1,treatment group
-1,"haq - di , mean ( sd )"
-1,"duration of copd ( years ) , mean ( sd )"
-1,"egfr < nmbr , ml / min / mnmbr"
-1,carotid infarct
-1,"negative ( < nmbr . nmbr ) , n ( % )"
-1,endpoint week nmbr
-1,"homa - ir , mean ( sd ) ( mu / l $ mmol / l ) b"
-1,lipid and lipoprotein values ( mg / dl )
-1,placebo no . of events / no .
-1,for treatment of index event
-1,mild ( > nmbr to < nmbr )
-1,heterogeneity p value
-1,number of stents ( per patient )
-1,preoperative serum creatinine > nmbr pmol / l
-1,sacubitril / valsartan ( n = nmbr )
-1,"mean ( s . d . ) apoc - ll nmbr , mg / dl"
-1,implanted cardioverter - defibrillator
-1,swollen joint count ( n / nmbr )
-1,postmenopausal ( % )
-1,coronary disease
-1,prior lev treatment
-1,rsg nmbr mg / day
-1,former or current smokers ( % )
-1,topiramate
-1,hydrochlorothiazide
-1,"toast classification of qualifying stroke , no . ( % )"
-1,class nmbr antiarrhythmic agents
-1,"age , mean nmbr sd years"
-1,"concomitant methotrexate , n ( % )"
-1,corticosteroids . immunosuppressants . and antimalarials
-1,"bl mean , mg / dl ( mmol / nmbr )"
-1,"history of diabetes mellitus , n ( % )"
-1,median ( iqr ) admission data
-1,not provided
-1,current bone disease
-1,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile]
-1,stent plus abciximab
-1,systolic blood pressure < nmbr mm hg and diastolic blood pressure < nmbr mm hg
-1,vasoprotectives
-1,"associatedproximaldeep - veinthrombosisatdiagnosis , no . ( % )"
-1,"discharge medication , n ( % )"
-1,"other cardiac surgery , n ( % )"
-1,induction - trial group assignment — no . ( % )
-1,"bw , mean ( sd ) , kg"
-1,first procedure
-1,"prior af ablation , n ( % )"
-1,"fevnmbr reversibilityz ( pre / post salbutamol ) , %"
-1,second - generation stent
-1,"msasss , mean ( sd )"
-1,total cholesterohhdl cholesterol ratio
-1,primary safety end point : severe / life - threatening
-1,nt - probnp ( pg / ml ) ( qnmbr - qnmbr )
-1,remodeling
-1,smoking past
-1,cigarette smoking status
-1,use of concomitant lipid - lowering therapy - no . ( % )
-1,"prior arrhythmias , n ( % )"
-1,thienopyridine at enrollment
-1,coronary risk factors — no . ( % )
-1,cardiovascular risk factors
-1,less than nmbr year
-1,anti - arthritic medications
-1,some physical activity
-1,first medical contact — no . ( % ) §
-1,premature cad among family members
-1,ppci in - nmbr
-1,"overall n = nmbr , nmbr"
-1,"fevnmbr % predicted , post - albuterol , %"
-1,medical therapy only
-1,aspirin and thienopyridine therapy
-1,"heart rate , mean ( sd ) , beats / min"
-1,"tg , median ( interquartile range )"
-1,non - hispanic black
-1,normal renal function
-1,renal parameters
-1,fasting blood glucose — mmol / liter
-1,glycoprotein iib / iiiareceptorinhibitor
-1,"plaque ( n , % )"
-1,coronary angiography
-1,"age , mean ( min - max ) ( yrs )"
-1,evolocumab nmbr mg every nmbrweeks ( n = nmbr )
-1,patients not receiving immunosuppressive agents at baseline
-1,no . ( % ) with event [incidence rate per nmbr patient - y]
-1,screening hbanmbrc ( % )
-1,modified rankin scale — no . ( % ) |
-1,"previous cancer , n ( % )"
-1,penetrating
-1,more than nmbr vessels stented
-1,changes ( a ) in metabolic syndrome parameters hdl cholesterol
-1,baseline acq - nmbr score
-1,"dm medication , n ( % ) c"
-1,left main disease
-1,> nmbr lesions per vessel
-1,xanthinesnmbr
-1,"tg ( mmol / l , median )"
-1,"verapamil sr strategy ( n = nmbr , nmbr )"
-1,aspirin ( asa ) ( » = nmbr nmbr )
-1,"weight , mean nmbr sd kg"
-1,hispanic black
-1,atrial fibrillation or flutter — no . ( % )
-1,on - treatment
-1,killip class i — no . ( % )
-1,killip class ( interaction : p = nmbr . nmbr )
-1,adjusted hr ( enl vs lcz ) ( nmbr % cl )
-1,"total basdai , mean ( sd )"
-1,"placebo + statin ( n = nmbr , nmbr )"
-1,thrombus aspiration
-1,"marital status , married"
-1,no . of days to randomization — median ( iqr )
-1,exacerbations in previous year
-1,pain ( nmbr mm vas )
-1,angiogenesis
-1,non - fatal mi
-1,who functional class — no . ( % ) : c
-1,diabetic patients
-1,"type nmbr , n ( % )"
-1,abatacept nmbr / — nmbr mg / kg ( n = nmbr )
-1,black race and ss < nmbr ( n = nmbr vs nmbr ) ■ -
-1,"baseline treatments , n ( % ) a"
-1,imm ( without corticosteroid )
-1,mean ( sd ) number of exacerbations *
-1,s . e .
-1,spiralcomputedtomographyangiography
-1,p ( losartan versus placebo )
-1,apo b / apo a - l ratio ( mean )
-1,mean ( s . d . ) non - hdl cholesterol
-1,secukinumab nmbr mg
-1,early - start group ( n = nmbr )
-1,p interaction ( rx arm * sex )
-1,"left ventricular hypertrophy , n ( % )"
-1,af pattern
-1,severity of copd
-1,"post - bronchodilator fev , , % predicted"
-1,"copd or asthma , ( % )"
-1,body - mass index — no . ( % ) $
-1,waist - to - hip ratio
-1,nmbr years or older
-1,years since myocardial infarction
-1,with alogliptin nmbr mg ( n nmbr nmbr )
-1,hoehn and yahr stage
-1,elevated cardiac markers — no . ( % ) : t
-1,scores for global and pain assessments §
-1,documented coronary artery disease
-1,large vessel atherosclerosis
-1,"hbalc < nmbr % ( < nmbr mmol / mol ) , n ( % )"
-1,copd severity
-1,geometric mean
-1,"assoc , with connective tissue disease"
-1,chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr )
-1,"haq - di ( nmbr - nmbr ) , mean ( sd )"
-1,egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr
-1,"baseline weight , kg"
-1,"bifurcation , n ( % )"
-1,pe ( with or without dvt )
-1,differencenmbr
-1,"dilatative , n ( % )"
-1,arterial access
-1,serum cholesterol ( mg / l ) *
-1,cerebral thrombosis
-1,rosuva nmbr mg
-1,dose of atorvastatin
-1,"mean ( sd ) weight , kg"
-1,congestive heart failure — %
-1,no prior ms therapies
-1,glucocorticoids only
-1,"background aha therapy at screening , n ( % )"
-1,established atherosclerotic cv disease §
-1,angina symptoms^
-1,pain ( vas )
-1,"stroke subtype , n ( % )"
-1,with placebo
-1,relative risk ( nmbr % confidence interval )
-1,r nmbr mg + fa ( « = nmbr )
-1,previous pci or cabg
-1,total pack - yrs
-1,baseline trl - c by quintiles
-1,mtx > nmbr and £ nmbr mg / week
-1,ff / vi nmbr / nmbr | ig ( n = nmbr )
-1,( nmbr % ell ' ll
-1,corticosteroids and immunosuppressants only
-1,"number of vessels treated , index pci"
-1,mra ( spironolactone or eplerenone )
-1,peripheral artery occlusive disease
-1,baseline value
-1,chronic cvd
-1,established ( n = nmbr )
-1,known thrombophilia
-1,normal > nmbr - nmbr
-1,estimated gfr renal function stage
-1,"tg , mmol / l ( mg / dl ) [median]"
-1,clinical characteristics
-1,interval after index event
-1,"country , n ( % )"
-1,fractures ( site not specified )
-1,number of previous dmards
-1,non - hispanic
-1,proportion of patients in corticosteroid - free clinical remission at week nmbr
-1,pramlintide
-1,"height , inches"
-1,antithrombotic agents
-1,"ambulance , n ( % )"
-1,chd risk - no . ( % )
-1,infusion administered — no . / total no . ( % )
-1,non - hdl cholesterol ( week nmbr )
-1,inhaled glucocorticoid use at screening
-1,type of vessel involved
-1,oral blood glucose - lowering drug nmbr ( nmbr . nmbr )
-1,"baseline pos frequency per nmbr days , median ( min , max )"
-1,"mean ( sd ) mtx dose , mg / week"
-1,"laboratory ae , n ( % }"
-1,use of concomitant lipid - lowering treatment
-1,"age ( y ) , median ( iqr )"
-1,"heart failure , lvef < nmbr % , or both"
-1,omalizumab ( lsm )
-1,"baseline cv medications , n ( % )"
-1,nmbr or nmbr high cardiovascular risk categories
-1,pack - years smoked
-1,exenatide lar
-1,concomitant treatment
-1,score on the minnesota living with heart failure scaled
-1,eosinophil count ( cells per pl )
-1,"disease duration ( yr ) , mean ± sd"
-1,baseline total pcsknmbr level by median
-1,antiplatelet agents ( % )
-1,"peripheral vascular disease , n ( % )"
-1,duration of disease — yr : t
-1,infarction nmbr - nmbr days
-1,estimated difference ( nmbr % ci )
-1,non - st - elevation myocardial infarction
-1,"aspirin i clopidogrel ( n = nmbr , nmbr )"
-1,pulmonary disease — no . ( % )
-1,etn nmbr mg + mtx n = nmbr
-1,all stroke
-1,previous respiratory disease other than copd — no . ( % )
-1,history of stroke or transient ischemic attack
-1,pelvic fractures
-1,standard care allocation
-1,ra duration ( months ) *
-1,other drugs — no . ( % )
-1,atherosclerotic disease *
-1,angiography and revascularization
-1,unfractionated heparin ( n = nmbr )
-1,demographic and clinical characteristics
-1,mean lixi dose ± sd ( lg / day )
-1,number ( % )
-1,age subgroups
-1,ind / gly nmbr / nmbr mg once daily ( n = nmbr )
-1,"glycated hemoglobin , mean ( sd ) , %"
-1,no . of events / no . of patients
-1,carotid artery intervention *
-1,hope patients with coronary - artery disease ( n = nmbr )
-1,linagliptin / metformin
-1,ultrasound carotid arteries
-1,pci or cabg surgery for index event
-1,dasnmbr - nmbr ( esr ) nmbr
-1,cardiac therapy §
-1,low - dose statin
-1,"oral anticoagulant , n ( % )"
-1,p - value for interaction nmbr . nmbr
-1,> nmbr des type
-1,placebo patients with events / total
-1,average age ( year )
-1,placebo + nmbr mg / d of simvastatin
-1,baseline hb nmbrg i nmbr n = nmbr
-1,type of end point
-1,copd medication at study entry
-1,emphysema
-1,"mean ( sd ) esr , mm / h *"
-1,"vilanterol , n = nmbr"
-1,latin america ( n = nmbr )
-1,third heart sound
-1,tnfi naive
-1,continued thienopyridine ( n = nmbr )
-1,total intravenous loop diuretic ( mg ) median
-1,mild to moderate
-1,median n - terminal probnp ( iqr ) — pg / ml
-1,"degree of stenosis , % of diameter"
-1,diagnostic angiography
-1,left ventricular hypertrophy on echo
-1,"fasting serum glucose , median ( sd ) , mg / dl"
-1,abatacept plus mtx ( n = nmbr )
-1,baseline measurements
-1,non - compliance
-1,duration of pre - randomization anticoagulant therapy
-1,bmi at baseline ( kg / mnmbr )
-1,average maximum common and bifurcation cimt ( mm )
-1,location
-1,kheeatne index dvt
-1,osteitis
-1,nmbr - nmbr months fn = nmbr . nmbr )
-1,glinide 一 no . ( % )
-1,below - knee popliteal crural
-1,pre - enrollment antihyperglycemic therapy
-1,symptom duration
-1,% patients with no progression
-1,measured at clinic visit with automated device §
-1,previous episode of heart failure
-1,liraglutide ( n = nmbr )
-1,"hbanmbrc , % ( sd )"
-1,post - bronchodilator fevnmbr — liters
-1,renal insufficiency
-1,"lvef within nmbr mo , %"
-1,"ldl cholesterol , mmol / l , mean ± sd"
-1,history of hypertension for nmbr mo or more
-1,fish oil ( n = nmbr )
-1,digitalis glycoside
-1,baseline mean
-1,no previous dmard therapy
-1,hbanmbrc at nmbr weeks *
-1,glycated hemoglobin
-1,elevated fasting glucose
-1,no adk / e cancer
-1,indacaterol + tiotropium ( n[nmbr )
-1,ras % target dose
-1,history of upper gastrointestinal event
-1,ibdq score |
-1,"first primary ( change in updrs score / wk , wk nmbr - nmbr )"
-1,overweight ( nmbr to < nmbr kg / mnmbr )
-1,symptom onset - to -
-1,"median ( iqr ) cholesterol ,"
-1,week nmbr mean ( se )
-1,"western europe , israel , australia , or south africa"
-1,"imm + corticosteroid , n"
-1,"tnmbrdm duration , y"
-1,"previous myocardial infarction , n ( % )"
-1,no . ( % ) of participants
-1,"previous tnf antagonist exposure , n ( % )"
-1,pharmacotherapy
-1,ulcerative colitis
-1,"received nmbr prior anti - tnf therapy , n"
-1,placebo n ( rate ) *
-1,low - density lipoprotein
-1,family history^
-1,fvc ( % predicted )
-1,"clinical ae , n ( % }"
-1,dietary epa - dha intake ( mg / day ) *
-1,other llt use
-1,ada nmbr / nmbr n[nmbr
-1,serious adverse events
-1,change from baseline at week nmbr
-1,medications at coronary angiography
-1,"nmbr nmbr years , n ( % )"
-1,no . of subjects
-1,"fpg , mean ( sd ) , mg / dl [mmol / l]"
-1,"acrnmbr response , n / n ( % )"
-1,"sfc nmbr / nmbr mg twice daily ( n = nmbr , nmbr )"
-1,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mmnmbr
-1,copd - placebo ( n = nmbr )
-1,pga subscore
-1,mafcaiancy at randorrtzaton
-1,nmbr . nmbr mg / dl triglycerides^
-1,antiplatelet within nmbr mo before randomization
-1,lesion characteristics
-1,"handihaler and diskus , n"
-1,baseline dyspnea index score
-1,creatinine clearance — no . ( % )
-1,any oral hypoglycemic drug 一 no . ( % )
-1,sfcnmbr / nmbr pg b . i . d . n = nmbr
-1,infarct related artery location
-1,pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % )
-1,other vasculars
-1,patients who received indeterminate results on test for antibodies to infliximabt
-1,history of diabetes requiring drugs
-1,coronary intervention
-1,elevated at wk nmbr — no . ( % ) !
-1,"body mass index category , no . ( % ) l"
-1,liraglutide nmbr . nmbr mg mean ( n )
-1,"habnmbrc ( mean ± sem ) , %"
-1,low risk ( nmbr - nmbr )
-1,gfr as assessed by mdrd
-1,history of ischemic stroke
-1,nmbr - minute walk distance — m
-1,"male / female , %"
-1,current inhaler +
-1,phosphate ( mmol / l )
-1,established cardiovascular disease
-1,smoker ( current / former )
-1,total cholesterol - to - hdl cholesterol ratio
-1,"oral anticoagulant drugs , n ( % )"
-1,definite
-1,abciximab - facilitated pci ( n = nmbr )
-1,computed tomographic angiography
-1,distribution — no . ( % )
-1,intravenous heparin
-1,nmbr . nmbr to < nmbr . nmbr % ( nmbr to < nmbr mmol / mol )
-1,nmbr - month follow - up median ( iq range )
-1,biventricular pacemaker
-1,warfarin group
-1,nmbr aspirin ( n = nmbr nmbr )
-1,short form nmbr ( sf - nmbr )
-1,individual intended study duration — no . ( % )
-1,male nyha class
-1,metoprolol group ( n = nmbr )
-1,fenofibric acid
-1,warfarin at enrollment
-1,global ischemia
-1,p value § ( < nmbr vs . > = nmbr years )
-1,hf or lvef < nmbr % associated with index event
-1,"subject completion status , n ( % )"
-1,egfr — ml / min / nmbr . nmbr m * *
-1,coronary angioplasty or stenting
-1,death from cardiovascular causes
-1,nmbr mg / dl ldl cholesterol | |
-1,femur fracture
-1,"erythrocyte sedimentation rate , mm / hour"
-1,insulin sensitivity — % §
-1,anti - tnf agent ( s )
-1,medication after enrolment
-1,number insulin glargine
-1,asian ( nmbr . nmbr % )
-1,lifestyle modifications
-1,change from
-1,"% change , nmbr % ci )"
-1,< nmbrnwrrtn
-1,moderate renal impairment
-1,"major diabetic eye disease , n ( % )"
-1,all participants
-1,"history of atrial fibrillation / flutter , ( % )"
-1,apixaban dose ( or matching placebo )
-1,symptom onset
-1,prosthetic
-1,disease hare . no . ( % ) i
-1,treatment by egfr stage
-1,hormonal therapy — no . ( % )
-1,"angina pectoris , ( % )"
-1,type of stent at index procedure
-1,blood pressure lowering medication use
-1,gpi used during pci
-1,lowzmedium intensity
-1,"antihypertensive therapy , n ( % )"
-1,any medication
-1,mean — mm hg level — no . ( % )
-1,chd simva nmbr = nmbr]
-1,diabetic history ( years ) x
-1,urine albumin / creatinine ratio ( mg / g )
-1,extensive colitis or pancolitis
-1,moderate ckd at randomization
-1,less than the median
-1,"qualifying cv event , n ( % )"
-1,peripheral artery occlusive disease ( stage nmbr / nmbr / nmbr / nmbr / nmbr )
-1,or placebo treatment
-1,diabetesnmbr ( % )
-1,continued thienopyridine ( n nmbr nmbr )
-1,saxagliptin nmbr . nmbr mg
-1,"patients with ra , as , or psa ( n = nmbr )"
-1,chronic bronchitis ( % )
-1,"reduction 
 in risk 
 ( nmbr % ci ) %"
-1,"moderate disease activity : > nmbr . nmbr to < nmbr . nmbr , n ( % )"
-1,age nmbr years or more
-1,valsartan / hctz ( n = nmbr )
-1,"ics users , n ( % )"
-1,since onset
-1,diabetes at randomization
-1,treated with pci — no . / total no . ( % )
-1,device group ( n = nmbr )
-1,"left main coronary artery , n ( % )"
-1,"statin use at study entry , n ( % )"
-1,lipid disorder
-1,"history of atrial fibrillation , type 一 no . ( % )"
-1,"total diuretic dose ( iv + oral ) on day nmbr , mg"
-1,"enthesitis , n ( % )"
-1,immobazaton
-1,digit symbol substitution
-1,prior coronary revascularization ( pci or cabg )
-1,"hbalc , median ( ql , qnmbr ) , %"
-1,fasting cholesterol — mg / dl
-1,idiopathic
-1,mean ( sd ) [range]
-1,inhaled corticosteroids
-1,fasting insulin — pmol / liter
-1,watchman ( n = nmbr )
-1,"apixaban , nmbr . nmbr mg ( n = nmbr )"
-1,primary renal endpoint
-1,"hgb , g / dl"
-1,normal ( > nmbr )
-1,type of des at index procedure
-1,nmbr vitamin e ( n = nmbr nmbr )
-1,persistent wrf ( n = nmbr )
-1,estonia
-1,score on modified rankin scale ( ' % / '
-1,atrial fibrillation or flutter ( ecg ) §
-1,adcs - adl score *
-1,mean sfnmbr score ( nmbr % ci )
-1,"qrs > nmbr ms , n ( % ) , available for nmbr patients"
-1,baseline high - sensitivity crp
-1,heart rates ( beats / minutes )
-1,insulin glargine allocation
-1,left side of colon
-1,left ventricular hypertrophy
-1,non - cortical
-1,"low - density lipoprotein cholesterol , median , ( nmbrth — nmbrth percentiles ) , mg / dl"
-1,unsuccessful procedure
-1,"previous angina , n ( % )"
-1,nmbr . nmbr to nmbr . nmbr ( % )
-1,nt - pro - bnp — pmol / liter - j -
-1,sirukumab nmbr mg qnmbrw
-1,"baseline post - bronchodilator % predicted fev , > nmbr % and concurrent tiotropium use"
-1,"euroscore additive , median ( nmbrth , nmbrth % ) §"
-1,lev - naive
-1,clinical disease activity index score ( nmbr - nmbr )
-1,black / african - american ( nmbr . nmbr % )
-1,chronic coxnmbr inhibitors
-1,no . of coronary vessels with > nmbr % diameter stenosis
-1,history of claudication
-1,"seated sbp at nmbr weeks , mmhg +"
-1,ended > nmbr days before trial entry
-1,rope score * *
-1,inter p - value
-1,risk factor profile index event
-1,"use of ace inhibitor , arb , or both — no . ( % )"
-1,"clopidogrel , nmbr mg loading dose !"
-1,adverse eventy
-1,discontinued
-1,duration of osteoarthritis symptoms — yr
-1,total cholesterol - mg / dl * *
-1,peripheral revascularization ( n = nmbr )
-1,smoking in past yr
-1,percentage of patients using ics or ics / laba on entry
-1,"mean change ,"
-1,neither ics nor laba
-1,combination - facilitated pci ( n = nmbr )
-1,bifurcation
-1,coronary heart disease death
-1,< nmbr mg / dl eze / simva ( n = nmbr }
-1,a / v ( n = nmbr ) v ( n = nmbr )
-1,hypertrophic cardiomyopathy
-1,"median body mass index , kg / mnmbr ( iqr )"
-1,nmbr - year framingham chd risk ( % ) nmbr mean / sd )
-1,"ecrcl , ml / min"
-1,time from longest event to randomisation
-1,no prior hf hospitalization
-1,conservative
-1,"serum creatinine ( pmol / l ) , mean ( sd )"
-1,"any cv history / risk factors , n ( % )"
-1,vte at day nmbr +
-1,"age of completion of highest education , years ( sd )"
-1,pfo + asa
-1,nmbr mg / day - placebo
-1,mtss cfb
-1,mental component summary
-1,"low - density lipoprotein cholesterol tx difference vs pbo , ls mean % change from baseline ( se )"
-1,dihydropyridine calcium - channel blocker
-1,germany
-1,high sensitivity c - reactive protein ( mg / l )
-1,azathioprine
-1,high risk ( ri ≥ nmbr )
-1,egfr ( ml / min per nmbr - nmbr m ' )
-1,ez / simva nmbr mg
-1,patients receiving immunosuppressive agents at baseline
-1,"demographics age , years , mean ( sd )"
-1,"previous aorta - femoral or lower extremity bypass surgery , pta of iliac , or infrainguinal artery"
-1,fracture
-1,clopidogrel loading dose nmbr mg
-1,renal insufficiency — no . ( % )
-1,caucasian eze / simva ( „ = nmbr }
-1,"tg mg / dl , median ( sd )"
-1,locafon of index dvt
-1,baseline nihss
-1,clinical details
-1,limited i -
-1,intracranial disease of major artery 寸
-1,mean bp ( mmhg )
-1,no chd eze / simva nmbr = nmbr }
-1,"heart rate , b . p . m . mean ± sd"
-1,estimated glomerular filtration rate - no . ( % ) : :
-1,moderate n z nmbr
-1,central nervous system
-1,drug - eluting stent implanted — no . ( % )
-1,"elevated bnp ( nmbr pg / ml ) , %"
-1,verapamil - sr strategy
-1,baseline steroids
-1,"c - reactive protein , median ( qnmbr , qnmbr )"
-1,albumin measurements^^
-1,dactylitis
-1,no hypertension ( n = nmbr )
-1,"history of other medical conditions , n ( % )"
-1,placebo allocation
-1,cyclosporin
-1,"symptom onset to hospital arrival , hours"
-1,before amendment
-1,baseline erosion
-1,minimal important change threshold ( improvement ) a
-1,digoxin
-1,"left ventricular ejection fraction , mean ( sd ) , %"
-1,new york heart association congestive heart failure class
-1,"haemoglobin ( g / dl ) , mean + sd , available for nmbr patients"
-1,peripheral arterial revascularization
-1,median daily dose - iu ™
-1,"hla - bnmbr positive , n ( % )"
-1,"renal function ( egfr , ml / min / nmbr . nmbr mnmbr )"
-1,ldl particle numbers ( week nmbr )
-1,serum ldl cholesterol
-1,all grafts
-1,stroke thought due to atherothrombotic disease
-1,first hhf
-1,primary angioplasty ( n = nmbr )
-1,atenolol strategy ( n = nmbr )
-1,prothrombin mutation ( % )
-1,cardiovascular risk factors and medical history
-1,"valsartan , n ( % )"
-1,qrs > nmbr msec nmbr - min walk test
-1,"immobilization at randomization , n ( % )"
-1,difference
-1,participants n
-1,"left ventricular ejection fraction , median ( iqr ) , %"
-1,associated with corrected
-1,ckd ( egfr < nmbrb )
-1,lowering drugs
-1,concomitant cardiovascular therapy ( taken > nmbr days )
-1,post - bronchodilator fevnmbr / fvc ( % ) a
-1,no . evenls
-1,medical treatment
-1,previous angina pectoris
-1,indeterminate ! !
-1,select lipids and lipoproteins
-1,nmbr - year framingham chd risk
-1,> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr ) — number / n ( % )
-1,"egfr ( ckd - epi , cystatin c ) , ml / min / nmbr . nmbr mnmbr"
-1,previous receipt of therapy against tnf - a — no . ( % )
-1,prior to index event
-1,"race , % of patients"
-1,"apo a - i , mg / dl"
-1,"vessel treated , n"
-1,"non - smokers receiving lipid - lowering drugs , p blockers ,"
-1,estrogen therapy
-1,"haq - di total score , mean ( sd )"
-1,high density lipoprotein cholesterol - mg / dl * *
-1,"systolic pulmonary arterial pressure , mean ( sd ) , mm hg"
-1,> qnmbr ( nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % )
-1,"das - nmbr ( crp ) , mean ( sd )"
-1,blood transfusion
-1,partial evolving to secondarily generalized ( ic )
-1,hscrp > nmbr to < nmbr mg / l
-1,ra symptom duration < nmbr months — number ( % )
-1,ldl - c < nmbr mg / dl
-1,ace / arb medication ( % )
-1,positive family history of type nmbr diabetes ( % )
-1,urinary albumimcreatinine ratio
-1,diabetes treatment
-1,mucolytics
-1,pooled analysis
-1,infliximab
-1,iduration of symptoms > nmbr min
-1,estrogens
-1,nmbr mg twice daily n = nmbr
-1,major gastro - intestinal bleeding
-1,"anti - ccp antibody positive , n ( % )"
-1,"egfrmdrd , ml / min / nmbr . nmbr mnmbr bsa"
-1,"weight > nmbr kg , n ( % )"
-1,multiple diagnoses
-1,cholecystitis chronic
-1,baseline % bsa involvement
-1,> nmbr corticosteroids or immunosuppressants
-1,"history of atrial arrhythmia , n ( % )"
-1,chronic pulmonary disease
-1,"> nmbr , obesity class nmbr"
-1,congestive heart failure ( definite )
-1,average dose ( mg / week )
-1,urinary albumin : creatinine ratio *
-1,previous pci ( % total )
-1,highest killip classiciation pre - pci
-1,"edss stratification , no . ( % )"
-1,exenatide no . of events / total no . ( % )
-1,"method used to diagnose the incident pulmonary embolism , no . ( % )"
-1,blood glucose
-1,rf or acpa positive
-1,congestive heart failure — no . ( % )
-1,mean ucsd - sobq score * ( sd )
-1,morphine use for index event / pci
-1,"albumin - to - creatinine ratio ,"
-1,"region , north america"
-1,medical therapy alone
-1,continuation
-1,nmbr ( fevi nmbr - < nmbr % pred )
-1,anmbrs - hydroxy -
-1,qrs interval > nmbr msec — no . ( % )
-1,streptokinase
-1,haq - di improvement > nmbr . nmbr
-1,"baseline cv treatment , n ( % ) y"
-1,"adalimumab croup , n / n ( % )"
-1,apob ( week nmbr )
-1,"systemic arterial hypertension , n ( % )"
-1,"reversibility to salbutamol , %"
-1,"overall , male : female"
-1,nmbr p value
-1,evolocumab ( nmbr mg )
-1,bifurcation lesion
-1,time from onset of symptoms to randomization — days
-1,thiazide at last follow - up
-1,% change median baseline crp > nmbrmg / l
-1,"blood pressure systolic , mm hg"
-1,"hf hospitalizations , median ( iqr )"
-1,history of carotid artery disease
-1,history of diabetes mellitus
-1,prior treatment historynmbr
-1,patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +
-1,interactionnmbr
-1,no history of migraine
-1,mild ( gold nmbr )
-1,iii : fevnmbr > nmbr % - < nmbr % predicted
-1,cat score category
-1,"baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr , nmbr"
-1,statin only
-1,drug therapy at admission 一 no . ( % ) aspirin
-1,fatty acid profile
-1,"residual deep - vein thrombosis , no . ( % )"
-1,"unstable angina , n ( % )"
-1,completed trial
-1,"duration of symptoms , h"
-1,"% predicted ” fev , at baseline , % *"
-1,aspirin dose at randomization
-1,normoglycemia^
-1,race / ethnicity
-1,oral antidiabetic drugs
-1,"ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )"
-1,cerebral embolism
-1,fevnmbr / fvc prebronchodilatort
-1,previous use of antiplatelet drugs
-1,laba non - users
-1,thiazolidinedione based
-1,chronic respiratory failure
-1,coronary artery disease history
-1,current prescribed medications
-1,current weekly alcohol use ( % )
-1,calcium ( mmol / l )
-1,region ( pooled )
-1,bdmard - naive
-1,general andthoracic epidural
-1,first co - primary outcome
-1,"cvd , mi , stroke , or recurrent ischemia - urgent revascularization , or hospitalization for unstable angina"
-1,"age at enrolment , years"
-1,not available
-1,use of antiplatelet agents^
-1,aspirin or thienopyridines ( % )
-1,baseline trig > nmbr millycerides g / dl
-1,baseline anti - hypertensive usea
-1,"intent - to - treat population , n ( % )"
-1,"dyslipidaemia and hypertension , n ( % )"
-1,saxa nmbr . nmbr mg ( n = nmbr )
-1,estimated response rate and odds ratio
-1,first loading dose
-1,ex - smokers nmbr
-1,atrial fibrillation ldl cholesterol level
-1,duration of
-1,"weight ab , %"
-1,race or ethnic group — no . / total no . ( % ) f
-1,loop at enrollment
-1,"current cigarette use , n ( % )"
-1,central europe
-1,atopic ( based on phadiatop test )
-1,"baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr change from baseline to nmbr weeks"
-1,kccq ( nmbr months )
-1,mean eq - nmbrd response ( nmbr % ci )
-1,tp vs no tp
-1,mitral insufficiency
-1,r nmbr mg + fa
-1,total study population
-1,subacute ( nmbr - nmbr days )
-1,"assoc , with corrected congenital shunts"
-1,spinal fractures
-1,"multivessel disease , n ( % )"
-1,normoalbuminuria or microalbuminuria
-1,low ( no risk factor )
-1,hospitalisation for chf within nmbr years of randomisation
-1,rec . ischemia due to ecg changes
-1,event / patients ( nmbr / pt - y )
-1,calcium - channel antagonists
-1,angiotensin receptor
-1,"dbp , mean ( sd ) , mm hg glycaemic parameters"
-1,priorother ( predefined ) medical conditions
-1,"tnmbr lesion volume , mmnmbr"
-1,african - american / african heritage ( n = nmbr )
-1,new anti - anginal therapy
-1,smoking : current smoker
-1,total cataract
-1,no . of patients ( % )
-1,ami nmbr mg n = nmbr
-1,baseline lvef
-1,change from baseline stage nmbr ckd
-1,indacaterol group ( n = nmbr )
-1,iv : fevnmbr < nmbr % predicted
-1,education nmbr - nmbr years
-1,waist circumference
-1,hispanic — no . ( % )
-1,> nmbr . nmbr ml / min / nmbr . nmbr mnmbr
-1,"rituximab , n = nmbr"
-1,"stroke , n ( % )"
-1,family history of premature
-1,"change in bp , mm hg"
-1,nonfatal ischemic stroke
-1,pci delay due to low risk
-1,prior percutaneous coronary intervention
-1,oral anticoagulant agent
-1,alcohol intake ( a )
-1,hbanmbrc subgroups
-1,history of atherosclerotic vascular disease — no . ( % ) §
-1,renal function : creatinine clearance
-1,mercaptopurine
-1,transient monocular blindness
-1,"nyha functional class , n ( % )"
-1,entire cohort gender
-1,inhaled §
-1,patient global assessment of pain ( vas nmbr - nmbr mm )
-1,rituximab ( nmbrxnmbr mg ) + mtx ( n = nmbr )
-1,peripheral artery revascularization without amputation
-1,"other cause , n ( % )"
-1,immunosuppressants and antimalarials only
-1,* * positive stress test
-1,aspirin use at baseline
-1,randomisation scheme
-1,ala carriers
-1,arterial hypertension — no . ( % )
-1,"bmi ( median , iqr ) , kg / mnmbr"
-1,alternative disability
-1,non - hdl cholesterol / apob ( ratio )
-1,other risk factors
-1,hf hospitalization or cardiovascular death
-1,no revascularization for index acs event
-1,p - value for variance
-1,"apo b , mean ( sd ) , mg / dl"
-1,at ldl - c ( bq ) goal * at baseline - no . ( % )
-1,missing data initial diagnosis — no .
-1,aspirin at enrollment
-1,prespecified analysis
-1,k ( rate )
-1,r | r ' ' ' ( nmbr % ci )
-1,glyburide dose duringthe study ( mg )
-1,ptca / cabg
-1,"score , %"
-1,"seizure types reported during baseline , b n ( % )"
-1,biologic therapeutic failure
-1,simva ( „ = nmbr }
-1,"partial mayo score , mean ( sd )"
-1,selected clinical characteristics — no . / total no . ( % )
-1,". nmbr . nmbr ml / s / mnmbr ( nmbr ml / min / nmbr . nmbr mnmbr ) , n ( % )"
-1,"prior use of conventional dmards only ( biologic - nai ' ve ) , n ( % )"
-1,"family history , n ( % )"
-1,patients with diabetes mellitus
-1,thiazolidinedione ( includes pioglitazone )
-1,corticosteroids and antimalarials only
-1,total pack - years mean ( sd )
-1,medications at study entry — no . / total no . ( % )
-1,gold iii - iv
-1,reason for enrollment in active a
-1,asia / australia / new zealand
-1,octave induction nmbr
-1,"tachyarrhythmias , n ( % )"
-1,europe n z nmbr
-1,atrial fibrillation alone ) ;
-1,supraventricular tachyarrhythmias ( incl . atrial
-1,previous cerebrovascular event
-1,stroke — no . ( % )
-1,"bronchodilator response , ml"
-1,nmbr ( fevi ^nmbr % pred )
-1,mental component
-1,apo a - l ( g / l )
-1,veflonzumao
-1,pfo with large shunt and atrial septal aneurysm
-1,classification of index venous thromboembolism — no . ( % )
-1,fevnmbr at baseline
-1,incidence rate per nmbr person - years
-1,time of randomization ( interaction : p = nmbr . nmbr )
-1,"chronic renal failure , n ( % )"
-1,both deep - vein thrombosis and pulmonary embolism
-1,myocardial infarction without st - segment elevation — no . ( % )
-1,pooled eze / simva
-1,other sglt - nmbr inhibitor
-1,clavicle fracture
-1,"ecg abnormality ( resting ) , %"
-1,musculoskeletal stiffness
-1,"psoriatic arthritis , %"
-1,"medication prior to admission , ( % )"
-1,death / st
-1,bdi focal score
-1,time to randomisation [hours] ( interaction : p = nmbr . nmbr )
-1,laboratory examination
-1,placebo patients with events
-1,"organ system involvement , no . ( % )"
-1,enalapril lcznmbr ( n = nmbr ) ( n = nmbr )
-1,high - dose statin
-1,peripheral
-1,ldl cholesicrol ( minol / l )
-1,"hispanic / latino ethnicity , n ( % )"
-1,nmbr - nmbr drinks
-1,aborted cardiac arrest
-1,baseline crp < nmbrmg / l
-1,relative risk reduction ( nmbr % cl ) percent
-1,unprotected left main stented
-1,catheterization performed for qualifying event
-1,fraction ( % )
-1,nmbr % ci for difference
-1,"index event to randomization , median ( iqr ) , h"
-1,inclusion criteria — no . ( % )
-1,normal hscrp
-1,^nmbr - cell function — % §
-1,"previous tnf - antagonist use , n ( % )"
-1,depressed only
-1,acute infection without septic shock
-1,mtss units
-1,previous statin use
-1,mean ( s . d . ) calculated ldl cholesterol
-1,nmbr % confidence interval
-1,type of concomitant statin by daily dose
-1,statin with ezetimibe
-1,history of ml or ischemic stroke
-1,within nmbr h
-1,placebo n = nmbr n ( % )
-1,nyha class not reported
-1,neither uh or lmw heparin
-1,"fpg tx difference vs pbo , median change from baseline ( se ) nmbr"
-1,iglarlixi ( fixed - ratio combination )
-1,previous congestive heart failure
-1,periostin ( ng / ml )
-1,belimumab nmbr mg sc ( n nmbr )
-1,"glycatedhemoglobin category , %"
-1,canvas - r
-1,"waist circumference , cm mean ( sd )"
-1,tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr )
-1,"africa , asia , or the middle east"
-1,history of gestational diabetes mellitus — no . ( % of women )
-1,non - black race ( n = nmbr vs nmbr )
-1,community hospital
-1,"not - japan n = nmbr , nmbr"
-1,stage > nmbr chronic kidney disease ( % )
-1,nmbr - hr plasma glucose — mg / dl
-1,not at goal
-1,"concomitant aminosalicylates , n [ % ] concomitant corticosteroids , n [ % ] mayo score , mean [sd]"
-1,baseline fecal caicrctectin
-1,hospitalization for unstable angina
-1,patients having exacerbation
-1,"regular alcohol consumption per week , no . ( % )"
-1,improving anemia bsl hb < nmbrg i - nmbr ; yr nmbr > nmbrg i - nmbr
-1,qualifying peripheral arterial disease
-1,"previous bypass surgery , n ( % )"
-1,anthropometric characteristics
-1,"baseline fevnmbr , l *"
-1,"nmbr - lead ecg heart rate , beats / min"
-1,aspirin + dipyridamole ( n = nmbr )
-1,patients entering pt period n = nmbr
-1,surgical technique
-1,psoriatic arthropathy
-1,with alogliptin nmbr mg
-1,"revascularisation but no antiplatelets , lipid - lowering agents , or p blockers"
-1,pfo with large shunt without atrial septal aneurysm
-1,clinical and patient - reported characteristics at baseline and randomization
-1,or ( unadjusted )
-1,unknown or missing
-1,reported high cholesterol ' !
-1,syndecan - nmbr ( ng / ml )
-1,long - acting
-1,use of antiarrhythmic agent
-1,"egfr using cg / mdrd formulae , % of patients"
-1,baseline body mass index
-1,swollen - joint count ( of nmbr joints )
-1,"region , n ( % )"
-1,> nmbr - nmbr mg / week
-1,hypertensionnmbr ( % )
-1,psa - modified total shs
-1,minor ischaemic stroke
-1,annualized rate ind / gly sfc
-1,sulfasalazine
-1,mean change at week nmbr
-1,"acpa positive ( > nmbr iu / ml ) , n ( % )"
-1,history of strokenmbr
-1,long - term warfarin ( n - nmbr )
-1,"crp ( mg / l ) , median ± sd"
-1,obese ( > nmbr kg / mnmbr )
-1,facit - fatigue . mean nmbrsd ( range nmbr - nmbr )
-1,infarct location ( interactsn $ : p = nmbr . nmbr )
-1,not hospitalized for heart failure in the year prior to study enrollment
-1,"calcification , n ( % )"
-1,all ischemic stroke
-1,"rosuvastatin , n ( % )"
-1,hormone replacement therapy use
-1,older than nmbr years
-1,rolofylline
-1,"apo a - nmbr , mean ( sd ) , mg / dl"
-1,long - term antiplatelet therapy
-1,prior bypass graft surgery
-1,"bone erosion ( judged by physician ) , n ( % )"
-1,triglyceride ( mm
-1,"cigarettesmoking , %"
-1,pentraxin - nmbr ( ng / ml )
-1,tnfi exposed
-1,"history of atrial fibrillation , n ( % )"
-1,asa or antiplatelet agent
-1,ischemic stroke ( vs . tia )
-1,men : women ( % )
-1,patients not treated with statins ( n = nmbr )
-1,severe renal impairment
-1,om nmbr mg / aml nmbr mg / hctz nmbr mg
-1,history of atrial fibrillation
-1,corticosteroid use at baseline
-1,sedentary
-1,no . of patients ( indacaterol / placebo )
-1,insulin plus oral
-1,"> nmbr . nmbr , n ( % )"
-1,"ics use , %"
-1,"age category ( years ) , n ( % )"
-1,atherosclerotic disease ( % )
-1,"copd duration , y"
-1,thrombolytic therapy
-1,"acpa positive , n ( % )"
-1,"baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr , nmbr change from baseline to nmbr weeks"
-1,acei vs . non - acei
-1,risk factors for atherosclerosis
-1,bifurcation lesion with side branch $ nmbr . nmbr mm stented
-1,"fevi , % predicted *"
-1,heart rate at rest in the supine position ( beats / min )
-1,feno nmbr mg / eze nmbr mg ( n = nmbr )
-1,"mean ( s . d . ) total pcsknmbr , ng / ml"
-1,"baseline cdai score , mean ( sd )"
-1,"severity of copd , combined assessment , n ( % )"
-1,ambulance ( % )
-1,estimated means and difference
-1,concomitant medication ( % )
-1,qualifying atherosclerosis
-1,ada impaired fasting glucose
-1,"death , q wave mi or ischemia - driven revasc"
-1,stented vessels
-1,"diabetes duration , n ( % )"
-1,"tender - joint count , of nmbr joints examined"
-1,verapamil sr
-1,thiazolidinedione 一 no . ( % )
-1,"difference , % median"
-1,"edema , ( % )"
-1,"medications on admission , %"
-1,"rf positive ( > nmbr iu / ml ) , n ( % )"
-1,worsening heart failure
-1,previous limb or foot amputation
-1,alcohol consumption ( % )
-1,"uacr , mgg nmbr ( gm )"
-1,om nmbr / aml nmbr /
-1,hypertension history
-1,"swollen - joint count , of nmbr joints examined"
-1,"racial group , n ( % )"
-1,nmbr to < nmbr ml per nmbr - nmbr mnmbr
-1,risk factors
-1,deep vein thrombosis only
-1,within last nmbr d
-1,"egfr at baseline , nmbr ml / min ( % ) b"
-1,"low - density lipoprotein cholesterol , mean ( sd ) , mmol / l"
-1,intermediate
-1,duration of hypertension ( months )
-1,wapnmbrc ( ng / ml )
-1,"left circumflex artery , n ( % )"
-1,"fpg , median ( ql , qnmbr ) , mmol / l"
-1,ischaemic cause
-1,total cholesterol > nmbr mg / dl
-1,intention - to - treat
-1,enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr )
-1,in - stent restenosis
-1,high risk without atherosclerotic vascular disease +
-1,priorother ( not predefined ) medical conditions
-1,reteplase / abciximab - facilitated pci ( n = nmbr )
-1,"established atherosclerotic disease , n ( % )"
-1,"concomitant drugs , %"
-1,after amendment ( % )
-1,antianginal medications
-1,eular good response
-1,ls means difference ( nmbr % ci ) nmbr
-1,prior stroke ( before index event )
-1,interval from onset of symptoms
-1,low risk ( ri = nmbr - nmbr )
-1,patients with prior copd - related
-1,"duration of ra , mean ( min - max ) ( yrs )"
-1,myocardial infarction / cabg / pci < nmbr years
-1,dilatative
-1,ncep atp iii risk factors
-1,"change from baseline , adjusted mean ( nmbr % ci )"
-1,antiarrhythmic therapy
-1,mean ( sd ) tender joint count *
-1,• ? sd ml / min
-1,"renal function ( egfr , ml / min / nmbr . nmbr mnmbr , according to mdrd ) , n ( % )"
-1,serum creatinine
-1,first - recorded event ; no . ( and % ) of patients
-1,"fevi , l , mean ( sd ) nmbr"
-1,male / female
-1,unknown ( none of the above )
-1,baseline creatinine clearance
-1,drug - eluting stent — no . ( % )
-1,"mean disease duration , years"
-1,spacer use during the study
-1,non - end - stage renal dysfunction
-1,"duration of epilepsy , years , mean ( sd )"
-1,blood pressure control
-1,medications through day nmbr
-1,nyha class ii ( n = nmbrlnmbr )
-1,nadroparin
-1,past smoking
-1,nmbr - min walk distance ( m )
-1,biologics user
-1,other medical history — no . ( % )
-1,blood pressure ( % )
-1,sfc nmbr mg / nmbr mg
-1,cardioversion in previous nmbr wk
-1,nmbr - nmbr ( low risk )
-1,hypercholesterolemia ( > nmbr mg / dl )
-1,use of medication at baseline — no . ( % )
-1,"revascularization during index hospitalization , %"
-1,"gender , %"
-1,"brv dosage , mg / d"
-1,not rando . in na *
-1,"age , median ( iqr ) , years"
-1,oral antidiabetic drugs / insulin ( % / % )
-1,risk factors specified as inclusion criteria — no . ( % ) f
-1,asian or pacific islander
-1,reversibility : > nmbr - < nmbr %
-1,average daily dose ( % of target ) *
-1,target - vessel revascularization
-1,severity of copd — no . ( % ) f
-1,"lvef , % , median ( iqr )"
-1,"fevnmbr / fvc , post - albuterol , %"
-1,esrd saxa nmbr . nmbr mg ( n = nmbr )
-1,time since diagnosis of pah — yrf
-1,"right coronary artery , n ( % )"
-1,younger patients ( agednmbr years )
-1,fvc ( l ) proportion taking pulmonary medications ( % ) b
-1,vein graft stented
-1,qualifying stroke
-1,difference vs . pbof mean ( s . e . ) t
-1,oral hypoglycaemics only
-1,baseline history of vascular disease ( % )
-1,prednisone - equivalent dose — mg
-1,aspirin alone group no of events / total n ( % )
-1,known thrombophilic condition — no . ( % )
-1,blood eosinophil proportion ( % )
-1,( a ) demographics
-1,cox bsl + yr nmbr hbd
-1,direct thrombin inhibitors
-1,"body - mass index - kg / mnmbr , median ( iqr )"
-1,acute coronary syndrome
-1,"waist circumference , cm ( sd )"
-1,moderate impairment ( egfr nmbr - nmbr )
-1,"use of supplemental oxygen , n ( % )"
-1,unadjusted or ( nmbr % ci ) p value
-1,rarely / never
-1,st - elevation myocardial infarction
-1,woscops
-1,"age ( yrs ) , mean *"
-1,non - ischaemic cardiomyopathy
-1,"history of myocardial infarction , n ( % )"
-1,cardiac catheterization
-1,"estimated glomerular filtration rate , n ( % )"
-1,no aspirin or ppi
-1,inadequate response
-1,"drinking , n ( % )"
-1,non - ics +
-1,endovascular
-1,"sbp ( mmhg ) , mean ± sd"
-1,hormone - refractory prostate carcinoma
-1,drug - eluting stent implanted ( at least one )
-1,pah origin / cause
-1,experience
-1,chinese subgroup
-1,history of cardiovascular events
-1,disease duration : < baseline mean
-1,physician ' s global assessment . mean nmbr sd
-1,glycated hemoglobin < median
-1,"% stenosis , as assessed by core laboratory"
-1,upper respiratory tract infection
-1,antibiotics * *
-1,normoalbuminuria — no . / total no . ( % )
-1,aggressive ( nmbr )
-1,patients with specific disease characteristics
-1,work and school
-1,activity ( nmbr - nmbr vas )
-1,age ( yrs ) nmbr - nmbr
-1,afcaps /
-1,clinical presentation of vte at initial diagnosis — no . ( % )
-1,aspirin < nmbr hours
-1,glucosamine ( n = nmbr )
-1,neither ace inhibitor nor arb
-1,previous coronary intervention
-1,time since diagnosis of diabetes — no . ( % )
-1,"egfr ( ckd - epi , cystatinc ) , ml / min / nmbr . nmbr mnmbr , n ( % )"
-1,dyslipidaemia and hypertensiont
-1,"presence of erosions , n ( % )"
-1,"sitting pulse , bpma"
-1,post - cabg
-1,"cigarette smoking , mean pack - years ( sd )"
-1,> nmbr - nmbr ( moderate risk )
-1,"triglycerides tx difference vs pbo , ls mean % change from baseline ( se )"
-1,nmbr - nmbr / nmbr - nmbr mm hg
-1,body mass indexa < median
-1,dmard user
-1,admission for hf in previous year
-1,duplex ultrasonography
-1,all of the colon
-1,"nmbr - nmbr - nmbr , obesity class nmbr"
-1,coronary artery disease — no . / total no . ( % )
-1,body mass index ; mean + sd ( kg / m )
-1,> nmbr previous venous thromboembolisms ( % )
-1,remission at maintenance - trial entry — no . ( % )
-1,improved
-1,treatment stratum^ :
-1,"red blood cell counting , nmbr / l"
-1,"nmbr - wk kaplan - meier rate , %"
-1,"continuous variables , mean ( sd )"
-1,intensified nmbr months ( n - nmbr )
-1,elevated troponin
-1,smoking history : current smoker
-1,jbs - nmbr primary prevention onlynmbr
-1,( se]tf hdl - c
-1,baseline hs - crp tertiles ( mg / i]
-1,not reported
-1,diabetes and currently on an oral hypoglycaemic agent orinsulin
-1,standard care n ( % ) / nmbrpy
-1,apremilast
-1,anterior myocardial infarction — no . ( % )
-1,oxcarbazepine
-1,mildly impaired
-1,incidence [n / n ( rate per nmbr person - years ) ]
-1,blood pressure at target level ( % ) §
-1,egfrmdrd ， ml - min - nmbr - nmbr . nmbr m_nmbr
-1,benign prostatic hyperplasia
-1,"> nmbr erosion , n ( % )"
-1,body - mass index > nmbr
-1,"alcohol consumption , n ( % )"
-1,rhabdomyolysis or myopathy
-1,treatment arm
-1,concomitant therapies at hospital discharge
-1,"hbanmbrc in patients with baseline hbanmbrc > nmbr % ( > nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )"
-1,specific risk of bleeding^
-1,number resulting in emergency department visit
-1,elevated troponin ( > nmbr . nmbr pg / l )
-1,hi ) ah ( % )
-1,number of exacerbations
-1,cpk > nmbr times uln
-1,glucosamine + chondroitin sulfate ( n = nmbr )
-1,serum trap - nmbrb ( u / liter )
-1,sex ( male ) ethnic origin
-1,no corticosteroids or immunosuppressants
-1,"lvef within nmbr months , %"
-1,ls mean change from baselinenmbr
-1,uric acid ( mg / dl ) creatinine clearance ( ml / min per nmbr . nmbr mnmbr )
-1,weight — kg ( median )
-1,non - black
-1,myocardial infarction
-1,duration of assigned regimen before surgery
-1,asian / black / white / hispanic / other ( % ) clinical parameters
-1,> nmbr mg / dl eze / simva nmbr = nmbr }
-1,risk factors for pad
-1,"baseline hemoglobin , median ( iqr , g / dl )"
-1,"insulin , iu / ml , median ( qnmbr , qnmbr )"
-1,prior percutaneous coronary intervention — no . ( % )
-1,other bdmard §
-1,icd therapy ( n =
-1,apo a - l ( mg / dl ) - mean ± sd
-1,with alogliptin nmbr . nmbr mg ( n nmbr nmbr )
-1,symptomatic pad of lower extremities *
-1,pfor heterogeneity
-1,severe impairment ( egfr < nmbr )
-1,previous use of amiodarone
-1,levetiracetam
-1,peri - op beta - blockers : no ( n = nmbr )
-1,patient global assessment ( nmbr - nmbr mm vas )
-1,"background treatment , n ( % )"
-1,"high titre ( > nmbr times of uln ) , n ( % )"
-1,"no corticosteroid , no imm"
-1,greater than or equal to nmbr mm hg
-1,antiarrhythmic agent
-1,white not of hispanic origin
-1,cause of dvt or pe — no . ( % )
-1,sulfonylurea — no . ( % )
-1,mean preoperative abpi of the index
-1,met criterion at finalt
-1,"orthopnea , ( % )"
-1,total mortality
-1,"pace , no . ( nmbr )"
-1,non - caucasian simva
-1,high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr )
-1,overall population
-1,all randomized women
-1,respiratory - related^
-1,treated vessel - native coronary
-1,< nmbr . nmbr mmol / liter estimated gfr
-1,prior ms treatment with ifn - beta or
-1,no hemoconcentration hemoconcentration
-1,"clopidogrel , nmbr - mg loading dose"
-1,"body weight ( kg ) , mean ( s . d . )"
-1,dasnmbr ( c - reactive protein )
-1,blood pressure ; pbo y patients with diabe teristics ( ncep atp i
-1,patients with normoalbuminuria at baseline
-1,stenting plus medical therapy ( n = nmbr )
-1,"mean - sd change in pre - bronchodilator fevnmbr , l"
-1,change from baseline in % predicted fevnmbr
-1,patients with uncomplicated events ( p = o - nmbr 十 )
-1,"post - bronchodilator percent of predicted fevnmbr , % ( sd )"
-1,comparison with baseline
-1,previous ml ( interaction : p = nmbr . nmbr )
-1,cardiac glycosides
-1,"previously taken any other dmards , n ( % )"
-1,"crp ( normal range : nmbr - nmbr . nmbr ) , mg / dl , mean ( sd )"
-1,modified rankin score
-1,a a ( nmbr ( % )
-1,"mean involved bsa , % ( nmbr % ci )"
-1,other defined
-1,without ( n = nmbr nmbr )
-1,treatment with drugeluting stent
-1,nmbr - nmbr ( moderate )
-1,angiography
-1,sbp / dbp $ nmbr / $ nmbr mmhg
-1,non - extensive
-1,electrocardiographic findings — no . ( % )
-1,beta receptor antagonist
-1,baseline triglycerides by quintiles
-1,median albumin - to - creatinine ratio ( interquartile range )
-1,< nmbr regardless of historical count
-1,stent type
-1,nmbr vessel pci
-1,body mass index subgroups
-1,pioglitazone
-1,b - agonists ( long - acting ) a
-1,"tg ( mg / dl ) , median ± sd"
-1,risk factors for recurrent vte — no . ( % ) f
-1,caucasian eze / simva
-1,nmbr - < nmbr mvmin
-1,"pioglitazone ( n = nmbr , nmbr )"
-1,"time from onset to medication , h , mean ± sd"
-1,baseline insulin daily dose / kg
-1,mean — ml / min / nmbr . nmbr mnmbr of body - surface area
-1,telmisartan group ( n = nmbr )
-1,total cholesterol ( mmo nmbr / nmbr )
-1,african - latin american
-1,more than nmbr lesions per vessel
-1,"fpg , mg / dl ( mmol / l )"
-1,> = nmbr % and < nmbr % ( > = nmbrand < nmbr mmol / mol )
-1,no . of events / total no . ( % )
-1,ind nmbr mg q . d . n = nmbr
-1,smoking history : ex - smoker
-1,troponin level
-1,duration of copd — days^
-1,"other antiplatelet agents , n ( % )"
-1,thienopyridine at randomization
-1,bmi ( kg / mnmbr ) cardiovascular history
-1,controllednmbr — no . ( % )
-1,sulfonylurea derivatives
-1,score nmbr - nmbr
-1,radial access site
-1,use of parenteral antithrombotic agents — no . ( % )
-1,immunosuppressant ( with or without corticosteroid )
-1,ml with st - segment elevation
-1,remission in overall population
-1,v / hctz
-1,pulse ( beats / min ) cholesterol ( mmol / l )
-1,number of participants
-1,beta - carotene
-1,hemispheric stroke n = nmbr
-1,pci for index mi ( % )
-1,absolute fvc decrease > nmbr %
-1,hemoglobin ( gl ' )
-1,"low ( nmbr - nmbr ) ( n = nmbr , nmbr ; nmbr % )"
-1,"> nmbr % and < nmbr % predicted arr ( n = nmbr , nmbr )"
-1,"duration from hospital admission to pci , h ( median , iqr )"
-1,prednisone
-1,enalapril dm = nmbr non - dm = nmbr
-1,entire cohort
-1,intravenous loop diuretics !
-1,peripheral revascularization
-1,"no ischemia ( n = nmbr , nmbr )"
-1,fp / sal nmbr / nmbr pg ( n = nmbr )
-1,antithrombotic use
-1,p lace of randomization ( interaction : p = nmbr . nmbr )
-1,km event rate ( % )
-1,revascularisation + antiplatelets + lipid - lowering agents + p blockers
-1,betanmbr selective
-1,iii and iv ejection fraction
-1,antiarrhythmic drug
-1,"median time since diagnosis * ( range ) , yr"
-1,"bmi , kg / mnmbr uac , no . ( % )"
-1,"high - density lipoprotein cholesterol , mean ( sd ) , mmol / l"
-1,serum potassium ( mmol / l )
-1,gissi prevention nmbr / nmbr - nmbr / nmbr
-1,nyha class nmbr or higher
-1,concomitant medication — no . ( % )
-1,"history of major cardiovascular disease , n ( % )"
-1,versus tiotropium nmbr pg
-1,nyha functional class at screening
-1,time from most recent qualifying
-1,"use of loop diuretics , n ( % )"
-1,"glycemia , mg / dl"
-1,"duration of asthma , years"
-1,bisphosphonates
-1,cardiovascular disease history
-1,no pci or cabg — no . ( % )
-1,any statin ( with / without llt )
-1,associated with drug / toxin
-1,non - diabetic patients
-1,baseline hbanmbrc in nmbr classes
-1,coronary artery disease — no . ( % ) : ! :
-1,"patients with egfr nmbr > nmbr to < nmbr ml / min / nmbr . nmbrmnmbr , n"
-1,"baseline corticosteroidst ( mean dose : nmbr . nmbr mg / day ) , n ( % )"
-1,"vka , only reason"
-1,reported in ecrf
-1,"evidence or thombus , n ( % )"
-1,prior aortocoronary bypass surgery 一 no . ( % )
-1,regional anaesthesia
-1,events / n
-1,anti - coagulants - no . ( % )
-1,other antihypertensive
-1,thrombus - containing lesion
-1,sgrq total score ( week
-1,americas ( n = nmbr )
-1,placebo - adjusted mean difference in % hbanmbrc ( nmbr % ci ; [ p value] )
-1,"serum total cholesterol ( mmol / l ) , mean ( sd )"
-1,creatinine level
-1,"heart rate , mean ( sd ) [range] , beats / min"
-1,cv death / mi / stroke / ucr
-1,irbesartan
-1,time from acs to randomization
-1,"time intervals , h"
-1,history of stroke or tia
-1,"medications at timing of randomization , n ( % )"
-1,cv death or hf hospitalization n
-1,cvd events
-1,nmbr - point mace
-1,low - dose aspirin use
-1,"moderate / severe exacerbations , itt population ; n ( % )"
-1,lp ( a ) §
-1,hbanmbrc levels
-1,weekly
-1,> nmbr ( high risk )
-1,"percentage of time in therapeutic inr range , mean ( sd )"
-1,> nmbr prior myocardial infarction — no . ( % )
-1,threatened abrupt vessel closure
-1,"prior therapy , %"
-1,"duration of pci ( min ) , median n ( iqr )"
-1,"age > nmbr y , n ( % )"
-1,"van der heijde mtss , mean ( sd )"
-1,form / bud
-1,no . of patients ind / gly sfc
-1,missing hb at yr nmbr
-1,within nmbr h after
-1,left ventricular ejection fraction < nmbr %
-1,mestizos
-1,ankle - brachial index < nmbr . nmbr
-1,p - value ( anova )
-1,patients with > nmbr exacerbations resulting in emergency department visit
-1,difference in change
-1,established atherosclerotic cardiovascular disease
-1,other vascular disease
-1,black race and ss > nmbr ( n = nmbr vs nmbr )
-1,qualifying mi : stemi
-1,coenzyme qnmbr
-1,history of a transient ischaemic attack
-1,known tiromtcch * c ccndifeon
-1,total patients
-1,"periprocedural medications , n ( % ) clopidogrel , nmbr mg *"
-1,swollen joint count ( nmbr - nmbr possible joints )
-1,prior amputation
-1,"weight , kg , median ( range )"
-1,arterial area ( mmnmbr )
-1,statin + fibrate or
-1,"presence of enthesitis , n ( % )"
-1,"nyha class ( when patient was last in stable condition before admission ) , %"
-1,"history of second prior mi , n ( % )"
-1,ischaemic ( n = nmbrlnmbr )
-1,sbp > nmbr mmhg and / or dbp > nmbr mmhg
-1,"caucasian , n ( % )"
-1,use of cardiac medication *
-1,pioglitazone ( n = nmbr )
-1,hdl cholesterol < nmbr ( men ) or < nmbr mg / dl ( women )
-1,cardiac valvular disease
-1,randomized to receive vitamin e
-1,indication for index procedure
-1,"total c ( mmol / l , mean )"
-1,left ventricular ejection fraction — %
-1,non - reversible ( % )
-1,peripheral neuropathy
-1,acuity major
-1,standard therapyy ( n = nmbr )
-1,acqnmbr score
-1,baseline cardiovascular disease
-1,myalgia
-1,"time since as diagnosis , mean ( sd ) years"
-1,"albumin / creatinine ratio - mg / mmol , median ( iqr )"
-1,change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr
-1,venous insufficiency
-1,pdqol scale
-1,baseline nmbr - asa
-1,"current medication , n ( % )"
-1,baseline pulmonary medication
-1,median ( range )
-1,mean ( sd ) aqlq
-1,humerus fracture
-1,"high - density lipoprotein cholesterol tx difference vs pbo , ls mean % change from baseline ( se )"
-1,clopidogrel pretreatment duration
-1,lower than normal range — % ^
-1,months ( log - transformed )
-1,saba reversibility
-1,previous stroke or tia
-1,"high disease activity : > nmbr . nmbr , n ( % )"
-1,alcohol use ( % )
-1,"americas , excluding us"
-1,acitretin
-1,stratification variables
-1,factor v leiden or prothrombin mutation
-1,simplified disease activity index score
-1,diabetic kidney disease
-1,prior coronary artery disease yes
-1,intravenous nitrates
-1,toast classification
-1,£ nmbr . nmbr % * *
-1,yes previous revascularization
-1,no . / nmbr person - yr
-1,p - blocker intake at randomisation ( n = nmbro )
-1,> l : nmbrhrs : min ( n = nmbr )
-1,oral glucocorticoid use at baseline — no . ( % ) : t
-1,adjusted mean change
-1,age at completion of highest level of
-1,age group 一 ％
-1,combined macro + micro
-1,race / ethnicity chinese
-1,history of more than nmbr prior mi ( % )
-1,physical activity §
-1,"systolic blood pressure , mm hg < nmbr"
-1,"diagnoses / risk factors , n ( % )"
-1,medication effects
-1,insulin glargine
-1,"mean age , years ( sd )"
-1,diuretic thiazide
-1,paclitaxel
-1,"total back pain , mean ( sd )"
-1,"previous intolerance of infliximab , n ( % ) *"
-1,"uae ( p , g / min )"
-1,any statin versus no statin at randomization
-1,adalimumab group ( n = nmbr ) t
-1,"hgb , g / dl < nmbr men , < nmbr women"
-1,fracture during follow - up
-1,biguanides
-1,> nmbr . nmbr kg / mnmbr hypertension :
-1,"values are expressed as percentages unless otherwise indicated . bmi , body mass index ; cabg , coronary artery bypass ischemic attack ; nsaids , nonsteroidal anti - inflammatory drugs , sbp , systolic bp ; dbp , diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications ."
-1,aminosalicylates
-1,prediabetes — no . ( % ) nmbr
-1,history of pci with stenting
-1,"brain volume , cmnmbr"
-1,swollen joint count ( nmbr - nmbr )
-1,no . of strokes ( % )
-1,demographic and medical variables
-1,australia / nz
-1,no . of events / patients
-1,"chd history , n ( % )"
-1,jsn score ( nmbr - nmbr )
-1,ascvdor > nmbr cv risk factors
-1,previous transient ischemic attack
-1,number of stent = l or nmbr or nmbr
-1,ischemic stroke with hemnrrhnaic cnnversinn
-1,chronic stable angina
-1,fenofibric acid + low - dose statin
-1,daily iglar dose at week nmbr ( u )
-1,anticholinergic
-1,contrast volume
-1,rituximab ( nmbrxnmbr mg ) + mtx
-1,> nmbr mg / dl simva nmbr = nmbr]
-1,glucagon - like peptide - nmbr agonist
-1,"acrnmbr response at week nmbr , n ( % )"
-1,alcohol intake ( + ) ( % )
-1,# of prior tnfi among non - tnfi naive
-1,remission
-1,"triglycerides ( median , iqr ) , mg / dl"
-1,total antihypertensive use
-1,anmbrc distribution ( % )
-1,middle third
-1,symptom score ( sd )
-1,atorvastatin factorial study
-1,former / non - drinker
-1,electrocardiographic findings at randomization
-1,lumbar spine bmd t - score
-1,multiple ( nmbr + ) chd risk
-1,"hyperlipidemia , n ( % )"
-1,place of randomization
-1,beta - blocker % target dose
-1,"left circumflex , n ( % )"
-1,ranolazine vs . placebo km failure rate
-1,"biomarker high ( periostin > nmbrng / ml or blood eosinophils > nmbrcells per pl ) , na"
-1,at or above the median
-1,indacaterol - glycopyrronium group ( n = nmbr )
-1,infarct on brain imaging 丰
-1,"baseline laboratory values , median ( iqr ) d"
-1,timi major or minor bleeding
-1,olodaterol nmbr mg ( n = nmbr )
-1,race / ethnicity white
-1,"tnfi ( no other bdmard taken ) t , n ( % )"
-1,patients treated
-1,distribution time
-1,previous treatment failure — no . ( % ) § * *
-1,median body weight — kg
-1,raas inhibitor use
-1,previous cardiovascular event at randomization
-1,aspirin alone ( n = nmbr )
-1,wml load at baseline mri
-1,clopidogrel plus aspirin
-1,alanine aminotransferase or aspartate aminotransferase > nmbrx upper limit of normal ( n = nmbr )
-1,non - endstage renal dysfunction *
-1,active inflammatory bowel disease
-1,current alcohol use — no . / total no . ( % )
-1,complex partial ( ib )
-1,"saxagliptin ( n = nmbr , nmbr )"
-1,low subgroup
-1,high - dose statin pretreatment ( n = nmbr )
-1,common study baseline
-1,lm bifurcation treated
-1,"renal impairment , n ( % )"
-1,> nmbr failure
-1,coronary revascularization procedure
-1,intensified baseline ( n - nmbr )
-1,time from onset of qualifying stroke to randomization
-1,statin non - users ( n = nmbr )
-1,barc nmbr - nmbr
-1,"laba use , % patients"
-1,enoxaparin ( n = nmbr )
-1,who / idf impaired fasting glucose
-1,"dip involvement , ! n ( % )"
-1,copd severity ( gold nmbr )
-1,erosion score ( nmbr - nmbr )
-1,st - segment depression > nmbr . nmbr mv
-1,fasting tgs §
-1,total cataract extraction
-1,nmbr mg / day early - start
-1,nmbr - nmbr with cv risk but not disease ( n = nmbr )
-1,oral treprostinil ( n = nmbr )
-1,acute ( < nmbr hr )
-1,total ldl - c *
-1,"obese patients , ! n ( % )"
-1,baseline aspirin dose < nmbr mg
-1,immunologic
-1,high - dose aspirin
-1,a - glucosidase inhibitor
-1,"history of stroke , n ( % )"
-1,crusade bleeding score
-1,% with haq - di decrease > nmbr . nmbr
-1,= nmbr ’ )
-1,simple partial ( ia )
-1,monitoring ( n = nmbr )
-1,"crp median ( se ) , rng / l"
-1,no . of previous venous thromboembolic events
-1,d / mi / idr / st
-1,smoking ( % ) laboratory parameters
-1,"female sex , n ( % ) race , n ( % )"
-1,"hypertension , treated"
-1,no . in the nmbr mo before screening
-1,"severity of copd , n ( % ) *"
-1,reduced ef
-1,"disease duration , years : median ( range )"
-1,absent ( < nmbr mg / dl )
-1,sgrq total score * *
-1,"black race , n ( % )"
-1,indication for index pci
-1,forearm fracture
-1,clinical copd phenotype^
-1,symptoms and feelings
-1,extent of index event
-1,gold stage — no . ( % ) * *
-1,drugs used in diabetes
-1,"baseline short - acting anticholinergics , n ( % )"
-1,stent plus medical therapy
-1,significant worsening in kccq clinical score ( > nmbr ) at nmbr monthsnmbr
-1,diet + pravastatin
-1,doubling of serum creatinine
-1,before index acs event
-1,global ischemia ( % ) * *
-1,"il - nmbr , ng / l"
-1,> nmbr . nmbr to < nmbr . nmbr mu / l $ mmol / l
-1,glycoprotein llb / llla inhibitors
-1,"statin intolerancenmbr , n ( % )"
-1,ccsc at nmbr month before enrollment
-1,fevi aucnmbr - nmbrl
-1,"total , adjusted weight of nmbr . nmbr for gastrointestinal bleeding"
-1,indacaterol n = nmbr
-1,"cv risk factors , % of patients"
-1,"egfr , median ( sd ) , ml / min"
-1,% rf +
-1,moderate or severe copd exacerbations
-1,beta - blocker use at randomization
-1,hscrp > nmbr mg / l
-1,exacerbation rate in the previous year ( range )
-1,bdp / ff / g ( n = nmbr )
-1,high density lipoprotein ( mg / dl )
-1,dose ( n )
-1,hormone replacement therapy
-1,europe ( eu )
-1,events / statin group
-1,site of disease — no . ( % )
-1,proximal - mainleft
-1,pharmaco - invasive n = nmbr
-1,nmbr % c . i .
-1,"metformin : no / yes , %"
-1,laba or lamab n = nmbr
-1,physical role
-1,colorectal cancer
-1,estimated odds ratio
-1,secukinumab intravenous nmbr mg ( n = nmbr )
-1,clopidogrel dose
-1,"ex - smoker / smoker , %"
-1,moderate ( > nmbr to < nmbr )
-1,stroke of undetermined cause
-1,screening visit
-1,medications before admission
-1,antiplatelet therapy dual
-1,fenofibric acid nmbr = nmbr
-1,asia / pacific ( % )
-1,number of patients with fractures
-1,before amendment ( % )
-1,"( haq - di , nmbr - nmbr )"
-1,race or ethnic group — no . f
-1,loss of response : ! : : ! :
-1,post - bronchodilator fevnmbr — % of predicted value
-1,medical history duration of heart failure ( years ) primary cause of heart failure
-1,major cardiovascular
-1,bmi > nmbr ( % )
-1,high risk ( nmbr - nmbr )
-1,seronegative ( rf - ve and acpa - ve ) subgroup
-1,functional outcome ( mrs nmbr - nmbr )
-1,previous balloon angioplasty
-1,mean number of exacerbations in previous nmbr months ( sd )
-1,"duration from clopidogrel / placebo to pci , min ( median , iqr )"
-1,( ci ) b
-1,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘
-1,"age , y . o ."
-1,"serum triglycerides , mg / dle"
-1,post - acute ischemic stroke
-1,death / mi / idr / st / gusto - defined moderate or severe bleeding
-1,"use of rescue albuterol , puffs / day *"
-1,"intent of conservative strategy , %"
-1,"> < nmbr . nmbr , < nmbr . nmbr , r < mmse = mini - mental ;"
-1,estimated gfr
-1,stenosis > nmbr %
-1,nmbr - year rates in placebo groups
-1,previously on acei + arb
-1,peripheral artery disease details
-1,"egfr ( median , iqr ) , ml / min / nmbr , nmbrmnmbr"
-1,dipeptidyl peptidase - nmbr inhibitor
-1,body mass indexnmbr
-1,traditional nsaid
-1,menopausal status and use of ht
-1,standard care
-1,non - european trial
-1,patient ' s assessment of pain ( nmbr - nmbr vas )
-1,tdi total score ( week nmbr
-1,"p , treatment - by - region interaction"
-1,insulin only
-1,"catscorecategory , n ( % )"
-1,"anacetrapib ( n = nmbr , nmbr )"
-1,control nmbr months ( n - nmbr )
-1,no immomtedion
-1,delayed reaction
-1,disease site — no . of patients ( % ) |
-1,nmbr . nmbr - < nmbr
-1,sgrq total score ( units ) : ! :
-1,qualifying myocardial infarction
-1,psoriasis
-1,no glucocorticoids or immunosuppressants
-1,mean ± s . d . hbanmbrc
-1,"time from last dose of pnmbrynmbr inhibitor , days"
-1,"snmbr gallop , n ( % )"
-1,any condition
-1,sitagliptin n = nmbr
-1,"mean weight , kg , mean = sd"
-1,abciximab ( n = nmbr )
-1,antiplatelet — no . ( % )
-1,ischemic heart disease indicator no ( n = nmbrl )
-1,ifg / prediabetes^
-1,no . of target vessels
-1,adjusted mean ± se ( nmbr % ci )
-1,albuminuria < nmbr gram / gram cr
-1,nyha lll - iv
-1,"chronic kidney disease , n ( % )"
-1,patients with fistulas at baseline
-1,standard control
-1,"cvd , mi , stroke , or recurrent ischemia - urgent revascularization"
-1,"white race , %"
-1,> nmbr / tmol / liter — no . ( % )
-1,renin inhibitors
-1,not localized
-1,ischemic stroke without hemorrhagic conversior
-1,constitutional
-1,"smoking status , n ( % ) former"
-1,crp ( mg / dl ) * *
-1,ularitide ( n = nmbr )
-1,vorapaxar placebo nmbr - yr . km %
-1,"cv death , ml , ischemic stroke , hosp . for hf , cor . revasc . , ua"
-1,prior anti - tnf therapy
-1,reinfarction
-1,sgrq total score
-1,first primary composite outcome
-1,score on modified mini - mental state examination — median ( iqr )
-1,hormone replacement
-1,"composite endpoint of doubling of serum creatinine , esrd ,"
-1,exercise ( % )
-1,history of ischemic heart disease — no . ( % )
-1,statin therapy
-1,stratified analyses
-1,"seated sbp at nmbr weeks , mmhg + * *"
-1,"former / current smoker , n ( % )"
-1,"( sd ) , mg / dl"
-1,primary trial end point
-1,fasting blood glucose
-1,number ( % ) reporting migraine on nmbr - month questionnaire
-1,concomitant corticosteroid use
-1,elevated bun ( > nmbr . nmbr meq / l )
-1,slowest third
-1,clinical features of hf
-1,tertile nmbr index pci performed
-1,"risk factor ( predefined ) for falling at screening , n ( % )"
-1,left ventricular dysfunction
-1,"serum cholesterol , mg / dld"
-1,acs treatment
-1,< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp
-1,"prednisone use , %"
-1,actual treatment strategy
-1,other antiplatelet agent 一 no . ( % )
-1,% change from baseline ls means ( se )
-1,use of blood pressure lowering medication *
-1,multivessel disease 一 no . ( % )
-1,patients using concurrent tiotropium
-1,time since copd diagnosis ( yrs )
-1,use of medications for pah — no . ( % )
-1,ace - i or arb use at baseline
-1,medical history of diabetic retinopathy §
-1,anmbr + ez n = nmbr anmbr n = nmbr
-1,anti - tnf - naive patientsnmbr
-1,"total patients , n"
-1,heterogeneity test
-1,"infarction , date not reported"
-1,rates per nmbr patient - years
-1,"% difference , nmbr % ci )"
-1,tofacitinib nmbr mg bid
-1,smoking index — pack - yr §
-1,"body weight ( kg ) , n ( % )"
-1,spironolactone
-1,non - frail
-1,nmbr vitamin e
-1,low potencyc
-1,osteopontin ( ng / ml )
-1,pvaluefor any mi versus no mi
-1,prerandomization statin therapy
-1,"multivessel cad , n ( % )"
-1,glomerular filtration rate §
-1,nmbr mg sirukumab every nmbr weeks ( n = nmbr )
-1,"baseline lvef , %"
-1,hypertension ( % ) : t
-1,"previous loss of response to infliximab , n ( % ) *"
-1,number of treated vessels
-1,"extracranial carotid stenosis , n ( % )"
-1,"coronary artery disease , n ( % )"
-1,telmisartan
-1,physician
-1,black and other
-1,"diclofenac nmbr mg ( n nmbr nmbr ) , . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . ."
-1,smokers ( at baseline )
-1,baseline use of hormone therapy ( % )
-1,high hdl - c ( for men ≥ nmbr   mg / dl / for women ≥ nmbr   mg / dl )
-1,myocardial infarction or angina
-1,exposed ( n = nmbr )
-1,primary composite end point
-1,fasting insulin ( giu / ml )
-1,met criterion at final ( n [ % ] )
-1,mean ( sd ) bmi ( kg / mnmbr )
-1,"mean body weight ( sd ) , kg"
-1,lean ( < nmbr kg / mnmbr )
-1,"previous treatment with a laba and / or lama , n ( % ) c"
-1,new des ( n = nmbr )
-1,homa - ir index — median ( iqr )
-1,timi risk score ( interaction : p = nmbr . nmbr )
-1,prior use of systemic
-1,all randomized
-1,obesity ( % ) §
-1,diabetes therapy
-1,balloon angioplasty
-1,"ibdq domain scores , mean [sd]"
-1,rosiglitazone ( n = nmbr )
-1,smoking ( ever )
-1,patella fracture
-1,screening
-1,medical history and risk factors
-1,ineffective therapy
-1,risk group
-1,hdl - c ( mg / dl ) - mean ± sd
-1,very severe ( gold nmbr )
-1,"glycated hemoglobin , n ( % )"
-1,antihypertensive therapy — no . ( % )
-1,non - ischaemic cause
-1,"low periostin subgroup ( , nmbr ng / ml ) ( n = nmbr )"
-1,infarct location — no . / total no . ( % )
-1,"enrollment by region , no . ( % )"
-1,fixed triple ( n = nmbr )
-1,multivessel stenting
-1,estimated creatinine clearance < nmbr rmb ' mint
-1,event rate
-1,"fevnmbr , litres ( pre salbutamol ) , mean ( sd )"
-1,gpifeellla inhibitor use before angography
-1,"gender , female , n ( % )"
-1,latin america or south africa
-1,patients with complicated events ( p = nmbr - nmbr 十 )
-1,triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l )
-1,patients with > nmbr exacerbations resulting in ed visit
-1,use of statins
-1,time between cessation of full - dose warfarin therapy and enrollment ( mo )
-1,egfr nmbr - nmbr
-1,"egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )"
-1,peri - op ace - inhibitors / arbs : no ( n = nmbr )
-1,cangrelor ( n = nmbr ) n / n ( % )
-1,baseline fevnmbr % predicted
-1,age ( range ) ( years )
-1,mean — yr age group — no . ( % )
-1,history of atrial fibrillation or flutter treatment at randomisation
-1,previous stenting ( % previous pci )
-1,bivalirudin only
-1,medical history ( % )
-1,clopidogrel given before procedure
-1,"ezetimibe + simvastatin ( n = nmbr , nmbr * )"
-1,aliskiren / valsartan ( n = nmbr )
-1,urinary protein - to - creatinine ratio | |
-1,cerebrovascular accident
-1,male sex — no . ( % ) weight — no . ( % )
-1,weight — no . ( % )
-1,nmbr non - mtx
-1,fasting triglycerides — mg / dl
-1,"concomitant csdmards other than methotrexate , n ( % )"
-1,( b ) concomitant respiratory medications [n ( % ) ]
-1,copd population ( n = nmbr )
-1,"ibdq score , mean ( sd )"
-1,lifestyle
-1,"disease location , %"
-1,"haq - di , number ( % )"
-1,cardiac pacemaker — no . ( % )
-1,patient ' s preference not to take
-1,"tofacitinib , nmbr mg twice daily"
-1,diet + pravastatin group
-1,glycated hemoglobin level
-1,asthma population ( n = nmbr )
-1,albumin creatinine ratio
-1,apolipoproiein b ( mij / nmbr )
-1,aliskiren ( dm - vs . dm + )
-1,regadenoson
-1,change in erosion score ( mean )
-1,fecal calprotectin — pg / g * *
-1,infarction before age nmbr ( a )
-1,"patients , no . / total no . ( % )"
-1,prior biologic use
-1,time since diagnosis of type nmbr diabetes - no . ( % )
-1,metabolic syndrome visit nmbr low - density lipoprotein cholesterol strata
-1,nonbiologic disease - modifying drug other than methotrexate : :
-1,moderate risk ( nmbr - nmbr )
-1,csf a ( nmbr ( pm )
-1,combination - facilitated pci ( % )
-1,"time since psa diagnosis ( years ) , mean ( sd )"
-1,deep - vein thrombosis
-1,> nmbr to < nmbr - nmbr mg / week
-1,aspirin alone ( n / n )
-1,prior treatment — %
-1,homa - ir ( % ) b
-1,"duration of diabetes , median ( iqr )"
-1,interquartile range height — cm
-1,mild thrombocytopenia ( < nmbrx nmbr / l )
-1,"reversibility ( anticholinergic ) , % , mean ( sd ) $"
-1,"number of exacerbation in the previous nmbr months , n ( % )"
-1,established cvd ( age > nmbr )
-1,crci > nmbr - < nmbr
-1,who functional class ii / iii
-1,( n nmbr nmbr )
-1,cigarette smoking in the past year
-1,candesartan
-1,"previous pci / cabg , n ( % )"
-1,coronary angiography during the index hospitalization
-1,baseline free pcsknmbr level by median
-1,( se]tf total - c
-1,continued thienopyridine %
-1,before pci
-1,"glomerular filtration rate , nmbr ml / min / nmbr . nmbr mnmbr"
-1,elevated troponin t ( > nmbr . nmbr / xg / l )
-1,rivaroxaban
-1,prior history ml or stroke
-1,"atorvastatin nmbr mg ( n = nmbr , nmbr )"
-1,"alcohol , % with > nmbr drink / d"
-1,western europe and lebanon
-1,"body mass index , kg / mnmbr ( sd )"
-1,current smoker ( > nmbr cigarettes / day ) — no . ( % )
-1,atorvastatin nmbr mg ( n = nmbr )
-1,unstable angina > nmbr mo ago
-1,amlodipine / valsartan nmbr / nmbr vs nmbr / nmbr mg
-1,"mean ( s . d . ) apob , mg / dl"
-1,tobacco use — no . ( % )
-1,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis
-1,dapagliflozin nmbr mg / day ( n = nmbr )
-1,"edema , peripheral"
-1,peripheral vascular disease
-1,angina ( past nmbr weeks )
-1,drug - eluting stent implanted
-1,rhabdomyolysis ( n = nmbr )
-1,"hospitalizations , n"
-1,"baseline heart failure severity amongthose with priorheartfailure , %"
-1,patients with end point
-1,us resident
-1,less than nmbr mm hg
-1,p value for mra vs no mra
-1,insulin - treated diabetes
-1,nmbrrrmnl )
-1,metastatic disease
-1,no stroke n = nmbr nmbr
-1,physical component score ( pcs )
-1,bmi > nmbr — no . ( % ) f
-1,oral contraceptive pills — no . / total no . ( % )
-1,"renal function , moderate"
-1,nmbr - yr risk of coronary heart disease ( % ) ^ |
-1,llt other than statin at randomization
-1,other antihypertensive agents
-1,ace inhibitor at enrollment
-1,b - agonists ( short - acting ) a
-1,"egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )"
-1,"hemoglobin anmbrc , mean ( sd ) , % b"
-1,duration of ulcerative colitis
-1,positive for rheumatoid factor — no . ( % ) : t
-1,"euroscore logistic , median ( nmbrth , nmbrth % ) £"
-1,simvastatin nmbr mg plus fenofibrate nmbr mg ( n = nmbr /
-1,age — mean ( sd ) ( years )
-1,"cerebrovascular or peripheral arterial disease , n ( % )"
-1,"low feno subgroup ( , nmbr . nmbr ppb ) ( n = nmbr )"
-1,blood - pressure medications at randomization — no . / total no . ( % )
-1,"index event , n ( % )"
-1,other or missing data
-1,"number of copd exacerbations in the previous year , n ( % )"
-1,rivaroxaban plus aspirin ( n = nmbr )
-1,diuretics * *
-1,one vessel
-1,intended duration of anticoagulation
-1,"non - stenotic vessels , n ( % )"
-1,gusto severe
-1,> nmbr . nmbr bpm current smoker
-1,patients with any clinical event
-1,previous diabetes
-1,"mmrc dyspnea scale , n ( % )"
-1,brv nmbr mg / day ( n = nmbr )
-1,urinary tract infection
-1,"baseline bmi > nmbr kg / mnmbr , n = nmbr , nmbr"
-1,hospitalization for heart failure
-1,any history of congestive heart failure
-1,"time from study drug administration to coronary revascularization , median ( iqr ) , h"
-1,heart failure ( class i — iii )
-1,c - reactive protein — mg / liter * *
-1,"liraglutide nmbr . nmbr mg , n = nmbr , nmbr"
-1,placebo nmbr yr km %
-1,prebronchodilator fevnmbr ( % predicted normal ) t
-1,rest of world
-1,"mean age ( sd ) , y"
-1,low - molecular weight heparin or intravenous unfractionated heparin
-1,nmbr early intervention ( n = nmbr )
-1,no statin ( + / - llt )
-1,treatment satisfaction
-1,pathologic q waves — no . ( % )
-1,"total periventricular wml score , mean ( sd )"
-1,laboratory values at admission ( median and iqr )
-1,"corticosteroid use , nmbr n ( % )"
-1,use of inhaled glucocorticoids at screening — no . ( % )
-1,"comorbidity score , mean ( sd ) t"
-1,non - smokers ( at baseline )
-1,tender joint count ( n / nmbr )
-1,"total intravenous loop diuretics , mg"
-1,atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr )
-1,angiotensin ll - receptor antagonist — no . ( % )
-1,"mean serum glucose , mg / dl , mean = sd"
-1,gold stage ( % ) f
-1,non - hdl - c / hdl - c
-1,"multivessel ( two vessel , three vessel , or left main )"
-1,body weight index ( kg / mnmbr )
-1,"triglycerides , mmoltnmbr ( gm * )"
-1,procalcitonin ( ng / ml )
-1,fasting blood glucose > nmbr mg / dl
-1,category nmbr
-1,type of event
-1,quality of life
-1,"diagnosis ( y ) , mean ( sd )"
-1,persistent or permanent immobilization
-1,"modified rankin scale at screening , nmbr - nmbr"
-1,placebo nmbr . nmbr pt yrs
-1,diet controlled or no
-1,body weight
-1,"cvd , mi , or stroke"
-1,no . of patients / no . of events
-1,intravenous study drug administered — no . ( % )
-1,number of females n ( % )
-1,> nmbr . nmbr % and ≤ nmbr . nmbr %
-1,treatment with statins
-1,"prior heart failure , n ( % )"
-1,systemic symptoms
-1,persistent or paroxysmal
-1,metabolic syndrome w / o tnmbrdm
-1,stroke — no . / total no . ( % )
-1,nice primary prevention onlyb
-1,"cv death , mi , ischemic stroke , hospitalization for hf , coronary revascularization , ua"
-1,change from pre - to
-1,any lipid - lowering agent
-1,abatacept
-1,indacaterol - glycopyrronium group
-1,warfarin naive
-1,prior or new diabetes
-1,tender and swollen joints — mean no . : :
-1,systolic blood pressure > nmbr mm hg or diastolic blood pressure > nmbr mm hg
-1,"rolofylline ( n = nmbr , nmbr )"
-1,"total stent length ( mm ) , mean ± sd"
-1,swollen joint count ( nmbr joints )
-1,mean nmbr sd
-1,"previously taken methotrexate , %"
-1,gusto moderate
-1,procedure * *
-1,hormone replacement ! !
-1,other cardiovascular risk factors
-1,severe copdc [n z nmbr]
-1,cardiac biomarker status !
-1,nmbr - mercaptopurine
-1,patient presentation
-1,"baseline serum k + , meq / l"
-1,other sulfonylurea 一 no . ( % )
-1,hctz * ( n = nmbr )
-1,"cardiometabolic syndrome , ^n ( % )"
-1,carotid artery — no . ( % )
-1,cardiac valve surgery : no ( n = nmbr )
-1,other cause
-1,beyond popliteal pedal
-1,> nmbr cv risk factors 咐 or established atherosclerotic cv disease
-1,oral anticoagulant drugs
-1,"fracture history ( predefined ) , n ( % )"
-1,any coronary revascularization
-1,ex - / current smoker
-1,vorapaxar nmbr - y
-1,"fluindione , no . ( % )"
-1,current n z nmbr
-1,"concomitant oral corticosteroids , n ( % ) * *"
-1,anaesthesia / analgesia
-1,local eosinophil count ( cells per pl ) t
-1,"age ( years ) , mean ( s . d . )"
-1,ethnic group ( % )
-1,physician ' s global assessment ( vas )
-1,antihypertensive drugs
-1,median age — yr §
-1,cad and / or crvd ( % )
-1,chronic obstructive lung disease
-1,exercise category ( % )
-1,prior congestive heart failure yes
-1,secondary prevention subgroup
-1,aspirin nmbr mg ( n = nmbr )
-1,night - time awakenings / week
-1,"non - hdl - c , mean ( sd ) , rng / dl"
-1,laa closure ( n - nmbr )
-1,p - value * ' '
-1,known prothrombotic genotype
-1,> nmbr concomitant medication
-1,function subscale
-1,high risk and more symptoms ( group d )
-1,white ( nmbr . nmbr % )
-1,osteoarthritis
-1,"age ( y ) , median ( nmbrth to nmbrth percentiles )"
-1,history of microalbuminuria — no . ( % )
-1,"tender joint count ( nmbr joints ) , mean ( sd )"
-1,nmbr mg / day delayed - start
-1,documented symptomatic chdb
-1,c - reactive protein
-1,"ejection fraction , percent ( sd )"
-1,previous pneumonia
-1,"dasnmbr - esr remission , %"
-1,budesonide — no . ( % )
-1,"linagliptin , patients with events / total patients"
-1,middle tg tertile
-1,density lipoprotein ; csf =
-1,"hscrp , median ( min , max ) , mg / l"
-1,concomitant medication after randomisation
-1,non - black ( n = nmbr )
-1,dmard or corticosteroid
-1,non - epa number of <
-1,"hbalc tx difference vs pbo , median change from baseline ( se ) nmbr"
-1,trough fevi l
-1,eq - nmbrd ( visual analog score )
-1,"antihypertensive medication , open - label , no . ( % )"
-1,mer ’ s disease assessment
-1,"baseline ldl - c strata , n ( ° / o )"
-1,with alogliptin nmbr . nmbr mg
-1,anacetrapib ( n = nmbr )
-1,secondary dvt . ' fe
-1,"with laba , n ( % ) pretreatment"
-1,basal insulin analogue dose * ( coefficient
-1,theophyllines
-1,angina class iii or iv — no . ( % )
-1,"n ( nmbryr km event rate , % )"
-1,age — year ( median )
-1,tnt and ideal ( pooled )
-1,cabg or ptca / pci
-1,ex - smoker ( n z nmbr )
-1,event rate ( % ) of primary endpoints
-1,insulin - dependent diabetes
-1,malignancy at randomization
-1,short - acting
-1,"serum potassium , meq / l"
-1,rest of world n z nmbr
-1,"never smoked , n ( % )"
-1,seizure worry
-1,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years )
-1,rest - of - world ( n = nmbr )
-1,no use ofdiabetes drugs — no . ( % )
-1,no estimate
-1,baseline ( n )
-1,pci > nmbr month ago
-1,"swollen joint count ( nmbr joints ) , mean ( sd )"
-1,> nmbr years nmbr / nmbr ( nmbr . nmbr )
-1,time in therapeutic range before inclusion
-1,initial diagnosis — no . ( % )
-1,angiotension converting enzyme - inhibitor
-1,xanthines
-1,management distribution medical treatment
-1,pharmaco - invasive ( n = nmbr )
-1,estrogen - containing hormones
-1,uac nmbr - nmbr mg / g
-1,nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr )
-1,mean ( s . d . ) measured ldl cholesterol
-1,history of hypertension — no . ( % )
-1,"prior cv history , n ( % )"
-1,"time to end - of - study ivus , median ( iqr ) , days"
-1,steroids ( inhaled ) a
-1,> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % )
-1,"previous angioplasty , n ( % )"
-1,time since diagnosis of diabetes
-1,uric acid tertile nmbr ( nmbr . nmbr to < nmbr . nmbr mg / dl )
-1,major hypoglycemia
-1,prosper
-1,"dyspnea at rest ( nyha iv ) , ( % )"
-1,czech republic
-1,gusto moderate or severe bleeding
-1,"baseline cdai ,"
-1,"% change from baseline , mean ( s . e . )"
-1,enalapril + aliskiren ( n = nmbr )
-1,non - calcium antagonist strategy ( n = nmbr nmbr )
-1,ankle fracture
-1,number standard care
-1,"digitalis , n ( % )"
-1,warfarin at last follow - up
-1,pci data
-1,end of follow - up
-1,"handihaler only , n"
-1,certolizumab pegol ( n = nmbr )
-1,mean — ml / min / nmbr . nmbr mnmbr level — no . ( % )
-1,egfr via mdrd ( ml / min / nmbr . nmbrmnmbr )
-1,core laboratory percent stenosis
-1,native american / alaskan
-1,mean cdai score ( sd )
-1,insulin glargine vs standard care least - squares mean ( nmbr % cl )
-1,difference in ls meannmbr ( nmbr % cl )
-1,prior diagnosis - no . ( % )
-1,moderate - dose statin
-1,tnf - alpha ( pg / ml )
-1,antithrombotic drug use at time of event
-1,jbs - nmbr secondary prevention onlynmbr
-1,full cohort
-1,c - peptide
-1,immobilization
-1,"death , mi , idr , st , or gusto moderate / severe bleeding"
-1,thienopyridine ( n = nmbr )
-1,"nmbr - year framingham chd risk , %"
-1,etoricoxib
-1,"previous coronary artery disease , n ( % )"
-1,elevated cardiac markers
-1,ifx + aza ( n = nmbr )
-1,open - label clopidogrel after completion of study drug
-1,baseline low - density lipoprotein cholesterol ( mg / dl )
-1,symptom onset to randomization
-1,stricturing
-1,"insulin tx difference vs pbo , median change from baseline ( se ) nmbr"
-1,duration of rheumatoid arthritis ( years )
-1,beta - blocker — no . / total no . ( % )
-1,second loading dose
-1,trochanter
-1,low perceived social support only
-1,white / other
-1,treatment groups [n / nb ( % ) ]
-1,cardiovascular medication usage
-1,non - calcium antagonist strategy ( ncas ) ( events / n )
-1,simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr )
-1,"baseline bmi > nmbr kg / mnmbr , n = nmbr"
-1,n / n nmbr / nmbr
-1,not - japan
-1,previous cardiovascular events
-1,trigl yeerides * ( m mol / l )
-1,total cholesterol : hdl - c ratio
-1,proadm ( ng / ml )
-1,interact !
-1,older des ( n = nmbr )
-1,second co - primary outcome
-1,pe ± dvt
-1,"previous warfarin use , no . ( % )"
-1,nice secondary prevention onlyb
-1,ankle / brachial index
-1,non - caucasian eze / simva
-1,"use of compression stockings , no . ( % )"
-1,"prior angiography showing stenosis > nmbr % , n = nmbr °"
-1,previous use of antiarrhythmic drugs
-1,"location , n ( % )"
-1,associated with ctd
-1,clopidogrel ( n = nmbr ) n / n ( % )
-1,physical exam oedema
-1,triglyceride ( mmol / l ) * blood pressure
-1,valproate
-1,ls - mean change from baseline ( nmbr % ci )
-1,median age ( iqr ; years )
-1,cardiac medications during index hospital stay and / or discharge
-1,"cardiac medications during index hospitalization , %"
-1,"no ipst ( n = nmbr , nmbr )"
-1,"non high dose statin ( n = nmbr , nmbr )"
-1,gall bladder adverse event ( n = nmbr )
-1,"elevated crp ( > ulnt ) , n ( % )"
-1,liraglutide
-1,"type of drug - eluting stent , n ( % )"
-1,ratio of fevnmbr to fvc
-1,"infarct localization , n ( % )"
-1,racial category *
-1,inhaled jnmbr - agonist §
-1,nonwhite race — no . ( % ) ejection fraction
-1,theophylline use at screening
-1,history of omalizumab treatment
-1,symptom onset to arrival in catheterization laboratory
-1,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl )
-1,"tnfi and other bdmardst , n ( % )"
-1,"atenolol strategy ( n = nmbr , nmbr )"
-1,left atrial diameter : < nmbr mm ( n = nmbr )
-1,ethnic group
-1,"baseline bmi > nmbr kg / mnmbr , n = nmbr , nmbr change from baseline to nmbr weeks"
-1,rf ( iu / ml )
-1,"coronary heart disease risk equivalents , n ( % ) c"
-1,medical history of hypertension
-1,mepolizumab group
-1,microalbuminuria or macroalbuminuria
-1,baseline ldl - c > nmbr mg / dl
-1,combination therapy * *
-1,uac > nmbr mg / g
-1,health assessment questionnaire score
-1,"age at onset , y"
-1,antidiabetes drug usage [ % ( n ) ]
-1,"ibdq total score , mean [sd]"
-1,fenofibric
-1,era and pdenmbr inhibitors
-1,allogliptin
-1,"current smoker ( n = nmbr , nmbr )"
-1,"weight ( kg ) , mean ( s . d . )"
-1,previous stroke or tia ( % )
-1,average of maximum common carotid cimt ( mm )
-1,new or suspected thrombus
-1,lacosamide
-1,natalizumab ( n = nmbr ) f
-1,family history of coronary disease
-1,multivessel cad ( % )
-1,long - acting bronchodilator use at screening
-1,"fevnmbr / fvc ratio , % ( sd )"
-1,mild impairment ( egfr nmbr - nmbr )
-1,all randomly assigned
-1,diet and exercise
-1,"diabetesduration , mean ( sd ) , y"
-1,"median feno , ppba"
-1,non - detectable / unknown
-1,"primary enrollment diagnoses , n ( % )"
-1,low hdl - c ( for men < nmbr   mg / dl / for women < nmbr   mg / dl )
-1,"mean body mass index ( sd ) , kg / mnmbr"
-1,ace inhibitor or angiotensin ii receptor
-1,diet diet + pravastatin
-1,unspecified
-1,atherosclerotic cardiovascular disease
-1,dilated cardiomyopathy
-1,participation in phase a
-1,region of enrollment
-1,"white race , n ( % )"
-1,after amendment
-1,laba + ics versus indzgly lsm difference ( nmbr % cl )
-1,number of patients > nmbr years ( % )
-1,hypoglycemia
-1,gold stage [n ( % ) ]
-1,not treated
-1,"motor subscale ( range , nmbr - nmbr )"
-1,feno + eze
-1,total group
-1,asthma control test score at baseline
-1,"lipid values , mmol / l"
-1,"esr , nmbr - nmbr mm / hour"
-1,europe and canada
-1,total mayo score $ | |
-1,"egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )"
-1,as - needed inhalations / day
-1,"warfarin , no . ( % )"
-1,habitual fish intake : < nmbr servings / wk ( n = nmbr )
-1,number resulting in hospital admission
-1,infarction > nmbr days previously
-1,"pasi score ( nmbr - nmbr ) t , mean ( sd )"
-1,"index mi ( n - nmbr , nmbr )"
-1,> nmbr % coronary stenosis
-1,"mean ( s . d . ) egfr , ml / min / nmbr . nmbr mnmbr"
-1,"triglycerides , mmol / l , mean ± sd"
-1,losartan + lisinopril
-1,"male , n / n ( % )"
-1,isolated deep - vein thrombosis
-1,esrd or death
-1,tiotropium nmbr . nmbr mg
-1,other major risk factors
-1,csf lathosterol ( | jlg / cll )
-1,diagnosis at presentation — no . ( % )
-1,"number of concomitant csdmards , n ( % )"
-1,radiographic characteristics at baseline and randomization
-1,"probability "" of event %"
-1,d - dimer ( ng / ml )
-1,"insulin , median ( ql , qnmbr ) , pmol / l"
-1,cerebrovascular
-1,methotrexate use at randomisation
-1,method of identification ofstenosis ( % )
-1,treatment of the index ml
-1,saba puffs per day at baseline
-1,joint space narrowing score
-1,evolocumab nmbr mg monthly ( n = nmbr )
-1,intent - to - treatb
-1,ace - i or angiotensin receptor blocker
-1,body mass index > nmbr — no . ( % ) f
-1,"mean change , % ( se )"
-1,prebronchodilator fevnmbr / fvc
-1,less than nmbr ml / min / nmbr . nmbrmnmbr
-1,previous tia or stroke
-1,non - ischaemic aetiology
-1,stroke n = nmbr
-1,"crp concentration > nmbr mg / l , n ( % ) \"
-1,european quality of life - nmbr dimensions - nmbr level ( eq - nmbrd )
-1,major clinical response
-1,mean ham - d score ( nmbr % ci )
-1,bowel function
-1,laa ostium
-1,"bnp o nmbr pg / ml or nt pro - bnp o nmbr pg / ml , n ( % )"
-1,laa length
-1,"patient ' s preference not to take vka , only reason * *"
-1,"risk factors and immobility level , n ( % )"
-1,pasi score > nmbr *
-1,cardiac history
-1,"drug - eluting stent , n ( % )"
-1,copd — no . ( % ) medication use
-1,interquartile range
-1,acute stroke of other determined cause
-1,"severe exacerbations , itt population ; n ( % )"
-1,europe nmbr
-1,male gender ( % )
-1,no . of vessels
-1,n - nmbr fatty acids - placebo lsm ( nmbr % cl )
-1,rheumatoid arthritis
-1,> nmbr % focal seizure frequency responders
-1,medication within nmbr days before enrolment
-1,sex ( male ) - no . ( % )
-1,worsened
-1,digoxin at enrollment
-1,prostate cancer
-1,pre - bronchodilator fvc ( l )
-1,creatinine clearance
-1,no . of treated lesions
-1,cholecystectomy ( n = nmbr )
-1,# of prior non - tnfi bdmards *
-1,immunosuppressive agents only
-1,enalapril ( n = nmbr )
-1,deep - vein thrombosis or pulmonary embolism — no . ( % )
-1,"age - years , median ( iqr )"
-1,total no . of patients
-1,n - nmbr fatty acids ( n = nmbr )
-1,baseline cv treatment
-1,selena - sledai ( range u - nmbrunmbr ) t
-1,"bnp > nmbr pg / ml , n = nmbr"
-1,ms & ng
-1,global assessment of disease status score
-1,all patients ( n = nmbr )
-1,isolated impaired glucose tolerance — no .
-1,angiographic extent of disease
-1,type of concomitant statin by daily dose - no . ( % )
-1,postoperative nsaid or glucocorticoid use
-1,airflow reversibility — no . ( % ) |
-1,devices
-1,age at enrollment ( years )
-1,"mean ( sd ) disease duration , years"
-1,"race - white ( n = nmbr , nmbr )"
-1,"fluticasone furoate , n = nmbr"
-1,"baseline hbanmbrc , n ( % )"
-1,aldosterone antagonists ( e . g . spironolactone )
-1,"pci duration in min ( median , iqr )"
-1,"age > nmbr years , n ( % )"
-1,active cancer — no . ( % )
-1,"insulina , n ( % )"
-1,"skull , and facial bone fractures"
-1,nmbr - aminosalicylates {
-1,hemorrhagic stroke
-1,"immy ( without corticosteroid ) , n"
-1,"renal function , normal - mild"
-1,log rank p - value
-1,"prior myocardial infarction , n ( % )"
-1,high - density lipoprotein
-1,"antibodies to infliximab , n ( % ) * *"
-1,safety : non - cabg - related bleeding
-1,diabetes mellitus — no . ( % )
-1,"mmrc grade , n ( % )"
-1,inspiratory capacity ( l )
-1,"hf , lvd , or both"
-1,percent of predicted fevnmbr
-1,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % )
-1,diuretics group ( n = nmbr )
-1,prior aortocoronary bypass surgery
-1,"neutrophils , nmbr / nl"
-1,antiplatelet or anti - inflammatory drugs
-1,presentation of index event
-1,statin at enrollment
-1,ethnicitya hispanic or latino
-1,waist circumference snmbr ( men ) or > nmbr cm ( women )
-1,"baseline mssbp / msdbp , mm hg"
-1,hispanic american
-1,hba]c ( mmol / mol )
-1,men / women
-1,pbo ( nnmbr nmbr )
-1,creatinine clearance < nmbr ml / min ( % )
-1,total comparators ( n = nmbr )
-1,heart rate ( b . p . m . )
-1,"smoking history , n ( % )"
-1,"disease duration , mean yr ( sd )"
-1,high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr )
-1,"hbanmbrc in patients with baseline hbanmbrc < nmbr % ( < nmbr mmol / l ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )"
-1,overall event rate
-1,"prior biologic therapeutic failures , n ( % )"
-1,losartan plus lisinopril ( n = nmbr )
-1,us site of enrollment
-1,killip class lll - iv
-1,coronary artery osteochondrosis
-1,"time from onset of pain to randomization , median ( nmbrth — nmbrth percentiles ) , n"
-1,subset of patients not on metformin
-1,"no persistent wrf ( n = nmbr , nmbr )"
-1,clopidogrel plus aspirin % / yr
-1,percutaneous coronary revascularization
-1,plus metformin
-1,calcium - channel inhibitor
-1,"uacra , mg / g , gmean = gcv"
-1,cure trial
-1,ratio ( nmbr % ci ) *
-1,"baseline pre - bronchodilator fevnmbr , l"
-1,physical component summary
-1,"placebo croup , n / n ( % )"
-1,smoking status at screening
-1,copd medication taken for at least nmbr months before st
-1,st - segment - elevation myocardial infarction — no . ( % )
-1,ada nmbr / nmbr ( n[nmbr )
-1,previous segmental resection — no . ( % )
-1,older patients ( aged > nmbr years )
-1,pre - operative cardiac medications *
-1,other forms of
-1,"mean ( s . d . ) hbalc , mmol / mol"
-1,number of ( % ) patients > nmbr years
-1,"ck - mb , ng / ml"
-1,prior cardiovascular disease
-1,current / past smoker
-1,on - pump time : < l : nmbrhrs : min ( n = nmbr )
-1,diuretic — no . ( % ) surgery
-1,"< nmbr ml / min / nmbr . nmbr mnmbr , n ( % )"
-1,types of fibrinolytic agent
-1,u » c » ( mg / g )
-1,anticoagulant group ( n = nmbr )
-1,< nmbr yr of education — no . ( % )
-1,non - colorectal cancer
-1,all bleeding
-1,"hbalc ( % ) , mean ( sd ) ^"
-1,"simvastatin nmbr mg ( n = nmbr , nmbr )"
-1,losmapimod ( n = nmbr )
-1,number of e
-1,"region , europe union"
-1,hydochlorothiazide ( n = nmbr )
-1,continued treatment study
-1,death / q - wave mi / idr
-1,p value for trend
-1,time since diagnosis of heart failure
-1,"mean ( s . d . ) ldl particle size , nm"
-1,single vessel pci
-1,pfo with mild - to - moderate shunt and atrial septal aneurysm
-1,"obesity ( bmi > nmbr kg / mnmbr ) , %"
-1,colon only
-1,lp ( a ) ( week nmbr )
-1,n - nmbr pufa events / patients ( % )
-1,arthritis type *
-1,"aml / val , nmbr / nmbr mg rr = nmbr *"
-1,in emergency department before ambulance transfer
0,gold d
0,saaca
0,ecg
0,之 nmbr
0,total ( n = nmbr )
0,"race , %"
0,race — no . ( % ) |
0,% nmbr - nmbr
0,severe
0,"pbo , n = nmbr"
0,bnp
0,"male sex , ( % )"
0,"females , %"
0,< nmbr mm
0,snmbr %
0,age ' ^nmbr yrs
0,atvnmbr mg ( n = nmbr )
0,"female , no . ( % )"
0,> nmbr mo
0,male sex — %
0,lvh
0,stent
0,acrnmbr
0,diet
0,cg / ld
0,age ( years ) *
0,nonsmoker
0,ics use
0,no ( % )
0,lips
0,≤ nmbr
0,ocs
0,tg < = nmbr . nmbr
0,vka
0,rate * ( n )
0,statin ( n - nmbr )
0,« snmbr - nmbr
0,nmbr to < nmbrmmhg
0,males ( % )
0,三 nmbr to < nmbr
0,cough
0,> median
0,smoking *
0,etd ( nmbr % ci )
0,% ( se )
0,"pm , n ( % )"
0,"placebo , n ( % )"
0,n ( % )
0,> nmbr beds
0,number
0,"male , no ( % )"
0,> nmbr years ( n = nmbr )
0,femaleb
0,< nmbr hr
0,> nmbr to < nmbr mm hg
0,deaths
0,uvb
0,asian ( n — nmbr )
0,bms
0,p - int
0,l ’ - value ’
0,abnormal
0,placebo
0,crt
0,sex :
0,icd
0,cabg
0,≤ median
0,nmbr - nmbr ft
0,lad
0,nmbr yrs
0,hs - crp
0,no prior llt
0,range
0,phi ( n = nmbr )
0,> nmbr h
0,women ( n = nmbr )
0,> nmbr - < nmbr years
0,men ( % )
0,> nmbr ug / g
0,cdai
0,age nmbr
0,age > = nmbr years
0,hbalc < median
0,arr ( nmbr % ci )
0,msdbp
0,ato nmbr mg ( n = nmbr )
0,redon
0,daily
0,placebo n / n ( % )
0,statin ( n = nmbr )
0,white
0,blockers
0,idr
0,p - valuec
0,nmbr ( > nmbr % )
0,≥ nmbr . nmbr years
0,"men , %"
0,anmbr n = nmbr
0,p valued
0,study
0,> nmbr % nmbr
0,no pci
0,igm
0,ex - smoker
0,"etn , no"
0,"rales , n ( % )"
0,pooled
0,total
0,female sex ( % )
0,acs
0,nmbr . nmbr min
0,motor
0,apo bt
0,"age , years"
0,"asian , n ( % )"
0,age < nmbr yr
0,hr nmbr % cl
0,sal nmbr mg
0,frail
0,> lnmbr years
0,iv ( n z nmbr )
0,( nmbr % cl )
0,* p value
0,arb
0,oad
0,fema le
0,nmbr enmbr years
0,black ( n = nmbr )
0,missing
0,single
0,events ( % )
0,> nmbr kg
0,s
0,< nmbr ng / ml
0,rr ( nmbr % ci )
0,result
0,"age > nmbr years , %"
0,patients n
0,placebo [n = nmbr |
0,nmbr % cl
0,nmbr nmbr
0,> nmbr %
0,hbak < median
0,yes
0,> nmbr yr sex
0,< nmbr
0,> = nmbr years
0,nmbr mg / g
0,"ascvd , n ( % )"
0,lgm ( n = nmbr )
0,mace
0,neither
0,> = nmbrkg
0,( se ) t *
0,esrd
0,placebo n[nmbr
0,death
0,mtx
0,loop
0,japanese
0,chda
0,> nmbr lb
0,age ( years ) +
0,l ( % )
0,chadsnmbr
0,( n = nmbr )
0,new om
0,nmbr % nmbr
0,"former , n ( % )"
0,b lack
0,median
0,nmbr — < nmbr years
0,hdl - cd
0,low
0,> nmbr ( n — nmbr )
0,rr *
0,iii / iv
0,pla
0,hr
0,"placebo ,"
0,bmi < nmbr
0,nmbr . nmbr yrs
0,plac
0,"women , n ( % )"
0,"other , n ( % )"
0,lmwh
0,mexico
0,lcznmbr ( n = nmbr )
0,nmbr % cit
0,black ( n — nmbr )
0,< nmbr yr
0,< nmbr » < nmbry
0,hba „ ( % )
0,htn
0,p for i
0,af
0,# nmbr year
0,beta - blocker use
0,naive ( n = nmbr )
0,changenmbr
0,< lnmbr years
0,treated
0,tnmbrd
0,mtx n = nmbr
0,white ( n — nmbr )
0,pasi *
0,aged ^nmbr years
0,> nmbr - < nmbr mmhg
0,copd ( n = nmbr )
0,nmbrto < nmbrmmhg
0,nmbr +
0,< nmbrkg
0,< nmbr ( n — nmbr )
0,bmi > nmbr
0,lsm ( nmbr % ci )
0,dd
0,x / n
0,age yrs
0,diet alone
0,sfc ( n [nmbr )
0,> nmbr / > nmbr mm hg
0,former
0,< nmbr ft
0,■ nmbr years
0,nmbr - nmbr years
0,p value *
0,beta blocker
0,< nmbr years ( n = nmbr )
0,"beta - blocker , %"
0,race ( % ) $
0,fibrate
0,primary pci
0,egfr
0,colon
0,n
0,"arb , n ( % )"
0,aphasia
0,heparin
0,"white , %"
0,low ’
0,f emale
0,igm ( n = nmbr )
0,> nmbr nmbr
0,< nmbr mg
0,ics : yes
0,< nmbr ml
0,placebo ( n = nmbr
0,unprovoked
0,strategy
0,asia ( n = nmbr )
0,"region , %"
0,cse] +
0,age > nmbr y * *
0,i % nmbr
0,mca
0,taci ( n = nmbr )
0,hdl - c
0,medium
0,placebo ( n = nmbr )
0,women men
0,both
0,"rca , n ( % )"
0,events
0,"patients , n"
0,italy
0,", nmbr"
0,> nmbr - nmbr years
0,snmbr
0,chf
0,^ - blockers
0,nmbr ( n = nmbr )
0,ale
0,p valuea
0,age ( yrs )
0,≤ nmbr %
0,nmbrmg
0,placebo n = nmbr
0,anemia
0,eze
0,mean *
0,atv nmbr mg
0,ef nmbr - nmbr %
0,open — no . ( % )
0,oriental
0,\nmbr %
0,anakinra
0,of patients
0,"arb , %"
0,"sex , men ( % )"
0,sedbp
0,£ nmbr kg
0,japan
0,> nmbr hrs
0,female ( % )
0,hbak > median
0,"aspirin , n ( % )"
0,other — no . ( % )
0,male ( n z nmbr )
0,dm absent
0,vora
0,* nmbr to < nmbry
0,male
0,never smoking
0,female sex — no . ( % )
0,( gm )
0,st +
0,≥ nmbr to < nmbr %
0,aqe inmbr
0,n / pyr
0,< nmbr kg
0,apobe
0,age : > nmbr years
0,crci > nmbr
0,nmbr mg bid
0,psa ( n = nmbr )
0,ldl *
0,pin /
0,overall
0,( se]tf
0,oa
0,grade nmbr
0,off omt
0,gold a
0,no ascvd
0,mean bmi
0,female sex
0,serum
0,othersc
0,eze nmbr mg
0,crt - p
0,itherchdt
0,dm present
0,non - smoker
0,> = nmbr - < nmbr mmhg
0,nmbr or nmbr days
0,group d
0,"age , nmbr years"
0,placebo pts / n ( % )
0,= snmbr
0,nmbr - nmbr min
0,ii ( n = nmbr )
0,rectum
0,"age , yrs *"
0,total *
0,", nmbr ( n = nmbr )"
0,< nmbr . nmbr %
0,cana nmbrmg ( n = nmbr )
0,mae
0,nmbr % - nmbr %
0,^nmbr - nmbr
0,on omt
0,race — no . ( % )
0,age : < nmbr years
0,hdl - cy
0,≥ nmbr %
0,africa
0,cardiac
0,feno nmbr mg ( n = nmbr )
0,lvef < nmbr %
0,pa
0,hr ( nmbr % ci )
0,nsaid
0,pe
0,white ( n = nmbr )
0,placebo n ( % )
0,egfr > nmbr
0,other *
0,> nmbr . nmbr yrs
0,past
0,< nmbr mm hg
0,> nmbr % to < nmbr %
0,known chd
0,"sex , n ( % )"
0,nnt
0,all ( n = nmbrf )
0,tia
0,nmbr / nmbr mg
0,mmse < nmbr
0,> nmbr - nmbr kg
0,< nmbr . nmbr bpm
0,placebo ( n z nmbr )
0,locf )
0,< nmbr days
0,erosion
0,"smokers , %"
0,weight
0,iiiv
0,( i - blocker
0,dasnmbr
0,all ( n = nmbr )
0,"placebo , n = nmbr"
0,no htn
0,"sex , no . ( % )"
0,race ( % )
0,vitality
0,us
0,pain
0,age — y £
0,< nmbr week
0,"hbalc , %"
0,open
0,> nmbr y
0,avm ( n = nmbr )
0,mild
0,ami nmbr mg
0,nmbr mg / day
0,ever - smoker
0,no . ( % )
0,lateral
0,"placebo , n / n ( % )"
0,region — no . ( % )
0,age ^nmbr
0,pvd
0,> nmbr mm hg
0,romania
0,nmbr < - nmbr
0,< nmbr mg / dl
0,patients
0,n / n ( % )
0,> = median
0,> nmbr ( n = nmbr )
0,nmbr — nmbr years
0,> nmbr % and < nmbr %
0,cancer
0,macce
0,£ nmbr to < nmbr years
0,or nmbr % ci
0,> i
0,any use
0,never
0,p - blocker
0,age > nmbr
0,period i
0,nmbr to < nmbr hr
0,swollen
0,rrr ( nmbr % cl )
0,≤ nmbr . nmbr %
0,hscrp
0,nmbr % ci
0,second ( n = nmbr )
0,chd death
0,pbo ( n = nmbr )
0,mean — kg
0,ab nmbr pg ( n = nmbr )
0,p +
0,yes *
0,age
0,ageadj
0,aqc < nmbr
0,rr^ ( nmbr % ci )
0,nmbr mmhg
0,nmbr - nmbr mo
0,> nmbr mg / dl
0,age - years
0,statin usage
0,age nmbr y
0,race — no . ( % ) 卞
0,> nmbr / day
0,des
0,< median
0,nmbr - < nmbr yrs
0,taiwan
0,nmbr - nmbr yrs
0,some
0,≥ nmbr years
0,> nmbr to < nmbr years
0,"female , no ( % )"
0,cabg — no . ( % )
0,women - no . ( % )
0,paci
0,anmbrc
0,age :
0,vldl
0,lvef ( % )
0,nmbr - nmbr hr
0,mi
0,ls mean
0,n *
0,ldl
0,risk *
0,present
0,"age > nmbr y , %"
0,sex
0,bid
0,pci
0,statin use
0,monthnmbr
0,primary
0,placebo ( n = nmbro )
0,< nmbr years
0,niacini
0,dm
0,nmbr to < nmbr yr
0,edge
0,spoke
0,bmi < = nmbr
0,epa ( n = nmbr )
0,mean ( sd )
0,cdmard
0,sd
0,nmbr mo to nmbr yr
0,pfor
0,nmbr - < nmbr %
0,alert
0,lvef
0,$ nmbr
0,apo - b
0,cohort
0,ali
0,ace
0,woman
0,apob
0,nmbr to < nmbr mm hg
0,£ median
0,ckd
0,or ( nmbr % cl )
0,af alone
0,"region ,"
0,nsclc
0,"other ( n , % )"
0,monthly
0,beta - blockers
0,"race , n ( % )"
0,australasia
0,fp nmbr mg
0,mean ( se )
0,iii - iv
0,nmbr or nmbr
0,or [nmbr % ci]
0,asian
0,itt
0,id ( n = nmbr )
0,state
0,anmbr
0,hub
0,> nmbr hr
0,lsm ( nmbr % cl )
0,"pci , n ( % )"
0,no . ( % ) *
0,≥ nmbr to < nmbr years
0,wssng
0,f
0,fp ( n [nmbr )
0,» nmbr yr
0,mean — yr
0,prior dm
0,pre - h
0,acid
0,hctz
0,rnmbr
0,korean
0,placebo %
0,. nmbr
0,age < median
0,nste - acs
0,age £ nmbr
0,w
0,p - value *
0,stent ( n = nmbr )
0,> nmbrh
0,value *
0,sso - nmbr
0,id
0,iorii ( n z nmbr )
0,belgium
0,hbalca median
0,use
0,male sex ( % )
0,> nmbr yrs sex :
0,female ( n z nmbr )
0,pci ( % )
0,or ( nmbr % ci )
0,( e - blocker
0,nsteacs
0,other '
0,bmi^
0,smoking
0,race n ( % )
0,risk
0,homa
0,africa *
0,sex ( % )
0,"jvp , ( % )"
0,rnmbr ( n = nmbr )
0,py = nmbr )
0,a - blocker
0,p blocker
0,"hba , c ( % )"
0,r nmbr mg
0,"female sex , n ( % )"
0,> nmbr
0,> nmbr to < nmbr
0,"rales , ( % )"
0,tion — no . ( % )
0,p trend
0,"ada , no"
0,macce ( % )
0,nonwhite
0,pt
0,apo b *
0,% ( nmbr % ci )
0,^ - blocker
0,no betablocker use
0,"age , ( years )"
0,> nmbr type
0,female
0,us ( n = nmbr )
0,tzd
0,nmbr - < nmbr
0,peace ( n = nmbr )
0,< nmbr lb
0,< nmbr mg / g
0,non - mtx
0,"age , year"
0,py *
0,feno
0,mental
0,smokers
0,> nmbr ft
0,"women , %"
0,mssbp
0,uac =
0,acei
0,usa
0,class > nmbr
0,europe ii
0,"/ ’ - value """
0,sabaa
0,prior mi
0,no statin
0,cv death
0,age > = nmbr
0,nmbr §
0,alone
0,r
0,ultra
0,paci ( n = nmbr )
0,age < nmbr
0,stage nmbr
0,laba alone
0,eze nmbr mg ( n = nmbr )
0,no prior ml
0,nmbr ( < nmbr % )
0,statin
0,nnmbr yrs
0,male ( n = nmbr )
0,psa
0,nmbr / nmbr
0,region - no . ( % )
0,placebo ( n = nmbrl )
0,otherz
0,nmbr years
0,nmbr yr
0,asp
0,aqe < nmbr
0,n = nmbr
0,fh ii
0,overallb
0,nitrate
0,age > nmbr y
0,black
0,new dm
0,< nmbr mon ( n = nmbr )
0,lower
0,"age , mean"
0,dvt
0,m
0,"black , n ( % )"
0,obesity
0,women
0,nmbr mg
0,il - nmbr
0,< nmbr y ( n = nmbr )
0,placebo r %
0,mg / dl
0,ml c
0,tg +
0,sotalol
0,cdai < nmbrt
0,nmbr ( nmbr % )
0,mmse > nmbr
0,tg §
0,v ( n = nmbr )
0,= nmbr
0,p
0,"race , no . ( % )"
0,fa nmbr mg
0,none
0,no smoking
0,usa ( n = nmbr )
0,rate *
0,gender
0,male ( n - nmbr )
0,austria
0,$ nmbr years
0,fh nmbr
0,no ?
0,dd ( n = nmbr )
0,lu / kg
0,no ststm
0,st -
0,p - valuea
0,yes ( n = nmbr )
0,abi < nmbr . nmbr
0,iv
0,sama
0,latvia
0,mra
0,asian *
0,bm i < nmbr
0,age > nmbr yrs
0,chf ( % )
0,"ef , %"
0,vi nmbr mg ( n = nmbr )
0,< nmbr % ( n = nmbr )
0,hbaic ( % )
0,tjc
0,cvd
0,> nmbr ml
0,nmbr to < nmbr
0,obese
0,"gold , n ( % )"
0,age $ nmbr yrs
0,placebo ( % )
0,rr ( nmbr % cl )
0,« nmbr - nmbr
0,whitea
0,age > : nmbr
0,stroke
0,median ( iqr )
0,sjc
0,< nmbr h
0,pbo
0,nmbr - nmbr yr
0,< nmbr %
0,chadsnmbr^
0,p blockers
0,£ nmbr years
0,> nmbr / week
0,nmbr - < nmbr y
0,non - c
0,group a
0,< nmbr - nmbr
0,ldu - c
0,$ nmbr ( n = nmbr )
0,≥ nmbr mg / dl
0,> nmbr % ( n = nmbr )
0,rca
0,"age , n ( % )"
0,nyha ii
0,nmbr . nmbr
0,£ nmbr yo ( n = nmbr )
0,ni
0,noneh
0,» nmbry
0,saba §
0,"cabg , n ( % )"
0,nitrates
0,sita nmbr
0,anmbr + eznmbr
0,"male sex , %"
0,laaca
0,> nmbr mmhg
0,age > nmbr yr
0,bmi
0,stemi ( % )
0,cabg ( % )
0,european
0,pvalue
0,lll - iv
0,bmi > = nmbr
0,onmbr
0,fp ( n = nmbr )
0,crt - d
0,severity
0,normal
0,"age > nmbr yrs , %"
0,patients ( n )
0,"hr , nmbr % cl"
0,sdai < nmbr t
0,no *
0,age years
0,row
0,beta blockers
0,lvmi ( nmbr
0,care
0,egfr -
0,prior om
0,n %
0,early ( n = nmbr )
0,nmbr to < nmbr cells
0,mm hg
0,any death
0,> nmbr < nmbr
0,cl nmbr %
0,poci ( n = nmbr )
0,pbo n ( % )
0,$ nmbr years ( n = nmbr )
0,all patients
0,laba '
0,< nmbr ( n = nmbr )
0,"smoking , %"
0,"male , %"
0,level nmbr
0,"placebo , n = inmbr"
0,< nmbr mmhg
0,no psa
0,nmbrenmbr
0,placebo [n z nmbr]
0,ls mean ( se )
0,prior stemi
0,betablocker use
0,aml nmbr /
0,acr
0,\nmbr
0,homa > median
0,p - blocker yes
0,> = nmbr mmhg
0,no dm ( n = nmbr )
0,otherx
0,age — yrf
0,fragile
0,no beta - blocker use
0,n o
0,asa > nmbr mg
0,"mra , ( % )"
0,india
0,gold nmbr
0,csf
0,nmbr mo
0,sites
0,aspirin ( n = nmbr )
0,< nmbr days ( n = nmbr )
0,first ( n = nmbr )
0,"age > nmbr , y"
0,sesbp
0,( se]t *
0,value
0,ics usage
0,> nmbr to < nmbr yr
0,< nmbr beds
0,ptca
0,≥ nmbr bpm ( n = nmbr )
0,no beta - blocker
0,age < nmbr y
0,fa nmbr mg ( « = nmbr )
0,p value 十
0,spinal
0,arr
0,acm
0,age > nmbr yrs *
0,orc ( nmbr % cl )
0,saba
0,in - h
0,males
0,"female , n ( % )"
0,brachial
0,month nmbr
0,nmbryr
0,age ( yr )
0,italy ( n = nmbr )
0,nmbr - nmbr
0,hiv
0,ale < nmbr
0,"chd * , n ( % )"
0,region
0,iglar
0,arbs
0,age in years
0,l / ll
0,> nmbr yrs
0,tg ’
0,age < nmbryrs
0,ff nmbr pg ( n = nmbr )
0,pad
0,arr ( nmbr % cl )
0,americas
0,st
0,hctz *
0,> nmbr . nmbr mm hg
0,placebo ( n - nmbr )
0,gold ii
0,lama
0,chd
0,"median , iqr"
0,cv death n
0,"ldl , - c"
0,p - value
0,edge ii
0,nmbr kg
0,both ( % )
0,ml
0,cana nmbr mg ( n = nmbr )
0,cad
0,all
0,age > nmbr years
0,sa
0,racea
0,"male sex , n ( % )"
0,others
0,reqion
0,m / f
0,cat > nmbr
0,atv n ( % )
0,< nmbry
0,> nmbr days
0,ebria
0,other
0,no pa
0,poland
0,prior pci
0,b - blocker
0,"( n = nmbr ,"
0,abi # nmbr . nmbr
0,oradj ( nmbr % cl )
0,labaa
0,hr nmbr % ci
0,minor
0,ufh
0,dm ( n = nmbr )
0,never smoked
0,copd
0,v total ( n = nmbr )
0,egfr < nmbr
0,other !
0,hba < median
0,event ( % )
0,general
0,≤ nmbr ug / g
0,rr ( nmbr % ci ) *
0,yes ( % )
0,post - mi
0,laba
0,", nmbr years ( n = nmbr )"
0,sdai
0,> nmbr mg
0,p value
0,stemi
0,< nmbr ( n z nmbr )
0,"age > nmbr , %"
0,area
0,male sex — no . ( % )
0,teaes
0,sex — no . ( % )
0,"age , y"
0,male ( % )
0,cvd death
0,chinese
0,nstemi
0,qmi
0,nmbr - nmbrh
0,apo b
0,> nmbr mm ( n = nmbr )
0,"female sex , %"
0,all n = nmbr
0,abi
0,any statin
0,tg > nmbr . nmbr
0,nmbry
0,race — no . ( % ) : c
0,e
0,angina
0,ns
0,"age , yr"
0,oretal
0,no smo king
0,"women , n ( % ) *"
0,p value c
0,mets
0,pbo ( n = nmbr ) vs
0,race — no . ( % ) f
0,lipid
0,females
0,nmbrmg ( n = nmbr )
0,"ada , yes"
0,placebo [n = nmbr]
0,< nmbr mo
0,$ nmbr %
0,> = nmbr . nmbr
0,< nmbr min
0,no .
0,hbaic — %
0,n .
0,russia
0,race *
0,< nmbr hrs
0,hps
0,patients ( ft )
0,prior stent
0,nmbr — < nmbr
0,all ( n = nmbr * )
0,asa < nmbr mg
0,< nmbr year
0,stage nmbrb
0,iv nitrates
0,pio nmbr
0,beta - blocker !
0,femoral
0,australia
0,placeboa
0,pint
0,hdl
0,", nmbr / week"
0,> nmbr y ( n = nmbr )
0,phi ( n - nmbr )
0,iii & iv
0,aqe ^nmbr
0,region ( % )
0,nmbr to < nmbr kg
0,< nmbr y
0,age # nmbr yrs
0,placebo ( n nmbr )
0,anemia ( % )
0,pbo ( nnmbr )
0,"ckdc , n ( % )"
0,provoked
0,race
0,mtx ( n = nmbr )
0,> nmbr years
0,upper
0,mean a ± sdt
0,no prior mi
0,mean ± sd
0,female ( n — nmbr )
0,tics — no . ( % )
0,apo a - i
0,ascvd
0,glipizide
0,years
0,stage nmbra
0,asian ( n = nmbr )
0,ics alone
0,i / ii
0,%
0,lesions
0,total c
0,> nmbr mon ( n = nmbr )
0,nstemi ( % )
0,ppci ( n = nmbr )
0,"women , no . ( % )"
0,no ipst
0,( n = ms )
0,uti
0,obesityj
0,asia
0,p [int]
0,rarely
0,tc
0,qd
0,"age , yrs"
0,age ( year )
0,"age , years *"
0,> nmbr mm
0,europe
0,≥ nmbr
0,nmbr min
0,statins
0,canvas
0,niacin
0,study nmbr
0,"graft , n ( % )"
0,c
0,ipst ( n = nmbr )
0,f * >
0,"high , %"
0,ml )
0,male sex 一 no . ( % )
0,£ nmbr %
0,no po
0,y es
0,ff - blocker
0,no prior stemi
0,< nmbr . nmbr years
0,african
0,fibrates
0,canada
0,nmbr mg ( n = nmbr )
0,venous
0,nmbr - < nmbr ( % )
0,total n = nmbr
0,mate
0,i
0,met ( n = nmbr )
0,nausea
0,other chd
0,"lda , %"
0,ics : no
0,aspirin
0,age ( years )
0,rrr
0,nmbr - nmbr days
0,hr ( nmbr % cl )
0,"etn , yes"
0,> nmbr and < nmbr %
0,male sex — no . ( % ) f
0,n nmbr
0,ipst
0,age > = nmbr yrs
0,m being
0,oral
0,"race , zz ( % )"
0,> nmbr - < nmbr
0,tgt
0,sfc ( n = nmbr )
0,prior llt
0,> = nmbr y
0,"p - value """
0,non - white
0,ldl - c
0,( nmbr % ci]h
0,gold b
0,"men , n ( % )"
0,hbalc ( % )
0,never smoker
0,men
0,≥ nmbr mg / g
0,≥ nmbr ng / ml
0,no psa ( n = nmbr )
0,nmbr - i
0,"low , %"
0,haq
0,beta - blocker
0,urti
0,renal
0,lama +
0,( sem )
0,primary *
0,no mi
0,age < nmbr yrs
0,statini
0,n_
0,metsyn
0,< nmbr / < nmbr mm hg
0,no use
0,> nmbr . nmbr %
0,tvr
0,laa
0,om nmbr /
0,arm
0,r nmbr mg ( « = nmbr )
0,"female , %"
0,cancer §
0,hbalc > median
0,men ( n = nmbr )
0,crcl < nmbr
0,"chd , n ( % )"
0,age — yr
0,gold c
0,mean = sd
0,avr
0,epa
0,lnmbr
0,treatment
0,< nmbr yo ( n = nmbr )
0,wegu
0,hbanmbrc
0,( se] +
0,cards
0,nmbr mg / dl
0,hdl *
0,year nmbr
0,p - blockers
0,< nmbr yrs
0,( se]t
0,no prior pci
0,nmbr . nmbr %
0,diet ( n 二 nmbr )
0,pnorpci
0,hr ( nmbr % cl ) *
0,iu
0,^median
0,> nmbr min
0,nmbr to < nmbr mo
0,> = nmbr yea ' s
0,median — yr
0,nnmbr
0,nmbr to < nmbr years
0,no des
0,> nmbr mg / g
0,> nmbr . nmbr
0,hrqol
0,p values
0,no acs
0,othernmbr
0,> nmbr to nmbr years
0,cat < nmbr
0,age > nmbr yr 十
0,smoker
0,"oads , n ( % )"
0,paod
0,nmbr or more
0,site
0,> = nmbr years ( n = nmbr )
0,ifg
0,cancer * *
0,race — no . ( % ) ' (
0,aged < nmbr years
0,( ri = nmbr )
0,x / n *
0,s £ nmbr
0,aml
0,age ( years ) :
0,htn hx
0,lvef > nmbr %
0,non - dm
0,group b
0,total hip
0,obesity t
0,b
0,no
0,"total , n = nmbr"
0,race - no . ( % )
0,< nmbrh
0,< nmbr . nmbr
0,r nmbr mg ( n = nmbr )
0,ics # #
0,off pump
0,china
0,abi > nmbr . nmbr
0,"male , n ( % )"
0,female ( n = nmbr )
0,"age , ya"
0,adl
0,ii - iv
0,any
0,ff nmbr | ig ( n = nmbr )
0,crp
0,nste - mi
0,n =
0,korea
0,"ckd , n ( % ) t"
0,"icd , n ( % )"
0,"poba , n ( % )"
0,no aspirin
0,"yes , n ( % )"
0,placebo nmbr
0,no chd
0,sfc
0,asthma
0,[nmbr % cl]
0,nmbr to < nmbr ( % )
0,"lvef , %"
0,> = nmbr
0,ynmbr
0,age < nmbr years
0,n / n
0,racenmbr
0,placebo ( n[nmbr )
0,vdhmtss
0,poci
0,> nmbr . nmbr min
0,placebo ( n = nmbr * )
0,"aicd , ( % )"
0,hscrp §
0,nmbr
0,major
0,prior
0,ccb
0,male - no . ( % )
0,b - blockers
0,placebo ( lsm )
0,median — vr
0,ileum
0,no ( n = nmbr )
0,> nmbr - nmbr
0,no statin use
0,absent
0,age $ nmbr years § *
0,ics
0,laci
0,< nmbr bpm ( n = nmbr )
0,% pred
0,prior ml
0,> nmbr yr
0,on nmbr
0,tg
0,> = nmbr kg
0,on pump
0,tnmbrdm
0,"others , n ( % )"
0,mean
0,high
0,hazard
0,p valuey
0,cana nmbr mg
0,age ( y )
0,( nmbr % ci )
0,age ( yij
0,ssi - nmbr
0,« = nmbr
0,ucr
0,tender
0,p *
0,iii ( n z nmbr )
0,cyclo
0,hbalc < medan
0,non - hdl
0,sodium
0,£ nmbr
0,simva
0,laci ( n = nmbr )
0,puva
0,icsa
0,ua
0,hr ( nmbr % ci ) “
0,asa
0,ng
0,patient
0,rr
0,race ( % ) ) '
0,> nmbr to nmbr
0,ii
0,otherb
0,ldl - cz
0,( a blocker
0,event
0,iii
0,^nmbr
0,ef < nmbr %
0,israel
0,glinide
0,brazil
0,nmbr to < nmbrkg
0,pasi^i
0,indian
0,europe i
0,male sex
0,", nmbr years"
0,ifx ( n = nmbr )
0,week nmbr
0,right
0,tg *
0,samanmbr
0,high *
0,hope ( n = nmbr )
0,active ( n = nmbr )
0,"> nmbr , < nmbr"
0,group c
0,ex - smokers
0,"male sex , no . ( % )"
0,with ( n = nmbr )
0,poor
0,radial
0,nnmbr / nnmbr
0,ef > nmbr %
0,stalin
0,> = nmbr yr
0,sfc ( n[nmbr )
0,"race , n ( % ) b"
0,ra
0,sal nmbr pg ( n = nmbr )
0,pci — no . ( % )
0,hrt
0,fp ( n[nmbr )
0,mtss
0,nmbre < nmbr %
0,yes '
0,ratio
0,sal ( n = nmbr )
0,nyhaii
0,women — no . ( % )
1,"smoking status , no . ( % )"
1,"smoking status , n ( % )"
1,smoking status — no . ( % )
2,"systolic bp , mm hg"
2,systolic bp ( mm hg )
2,diastolic ( mmhg )
2,systolic — mm hg
2,diastolic ( mm hg )
2,systolic bp ( mmhg )
2,systolic ( mm hg )
2,"diastolic bp , mm hg"
2,systolic ( mmhg )
2,diastolic bp ( mmhg )
2,diastolic — mm hg
2,diastolic bp ( mm hg )
3,dasnmbr ( esr )
3,dasnmbr - crp §
3,dasnmbr - hscrp
3,dasnmbr ( crp )
3,dasnmbr - crp
3,dasnmbr - esr
4,unadjusted
4,unadjusted hr
4,unadjusted irr
4,adjusted
4,unadjusted hr .
5,ejection fraction
5,lv ejection fraction
6,apolipoprotein anmbr ( g / l )
6,apolipoprotein anmbr ( mg / dl )
7,"fpg , mmol / l"
7,fpg ( mmol / l )
7,tg ( mmol / l ) c
7,na ( mmol / l )
7,k ( mmol / l )
7,ldl ( mmol / l )
7,"bun , mmol / l"
7,tc ( mmol / l )
7,tg ( mmol / l )
7,ffa ( mmol / l )
7,"fpg , mmol / lt"
7,mdg ( mmol / l )
7,"ppg , mmol / l"
7,hdl ( mmol / l )
8,"mssbp , mm hg"
8,dbp ( mmhg )
8,sbp ( mm hg )
8,"sbp , mmhg"
8,"dbp , mm hg"
8,sbp ( mmhg )
8,"dbp , mmhg"
8,"msdbp , mm hg"
8,"msdbp , mm hga"
8,"mssbp , mm hga"
8,"sbp , mm hg"
8,dbp ( mm hg )
8,map ( mmhg )
9,cvd subjects
9,all subjects
9,mrf subjects
10,c - reactive protein ( mg / l )
10,c - reactive protein ( mg / dl )
10,"c - reactive protein , mg / l"
10,"c - reactive protein , * mg / l"
10,c - reactive protein ( mg / dl_ )
11,body - mass index ( kg / mnmbr ) t
11,body mass index - kg / mnmbrt
11,"body mass index ( kg / mnmbr ) ,"
11,"body mass index , kg / mnmbr"
11,body mass index ( kg / nr )
11,body mass index ( kg / mnmbr )
11,body - mass index ( kg / mnmbr )
11,bodymass index ( kg / mnmbr )
11,body mass index ( kg / mnmbr ) * '
11,"body mass index , * kg / mnmbr"
12,"comorbidities , n ( % ) a"
12,"comorbidites , n ( % )"
13,controls ( n = nmbr )
13,control ( n z nmbr )
13,control ( nznmbr )
13,control ( n = nmbr )
13,control ( n - nmbr )
14,african - american
14,african american
14,african americans
14,african america
15,history of hypertension ( n = nmbr )
15,no history of hypertension ( n = nmbr )
16,egfr ( ml / min )
16,"egfr , ml / min"
17,- ics / + laba n z nmbr
17,+ ics / + laba nz nmbr
18,baseline mean ( se )
18,"baseline ( mean , sd )"
18,"baseline , mean ( sd )"
19,no current smoking
19,"current smoker , %"
19,current smokers
19,current smokers ( % )
19,current smoker ( % )
19,current smoker
19,current non - smoker
19,current smoking
19,"current smokers , %"
19,current smokers *
19,current smoking *
19,current nonsmoker
19,"current smoker ,"
19,current smoker yes
19,current nonsmokers
20,prior ptca or pci
20,prior ptca / pci
21,interactior p - value
21,interaction p - value
21,interaction p value 中
21,interaction p value §
21,interaction p value
22,duration of copd ( yr )
22,"duration of copd , y"
22,duration of copd — yr
22,"duration of copd , yr"
22,"duration of copd , years"
22,"duration of pd , y"
22,"duration of copd ,"
22,duration of copd ( years )
23,multivariate p - value
23,univariate p - value
24,group b ( n = nmbr )
24,group c ( n = nmbr )
24,group a ( n = nmbr )
25,rage ( ng / ml )
25,ltbr ( ng / ml )
25,pigr ( ng / ml )
25,vegfr ( ng / ml )
26,imt ( nmbr )
26,imt ( mm )
27,haq - di *
27,haq - di
27,haq - di * *
28,non - fatal stroke
28,nonfatal stroke
29,antiplatelet or anticoagulant
29,antiplatelets or anticoagulants
30,hypercholesterolemia — no . ( % ) *
30,hypercholesterolemia — no . ( % )
30,hypercholesterolemia 一 no . ( % )
31,pre - menopausal without hormone replacement
31,post - menopausal with hormone replacement
31,pre - menopausal with hormone replacement
31,post - menopausal without hormone replacement
32,bumetanide
32,budesonide
33,"nmbr - hour madbp , mm hg"
33,"nmbr - hour masbp , mm hg"
34,no prior heart failure
34,prior heart failure
35,prior cancer
35,no prior cancer
36,nmbr to < nmbr ( n = nmbr )
36,"$ nmbr to , nmbr ( n = nmbr )"
36,nmbr to < nmbr ( n z nmbr )
37,ace - i or arb
37,no ace - i / arb
37,ace - lorarb
37,ace - i / arb
37,acei or arb
37,ace - l / arbs
37,aceis / arbs
37,acei / arb
38,triglycerides
38,triglyceride a
38,triglycerides *
38,triglycerides * *
38,triglyceride
39,fluvastatin ( n = nmbr )
39,simvastatin ( n = nmbr )
39,rosuvastatin ( n = nmbr )
40,diabetic yes
40,diabetes
40,antidiabetic
40,diabetesnmbr
40,nondiabetic
40,"prediabetes , %"
40,diabetic no
40,non - diabetic
40,diabetes ( % )
40,diuretics
40,diuretic use
40,diabeticnmbr
40,diabetesf
40,"diabetes , %"
40,prediabeticb
40,diureticff
40,n o diabetes
40,diabetes *
40,dabetes
40,non - diabetes
40,non - diabetics
40,diabetics
40,diuretic
40,no diabetes
40,diurciic
40,diabetic
40,diabeticb
41,stage nmbra : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr
41,stage nmbrb : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr
42,"pm pef ( sd ) , l / min"
42,"am pef ( sd ) , l / min"
43,fevnmbr : fvc ratio
43,fevnmbr : fvc ratio ;
43,fevnmbr / fvc ratio *
44,"egfr , * ml / min / nmbr . nmbr mnmbr"
44,"egfr , ml / min / nmbr . nmbr mnmbr"
44,egfr ( ml / min / nmbr . nmbrmnmbr )
44,egfr ( ml / min / nmbr . nmbr mnmbr )
44,egfr ( ml / min / nmbr . nmbr mnmbr ) §
45,dyslipidaemiat
45,dyslipidaemia
45,dyslipidaemia 本
45,dyslipidemia
46,nmbr st < nmbr . nmbr
46,nmbr / nmbr ( nmbr )
46,"nmbr ( nmbr , nmbr )"
46,nmbr ( nmbr . nmbr % )
46,nmbr ( nmbre < nmbr % )
46,> nmbr - nmbr - nmbr
46,nmbrrd > nmbr . nmbr
46,nmbr - nmbr . nmbr
46,nmbr ( nmbr . nmbr )
46,nmbr . nmbr % ( nmbr )
46,nmbr - < nmbr . nmbr
47,oral hypoglycemic
47,oral hypoglycemics
48,north america ( % )
48,south america ( % )
49,sitagliptin nmbr mg n = nmbr
49,sitagliptin nmbrmg n = nmbr
50,disease activity]
50,disease activity
50,ease activity]
51,class i
51,class ia
51,class iii
51,class ii
51,class ib
51,class ic
51,class iv
52,"nt - probnp , pg / mlt"
52,nt - probnp ( pg / ml ) h
52,nt - probnp ( pg / ml )
52,nt - probnp — pg / ml * *
52,"nt - probnp , pg / ml"
53,drug - eluting stent
53,drug eluting stent
54,race : non - white
54,"race , nonwhite"
54,race - non - white
54,race nonwhitet
54,"race , % nonwhite"
54,"race , non - white"
55,smoking status *
55,smokinq status
55,smoking status
56,nyha iii or iv
56,nyhaiiioriv
57,csf cholesterol
57,hdl - cholesterol
57,vldl cholesterol
57,ldl cholesterolt
57,ldl - cholesterol (
57,hdl cholesterol §
57,ldl cholesterol
57,tolal choleslerol
57,total cholesterol *
57,hdl cholesterol *
57,"total cholesterol , %"
57,total cholesterol
57,hdl choleslerol
57,ldl choleslerol
57,aldl cholesterol
57,hdl cholesterol
57,ldl - cholesterol
58,medical therapy
58,medical therapies
58,topical therapy
59,hbanmbrc ( n )
59,"> nmbr , no . ( % )"
59,"> nmbr h , n ( % )"
59,> nmbr days ( % )
59,"< nmbr h , n ( % )"
59,"< nmbr % , n ( % )"
59,> nmbr ( % )
59,anmbrc ( % )
59,"> nmbry , no . ( % )"
59,"hbanmbrc , %"
59,"hbanmbrc , % §"
59,"> nmbr % , n ( % )"
59,hbanmbrc ( % )
59,> nmbr yr — no . ( % )
59,< nmbr vr — no . ( % )
59,"$ nmbr % , n ( % )"
59,"> nmbr , n ( % )"
59,< nmbr { % )
59,"< nmbr y , n ( % )"
59,"^nmbr y , n ( % )"
59,aabnmbr ( % )
59,< nmbr yr — no . ( % )
59,< nmbr ( % )
59,> = nmbr * ( % )
59,> nmbr yr ( % )
59,> = nmbr ( % )
59,"> nmbr y , n ( % )"
59,"> nmbr y , no . ( % )"
59,< nmbr days ( % )
59,> nmbr y . n ( % )
59,"< nmbr , n ( % )"
60,£ median ( nmbr )
60,> median ( nmbr % )
60,> median ( nmbr kg )
60,> median ( nmbr mm )
60,> median ( nmbr )
60,< median ( nmbr kg )
61,women < nmbr years
61,women > nmbr years
62,"diclofenac ( n = nmbr , nmbr )"
62,diclofenac ( n = nmbr nmbr )
63,previous mi — no . ( % )
63,previous vte — no . ( % )
63,previous chf — no . ( % )
64,bl h / y : bilateral
64,bl h / y : unilateral
65,diabetes status
65,diabetic status
66,mean ( sd ) age in years
66,"mean ( sd ) age , yr"
66,"mean ( sd ) age , years"
66,mean ( sd ) age ( years )
67,no symptoms
67,symptoms
68,age at randomization
68,age at randomisation
69,vadas score *
69,mmse score *
69,mean acrn
69,rope score
69,cat score
69,sss score
69,gds score *
69,mmse score
69,edss score
69,chads score
69,mean score
69,mhis score
69,cat scoreff
69,kccq score
69,aqlq score
69,accp score
70,baseline sbp ( mm hg )
70,baseline dbp ( mm hg )
71,itt population
71,mitt population
72,tiotropium + placebo ( n[nmbr )
72,tiotropium + placeb ( n[nmbr )
73,"myocardial infarction , n ( % )"
73,"myocardial infarction , ( % )"
74,sinusitis
74,synovitis
75,no history of tia / stroke
75,history of tia or stroke
75,history of tia / stroke
76,heart rate ( beats per min )
76,"heart rate , beats / min"
76,"heart rate , beats per min"
76,heart rate — beats / min
76,heart rate ( beats / min )
76,heart rate ( beats per minute )
77,"pga , nmbr - nmbr"
77,"tjc , nmbr - nmbr"
77,"sjc , nmbr - nmbr"
77,"ptga , nmbr - nmbr"
78,region latin american
78,"region , latin america"
79,calcium - channel blockers
79,calcium channel blockers
79,calcium - channel blocker
79,calcium channel blocker
79,calcium - channel blockerf
80,baseline median [mg / l]
80,"baseline median , mg / dl"
80,"baseline mean , mg / dl"
80,baseline mean ( mg / dl]
80,"baseline median , mg / l"
81,baseline mean mtss
81,baseline mean 士 sd
82,glucocorticoids
82,glucocorticoid
82,glucocorticoids *
83,esr ( mm / h )
83,"esr , mm / hour"
83,esr — mm / hr
83,esr ( mm / hour )git config --global user.name "Your Name"
84,ns cardiac cisease
84,cardiac disease
84,no cardiac disease
85,education < nmbr years
85,education > nmbr years
86,triglyceride ( mmol / l )
86,triglyceride ( mmol / l ) t
86,"triglyceride , mmol / l"
86,triglycerides ( mmol / l ) :
86,triglycerides ( mmol / l )
86,"triglycerides , mg / l"
86,"triglycerides , mmol / l §"
86,triglycerides * ( mg / dl )
86,"triglycerides , mg / dl"
86,triglyceride ( mg / dl ) d
86,triglycerides — mg / dl
86,triglycerides ( mg / dl )
86,"triglycerides , mg / dl^"
86,"triglycerides , mmol / l"
86,triglyceride ( mg / dl )
86,"triglycerides , mmol / lf"
87,patients without diabetesb
87,patients with diabetesb
88,"no prior heart failure ( n = nmbr , nmbr )"
88,"prior heart failure ( n = nmbr , nmbr )"
89,prior lev use
89,prior asa use
90,"postmenopausal ,"
90,postmenopausal
90,premenopausal
91,hs - crp ( mg / l )
91,"apob , mg / dl"
91,"fpg , mg / dl"
91,bnp ( pg / ml )
91,fpg ( mg / dl )
91,"hs - crp , mg / l"
91,"bun , mg / dl"
91,crp — mg / l
91,crp ( ng / ml )
91,"hscrp , mg / l"
91,"apob , g / l"
91,bun ( mg / dl )
91,tgs ( mg / dl )
91,hdl ( mg / dl )
91,"ppg , mg / dl"
91,"bnp , pg / ml"
91,apo b ( g / l )
91,crp ( mg / dl )
91,"apoal , mg / dl"
91,mpo ( ng / ml )
91,hscrp ( mg / l )
91,"hscrp , mg / dl"
91,hscrp ( mg / l ) c
91,"apo b , mg / dl"
91,hscrp ( nmol / l )
91,troy ( ng / ml )
91,apob ( mg / dl )
91,bnp ( pg / ml ) h
91,"crp , mg / l"
91,"bnp , pg / mlt"
92,"triglycerides nmbr , d third"
92,triglycerides nmbrst third
92,triglycerides nmbrnd third
93,no multivessel disease
93,multivessel disease
94,fastng plasma glucose < median
94,fascng plasma glucose a medan
94,fasting plasma glucose < median
95,"caucasian , %"
95,caucasian ( % )
95,caucasiana ( % )
96,concomitant cardiovascular therapies — no . ( % )
96,concomitant cardiovascular therapy — no . ( % )
97,dissatisfied with / stopped $ nmbr prior systemic therapies because of side effects
97,dissatisfied with / stopped $ nmbr prior systemic therapy because of side effects
98,linagliptin ( n z nmbr )
98,vildagliptin ( n = nmbr )
98,linagliptin ( n = nmbr )
98,sitagliptin ( n = nmbr )
99,smoking — current
99,"smoking , % current"
100,current smoking — no . ( % )
100,"current smoking , n ( % )"
100,current smoker 一 no . ( % )
100,"current smokers , n ( % )"
100,current smoker — no . ( % )
100,"current smoker , n ( % )"
100,"current smoker , no ( % )"
101,without tnmbrdm n = nmbr
101,with tnmbrdm n = nmbr
102,val / hctz ( n = nmbr )
102,v / hctz ( n = nmbr )
102,aml / hctz ( n = nmbr )
103,ind / gly
103,indzgly
104,gdf - nmbr ( ng / ml )
104,mmp - nmbr ( ng / ml )
104,st - nmbr ( ng / ml )
104,mmp - nmbr ( ng / ml ) *
104,il - nmbr ( pg / ml )
105,"diabetes , n ( % )"
105,diabetes — no . ( % )
105,"diabetes , no . ( % )"
105,"diabetes , * n ( % )"
105,"prediabetes , n ( % )"
106,unstable angina — no . ( % )
106,stable angina — no . ( % )
107,anmbrc < nmbr . nmbr % ( median )
107,anmbr = nmbr . nmbr % ( median )
108,hazard ratio ( nmbr % cl )
108,hazard ratio ( nmbr % ci ) *
108,hazard ratio ( nmbr % ci )
108,hazard ratio * ( nmbr % ci )
108,hazard ratiof ( nmbr % ci )
109,lipid - lowering agent §
109,lipid - lowering agents
109,lipid - lowering agent
110,zotarolimus
110,zotarolimust
111,pci orcabg
111,prior cabg
111,no prior cabg
111,pnorcabg
112,"diastolic blood pressure , mm hg , median ( range )"
112,"systolic blood pressure , mm hg , median ( range )"
113,very severe
113,more severe^
113,less severe
113,more severe
114,cholesterol ( mg / dl )
114,cholesterol — mg / dl
115,treatment difference ( nmbr % cl )
115,treatment difference ( nmbr % ci )
116,insulin
116,insulina
117,> median ( nmbr ) — number / n ( % )
117,< median ( nmbr ) — number / n ( % )
118,"baseline mssbp ( mmhg ) , mean ± sd"
118,"baseline msdbp ( mmhg ) , mean ± sd"
119,age range ( years )
119,"age range , years"
120,inflammation
120,inflammatory
121,hispanic or latino
121,hispanic / latino
122,< nmbr cells / pl
122,> nmbr cells / pl
123,american indian
123,american indian /
124,with an sfua
124,without an sfua
125,"men , > nmbr cm"
125,"men , < nmbr cm"
125,"women , < nmbr cm"
125,"women , > nmbr cm"
126,sulphonylureas
126,sulphonylurea
126,on sulfonylurea
126,sulfonylureaa
126,sulfonylurea
127,pbo + mtx
127,czp + mtx
128,caucasians
128,caucasian
128,noncaucasian
128,non - caucasian
129,"ldl cholesterol ( mg / dl ) , mean + sd , available for nmbr patients"
129,"hdl cholesterol ( mg / dl ) , mean + sd , available for nmbr patients"
130,previous or current use of im or cs : no
130,previous or current use of im and cs : no
131,nmbr to < nmbr ml / min / nmbr . nmbrmnmbr
131,nmbr to o nmbr ml / min / nmbr . nmbr mnmbr
131,nmbr to onmbr ml / min / nmbr . nmbr mnmbr
131,≥ nmbr to < nmbr ml / min / nmbr . nmbr mnmbr
131,nmbr to < nmbr ml / min / nmbr . nmbr mnmbr
132,without psoriasis ( zi = nmbr )
132,with psoriasis ( n = nmbr )
132,with psoriasis ( zi = nmbr )
133,placebo events / patients ( % )
133,"placebo , events / patients ( % )"
134,ldl - cholesterol ( mg / dl )
134,"ldl cholesterol , mg / dl"
134,hdl cholesterol ( mg / dl )
134,ldl cholesterol — mg / dl
134,i idl cholesterol ( mg / dl )
134,hdl cholesterol — mg / dl
134,"hdl cholesterol , mg / dl"
134,ldl cholesterol ( mg / dl )
134,hdl - cholesterol ( mg / dl )
135,baseline ldl - c
135,baseline ldl - c :
136,who fc ii symptoms at baseline
136,who fc iii symptoms at baseline
137,nmbr . nmbr - < nmbr . nmbr
137,> nmbr - nmbr - nmbr - nmbr
137,nmbr - nmbr - nmbr - nmbr
137,nmbr . nmbr to nmbr . nmbr %
137,> nmbr . nmbr - < nmbr . nmbr
137,nmbr . nmbr - nmbr . nmbr
137,nmbr . nmbr + nmbr . nmbr
137,nmbr nmbr ( nmbr . nmbr )
137,nmbr . nmbr - < nmbr . nmbr %
137,"nmbr , nmbr ( nmbr . nmbr )"
137,"nmbr , nmbr - < nmbr . nmbr"
137,nmbr / nmbr ( nmbr . nmbr )
137,nmbr . nmbr to nmbr . nmbr
137,> nmbr . nmbr to < nmbr . nmbr
137,nmbr . nmbr ( nmbr . nmbr )
137,> nmbr . nmbrto < nmbr . nmbr %
137,nmbr . nmbr % - nmbr . nmbr %
138,no mra at baseline
138,mra at baseline
138,ss at baseline
138,mmrc at baseline
138,pad at baseline
138,nihss at baseline
139,aspirin dose
139,aspirin alone
139,aspirin use
140,arrhythmia
140,arrhythmia !
140,arrhythmias
141,hypertensive
141,hypertensiont
141,"hypertension , n ( % )"
141,hypertension 本
141,hypotension
141,"hypertension , * n ( % )"
141,hyper - tension
141,hypertension
141,"hypertension , %"
141,hypertension ( % )
141,"hypertension , ( % )"
141,no hypertension
141,hyperlension
141,hypertension *
141,"hypertensive , n ( % )"
141,hypertension §
141,hypertension !
142,unstable angina *
142,unstable angina age
142,unstable angina §
142,unstable anginad
142,unstableangina
142,stable angina
142,unstable anginat
142,unstable angina
143,arb monotherapy
143,era monotherapy
144,cardioembolism
144,cardioembolic
145,age category >
145,bmi category
145,age category
146,aspirin or other antiplatelet agents
146,aspirin or other antiplatelet agent
147,mean ( sd ) pga vas *
147,mean ( sd ) ptga vas *
147,mean ( sd ) pain vas *
148,previous ml ( before index acs )
148,previous pci ( before index acs )
149,fibula fracture
149,tibia fracture
150,"weight in kg , mean ( sd )"
150,"weight , kg , mean ( sd )"
150,"weight , kg : mean ( sd )"
150,"weight ( kg ) , mean ( sd )"
150,"weight ( kg ) , mean ± sd"
151,"serum creatinine , umol / lf"
151,"serum creatinine , gmol / l |"
151,serum creatinine ( gmol / )
151,serum creatinine ( mmol / l )
151,"serum creatinine , ^mol / l"
152,> nmbr years eze / simva ( „ = nmbr }
152,< nmbr years eze / simva ( n = nmbr }
153,im use : no
153,cs use : no
154,stent diameter < nmbr mm
154,stent diameter $ nmbr mm
155,"overall ( n = nmbr , nmbr )"
155,overall ( n = nmbr vs nmbr )
156,leukotriene receptor antagonists
156,leukotriene - receptor antagonist
157,"high - sensitivity c - reactive protein , mg / ltt"
157,"high - sensitivityc - reactive protein , mg / l"
158,etn + mtx ( n = nmbr )
158,hcq + mtx ( n = nmbr )
158,ssz + mtx ( n = nmbr )
158,lef + mtx ( n = nmbr )
159,> nmbr drinks
159,nmbr drinks
160,glucose ( mg / dl )
160,glucose — mg / dl
161,thienopyridine
161,+ thienopyridine
161,no thienopyridine
161,- thienopyridine
162,acholesterol ( % )
162,cholesterol ( % )
163,< nmbr . nmbr mg / dl
163,> nmbr . nmbr mg / mmol
163,> nmbr . nmbr - g / l
163,nmbr - nmbr mg / g
163,nmbr nmbr mg / dl
163,≥ nmbr to < nmbr mg / g
163,> nmbr . nmbr mg / l
163,> nmbr . nmbr mmol / l
163,≥ nmbr to < nmbr mg / dl
163,< nmbr . nmbr mmol / l
163,< nmbr . nmbr mg / mmol
163,> nmbr & < nmbr mg / dl
163,> nmbr and < nmbr mg / dl
163,> nmbr to nmbr mg / g
163,> nmbr but < nmbr mg / dl
163,< nmbr . nmbr ng / ml
163,> nmbr + nmbr mmol / l
163,nmbr - nmbr mg / dl
163,. nmbr . nmbr mg / mmol
163,< nmbr - nmbr mmol / l
163,", nmbr . nmbr mg / mmol"
163,nmbr to nmbr mg / g
163,nmbr to < nmbr mg / dl
163,> nmbr . nmbr mg / dl
163,"> nmbr , < nmbr mg / dl"
163,< nmbr . nmbr l - g / l
163,> nmbr . nmbr ng / ml
163,> nmbr ' nmbr mmol / l
163,> nmbr - nmbr mmol / l
163,< nmbr . nmbrmg / l
164,cerebral vascular disease
164,cerebrovascular disease
165,linagliptin
165,vildagliptin
165,sitagliptin
165,saxagliptin
166,mean ( s . e . )
166,mean ( s . e . ) t
166,mean ( s . d . )
167,"mean bmi , kg / mnmbr ( sd )"
167,mean bmi ( kg / mnmbr ) ( sd )
168,tiotropium ( nznmbr )
168,tiotropium ( n z nmbr )
168,tiotropium ( n = nmbr )
169,gastroduodenum
169,gastroduodenal
170,primary endpoint
170,"primary end point """
170,primary end point
171,dyslipidemia — no . ( % )
171,dyslipidemia — no . ( % ) |
172,"tjc ( nmbr - nmbr ) , mean ( sd )"
172,"sjc ( nmbr - nmbr ) , mean ( sd )"
173,non cv mortality
173,non - cv mortality
174,patients with prevalent kidney disease at baseline
174,patients without prevalent kidney disease at baseline
175,"mean ( s . d . ) age , years"
175,"mean ± s . d . age , years"
176,nmbr mg / day early - start - delayed - start
176,nmbr mg / day early - start - delayed start
177,£ nmbr kg / mnmbr
177,anmbr kg / mnmbr
177,< nmbr kg / m nmbr
177,> nmbrkg / mnmbr
177,< nmbrkg / mnmbr
177,snmbr kg / mnmbr
177,< nmbr kg / mnmbr
177,≥ nmbr kg / mnmbr
177,> nmbr kg / mnmbr
178,hypokalemia ‡   ( potassium < nmbr . nmbr mmol / l )
178,hyperkalemia ‡   ( potassium ≥ nmbr . nmbr mmol / l )
179,heparin only
179,aspirin only
180,"mitral regurgitation , n ( % )"
180,"mitral regurgitation , ( % )"
181,< nmbr years n z nmbr
181,> nmbr years n z nmbr
182,age < nmbr y ( n = nmbr )
182,age ' nmbr y ( n nmbr )
182,age > nmbr y ( n = nmbr )
183,"ace inhibitor , %"
183,ace inhibitor
183,ace inhibitors
183,tnf inhibitors
183,tnf inhibitor
183,ace inhibitor yes
184,body - mass index : ! :
184,body - mass index ; ! ;
185,"change from baseline to eos , uu / ml"
185,"change from baseline to eos , mg / dl"
186,right coronary artery
186,r ight coronar y artery
187,duration of tnmbrdm > nmbr years
187,duration of tnmbrdm < nmbr years
188,time to randomization
188,time of randomization
189,p value ( cangrelor versus clopidogrel in men )
189,p value ( cangrelor versus clopidogrel in women )
190,weight ( kg )
190,"weight , kg *"
190,height — cm
190,w eight ( k g )
190,"weight , lbs"
190,"weight , kg"
190,"height , cm"
190,weight 一 kg
190,height ( cm )
190,weight — kg
190,weight - kg
190,"height , cm *"
191,"ldl - c , mmol / l ( mg / dl )"
191,"hdl - c , mmol / l ( mg / dl )"
192,body - mass index ) -
192,"body mass index , %"
192,body - mass indexj
192,body - mass indexf
192,"body - mass index ) """
192,body - mass index )
192,body - mass index *
192,body - mass index §
192,body mass index *
192,body - mass index $
192,body mass indexc
192,body mass index +
192,body mass index
192,body mass index :
192,body - mass index
193,family history of premature chd
193,family history of premature chdj
194,abatacept nmbr mg / kg ( n = nmbr )
194,abatacept ~ nmbr mg / kg ( n = nmbr )
195,prior tnf antagonist failure - no
195,prior tnf antagonist failure - yes
196,previous cabg
196,previous mi
196,previous ptca
196,previous pci
196,previous hf
196,previous tia
196,previous ml
196,previous chf
196,previous cad
196,previous ami
196,previously
196,previous
197,w event ( rate )
197,n event ( rate )
198,"type nmbr diabetes ( n = nmbr , nmbr )"
198,"no type nmbr diabetes ( n = nmbr , nmbr )"
199,family history of vte
199,family history of cad
200,with p blockers
200,without p blockers
201,triglycerides < nmbr - nmbr mmol / l
201,triglycerides > nmbr - nmbr mmol / l
202,"non - hdl - c , mg / dl"
202,non - hdl - c ( mg / dl )
203,lipid - lowering medications^
203,lipid - lowering medications
203,lipid - lowering medication
204,history of cad
204,no history of af
204,history of pci
204,history of copd
204,history pci
204,history of mi
204,history of vte
204,history of chf
204,history of chd
204,history of cabg
204,no history of chf
204,history of pad
204,history of ml
204,history of hf
204,history of af
205,lesion length $ nmbr mm
205,lesion length > nmbr mm
206,male gender
206,female gender
207,"ratio of hrs ( nmbr % cl ) , p for sex interaction"
207,"ratio of hrs ( nmbr % ci ) , p for sex interaction"
208,statins / ezetimibe
208,statin or ezetimibe
209,> median ( nmbr . nmbr ) — number / n ( % )
209,< median ( nmbr . nmbr ) — number / n ( % )
210,renal impairment
210,renal impairmentt
211,antiplatelet drugs
211,antiplatelet drug
212,chanmbrdsnmbr - vasc $ nmbr
212,chanmbrdsnmbr - vasc # nmbr
212,chanmbrdsnmbr - vasc > nmbr
213,reversibility to
213,reversibility ( % ) t
213,reversibility *
213,reversibility
213,"reversibility , %"
213,reversibility ( % )
213,reversibility %
214,present ( £ nmbr mg / dl )
214,present ( > nmbr mg / dl )
215,hbanmbrc < = nmbr %
215,hbanmbrc < nmbr %
215,hbanmbrc > nmbr %
215,hbanmbrc > = nmbr %
216,metformin 一 no . ( % )
216,metformin — no . ( % )
217,women / men [ % ]
217,"women / men , %"
218,nmbr . nmbr to # nmbr . nmbr mg / mmol
218,nmbr . nmbr - < nmbr . nmbr mg / mmol
219,"baseline tav - > = median ( n = nmbr , nmbr )"
219,"baseline pav - > = median ( n = nmbr , nmbr )"
219,"baseline tav - < median ( n = nmbr , nmbr )"
219,"baseline pav - < median ( n = nmbr , nmbr )"
220,ifg / igt
220,ifg and igt
221,< nmbr % ( < nmbr mmol / mol )
221,> nmbr % ( > nmbr mmol / mol )
221,> = nmbr % ( nmbr mmol / mol )
221,< nmbr % ( nmbr mmol / mol )
222,"no mi ( n - nmbr , nmbr )"
222,"pad ( n - nmbr , nmbr )"
222,"no mvd ( n - nmbr , nmbr )"
222,"acs ( n - nmbr , nmbr )"
222,"mvd ( n - nmbr , nmbr )"
222,"any mi ( n - nmbr , nmbr )"
222,"no pad ( n - nmbr , nmbr )"
223,total cholesterol > nmbr - nmbr mmol / lt
223,total cholesterol < nmbr nmbr mmol / lt
223,total cholesterol < nmbr - nmbr mmol / lt
223,total cholesterol > nmbr ' nmbr mmol / lt
224,"body mass index , mean ( sd )"
224,"body mass index , mean ( sd ) t"
224,"body massindex , mean ( sd ) a"
224,"body - mass index , mean ( sd )"
224,"body mass index , mean ( sd ) d"
225,change from baseline *
225,change from baseline
225,% change from baseline
226,rectal bleeding subscore {
226,rectal bleeding subscore
227,ldl - c ( mmol / l )
227,"ldl - c , mmol / l"
227,"hdl - c , mmol / l"
227,hdl - c ( mmol / l )
227,ldl - c * ( mmol / l )
228,insulin - dependent
228,insulin dependentc
229,antihypertensive therapy
229,anti - hypertensive therapy
230,ace inhibitors or angiotensin - receptor blockers^
230,ace inhibitor or angiotensin receptor blocker
230,ace inhibitor or angiotensin ii receptor blocker
230,ace inhibitors or angiotensin receptor blockers
231,"diabetes duration , years"
231,diabetes duration ( years )
232,age ( years ) mean ± sd
232,"age , y , mean ( sd )"
232,"cdai , mean ( sd )"
232,"age , years ( sd )"
232,"age , years , mean + sd"
232,"age , yr mean ( sd )"
232,"age , mean ( sd )"
232,"bmi , mean ( sd )"
232,age ( years ) mean ( sd )
232,"age ( years ) ( mean , sd )"
232,"tc , mean ( sd )"
232,"bmi , mean ( sd ) b"
232,"ibdq , mean ± sd"
232,"age ( years ) , mean ± sd"
232,"age , y , mean ± sd"
232,"age , years , mean ( sd )"
232,"bmi , mean ± sd"
232,"age , yr , mean ( sd )"
232,"sdai , mean ( sd )"
232,"age , mean ± sd"
232,"age ( yrs ) , mean ± sd"
232,"age ( years ) , mean ( sd )"
232,"age , years , mean ± sd"
232,"age , mean yr ( sd )"
232,"basfi , mean ( sd )"
232,"age in years , mean ( sd )"
232,age ( years ) - mean ± sd
232,"age , yrs , mean ( sd )"
233,one of the above
233,two of the above
233,all of the above
233,none of the above
233,any of the above
234,asian or oriental
234,asian / oriental
235,no . of stents
235,no . of events
235,no . of patients
236,serum creatinine — mg / dl §
236,serum creatinine ( mg / dl )
236,serum creatinine — mg / dl
236,"serum creatinine , mg / dlb"
236,"serum creatinine , mg / dl"
237,"no diabetes ( n - nmbr , nmbr )"
237,"diabetes ( n - nmbr , nmbr )"
238,"final median , mg / l"
238,"final mean , mg / dl"
239,nonwhite race !
239,nonwhite race
239,white race
239,non - white race
239,non - white raceb
240,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr"
240,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a"
241,current cigarette smoker
241,current cigarette smoking
242,at home systolic pressure > nmbr mm hg
242,at home diastolic pressure < nmbr mm hg
242,at home diastolic pressure > nmbr mm hg
242,at home systolic pressure < nmbr mm hg
243,hx stroke / tia
243,stroke or tia
243,stroke ortiab
243,stroke / tia
243,no stroke / tia
244,clinical history — no . ( % )
244,"clinical history , no . ( % )"
244,"clinical history , n ( % )"
245,combination therapy ( n = nmbr )
245,"combination therapy , n = nmbr"
246,anmbrc at baseline < nmbr . nmbr %
246,anmbrc at baseline ≥ nmbr . nmbr %
247,native american
247,latin american
247,latin america
248,"liraglutide nmbr . nmbr mg ,"
248,liraglutide nmbr . nmbr mg
249,"medical history , no . ( % )"
249,medical history — no . ( % )
249,"medical history , n ( % )"
250,diabetes mellitus :
250,diabetes mellitus
250,no diabetes mellitus
250,"diabetes mellitus , n ( % )"
250,diabetes mellitus !
250,"diabetes mellitus , § n ( % )"
250,"diabetes mellitus , %"
250,diabetes mellitus ( % )
250,"diabetes mellitus , ( % )"
251,since diagnosis
251,index diagnosis
252,"> nmbr months , mean ( sd )"
252,"< nmbr months , mean ( sd )"
253,placebo ( n = nmbr nmbr )
253,"placebo ( n = nmbr , nmbr )"
253,placebo ( n - nmbr . nmbr )
253,placebo ( n nmbr nmbr )
254,second mi
254,no second mi
255,controlled
255,coronary
255,country
255,controlld
255,uncontrolled
255,control
256,"diabetes status , n ( % )"
256,"diabetes status , no . ( % )"
257,ezetimibe nmbr mg ( n = nmbr * )
257,ezetimibe nmbr mg ( n = nmbr )
258,chadsnmbr score
258,chadsnmbr score *
258,chadsnmbr scoreb
259,"age , mean = sd , years"
259,"age , mean ± sd ( year )"
259,"age , mean ± sd years"
259,"age , mean ( sd ) years"
259,"age , mean ( sd ) , years"
259,"age , mean ( sd ) , y"
259,"age , mean ( sd ) , yrs"
259,"age , mean ± sd , years"
260,aiirocumab ( n = nmbr )
260,alirocumab ( n = nmbr )
261,< nmbr enroll
261,> nmbr enroll
262,"dasnmbr - crp , ls mean change from baseline ( se ) ¥"
262,"dasnmbr - crp , ls mean change from baseline ( se ) §"
263,anacetrapib nmbr mg ( n = nmbr )
263,anacetrapib nmbrmg ( n = nmbr )
263,anacetrapib nmbr mg ( n - nmbr )
264,current
264,currently
265,total stent length - mm
265,"total stent length , mm"
266,body mass index > nmbr kg / mnmbr *
266,body mass index < nmbr kg / mnmbr
267,p inleraclion
267,p nmbr interaction
267,p for interaction
267,pfor interaction
267,p interaction
267,pinteraction
267,"p , interaction !"
267,p for interaction *
267,interaction p
267,age - interaction
267,interaction - p
267,p - interaction
267,p . interaction
267,p : interaction
267,p - interactio n
268,angiotensin receptor blockers
268,angiotensin receptor blocker yes
268,angiotensin ii receptor blocker
268,angiotensin - receptor blocker
268,angiotensin receptor blocker
268,angiotensin ll - receptor blocker
269,creatinine — mg / dl
269,"creatinine , mg / dl_"
269,creatinine ( mg / dl )
269,"creatinine , mg / dl"
270,"baseline post - bronchodilator % predicted fev , > nmbr % and no prior ics use"
270,"baseline post - bronchodilator % predicted fev , > nmbr % and prior ics use"
271,fevnmbr ( % predicted )
271,"fevnmbr , % predicted"
271,"fevnmbr , % predicteda"
271,fevnmbr % predicted
272,"fevnmbr , l *"
272,"fevnmbr , l"
272,"fevnmbr , la"
272,fevnmbr ( l )
273,mean sitting sbp ( mmhg )
273,mean sitting dbp ( mmhg )
274,potassium ( mmol / l )
274,potassium ( meq / l )
274,"potassium , mmol / l"
275,£ nmbr ( men ) / £ nmbr ( women )
275,< nmbr ( men ) / < nmbr ( women )
276,creat clearance < nmbr ml / min
276,creat clearance > nmbr ml / min
277,pre - bronchodilator
277,prebronchodilator
277,post - bronchodilator
277,postbronchodilator
278,heritable
278,variable
279,apolipoprotein b ( mg / dl )
279,apolipoprotein b ( g / l )
280,tiotropiumc
280,tiotropium
281,no prior statin use
281,prior statin use
282,"nyha iv , n ( % )"
282,"nyha ii , n ( % )"
282,"nyha iii , n ( % )"
283,metabolic syndrome
283,"metabolic syndrome ,"
283,metabolic syndrome *
284,tiotropium nmbr mg
284,tiotropium nmbrmg
284,tiotropium nmbr m g
285,pitavastatin nmbr mg
285,pravastatin nmbr mg
285,rosuvastatin nmbr mg
285,simvastatin nmbr mg
285,atorvastatin nmbr mg
285,fluvastatin nmbr mg
285,lovastatin nmbr mg
286,stage nmbrb : nmbr - nmbr ml / min / nmbr . nmbr mnmbr
286,stage nmbra : nmbr - nmbr ml / min / nmbr . nmbr mnmbr
286,stage nmbr : nmbr - nmbr ml / min / nmbr . nmbr mnmbr
287,readmission ( n = nmbr )
287,no readmission ( n = nmbr )
288,nyha class iii
288,nyha class iv
288,nyha class
288,nyha class ii
288,nyha class > ii
288,nyha class i
289,no prior cv event
289,prior lgi event
289,prior ugi event
289,no prior ugi event
289,prior cv event
289,major cv event
289,no prior lgi event
290,prior peripheralarterialdisease
290,prior peripheral arterial disease
291,pre - bronchodilator fevnmbr ( l )
291,"post - bronchodilator fevnmbr , l"
291,"post - bronchodilator fevnmbr , l *"
291,"postbronchodilator fevnmbr , l"
291,prebronchodilator fevnmbr ( l ) t
291,post - bronchodilator fevnmbr ( l ) a
291,post - bronchodilator fevnmbr ( l ) *
291,prebronchodilator fevnmbr ( l )
291,"prebronchodilator fevnmbr , l"
291,post - bronchodilator fevnmbr ( l )
291,"pre - bronchodilator fevnmbr , l *"
292,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr )
292,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri )
293,noncardiovascular
293,cardiovascular
294,"etoricoxib ( n = nmbr , nmbr )"
294,etoricoxib ( n = nmbr nmbr )
295,no previous cv event
295,previous cv event
296,"asa use at baseline , n ( % )"
296,"ics use at baseline , n ( % )"
296,"ics users at baseline , n ( % )"
296,"icsusers atbaseline , n ( % )"
297,mean fvc ± sd
297,mean dlco ± sd
298,saphenous vein graft
298,saphenous - vein graft
299,hypercholesterolemia
299,hypercholesterolemia *
299,hypercholesterolemiat
299,hypercholesterolaemia
300,one tnfi and
300,one tnfi *
301,with stent^l
301,with stent
301,without stent
302,postmenopausal and current hrt
302,postmenopausal and current ht
302,"postmenopausal , current hrt"
303,end point
303,endpoint
303,end points
303,endpointc
304,telmisartan ( n = nmbr )
304,irbesartan ( n = nmbr )
304,olmesartan ( n = nmbr )
305,"duration of rheumatoid arthritis , year"
305,duration of rheumatoid arthritis — yr
306,"dyslipidaemia , n ( % )"
306,"dyslipidemia , n ( % )"
307,heart failure nmbr mo before admission
307,heart failure nmbr month before admission
308,no anemia bsl hb > nmbrg i - nmbr ; yr nmbr > nmbrg i - nmbr
308,new anemia bsl hb > nmbrg i - nmbr ; yr nmbr < nmbrg i - nmbr
309,no previous myocardial infarction
309,previous myocardial infarction
310,peripheral artery disease
310,peripheral arterial disease
310,peripheral - artery disease
310,peripheral artery disease *
310,peripheral artery diseasef
311,"history of pvd , n ( % )"
311,"history of chd , n ( % )"
311,"history of mi , n ( % )"
311,"history of chf , n ( % )"
311,"history of tia , n ( % )"
311,"history of pci , n ( % )"
311,"history of cabg , n ( % )"
312,white race — no . / total no . ( % ) $
312,white race — no . / total no . ( % ) f
313,aspirin nmbr
313,aspirin nmbr mg
314,"total cholesterol , mmol / l"
314,total cholesterol ( mmol / l )
314,"total cholesterol , mmol / l 本"
314,total cholesterol ( mmol / l ) :
315,no myocardial infarction at presentation ( n = nmbr )
315,myocardial infarction at presentation ( n = nmbr )
316,< nmbr mmol / l
316,> nmbr mmol / l
317,black / african american
317,black or african - american
317,black / african - american
317,black or african american
317,black or african america
317,black / african american *
318,saxagliptin nmbr . nmbr mg ( n = nmbr )
318,saxagliptin nmbr . nmbr mg ( n z nmbr )
319,"bmi ( kg / mnmbr ) , mean ± sd"
319,bmi ( kg / mnmbr ) mean ± sd
319,"bmi ( kg / mnmbr ) , mean ( sd )"
319,"bmi , kg / mnmbr , mean + sd"
319,"bmi , kg / mnmbr , mean ( sd )"
319,"bmi , kg / mnmbr , mean ± sd"
319,"bmi in kg / mnmbr , mean ( sd )"
319,bmi ( kg / mnmbr ) mean ( sd )
320,"> nmbr years , n ( % )"
320,"< nmbr years , n ( % )"
321,hazard ratio or differencenmbr * ( nmbr % cl ) p - value
321,hazard ratio or differencenmbr ( nmbr % cl ) p - value
322,history of hypertension ( a ) c
322,history of hypertension ( % )
323,"women ( n = nmbr ) , n / n ( % )"
323,"men ( n = nmbr ) , n / n ( % )"
324,aldosterone antagonists
324,aldosterone antagonist
325,"diastolic blood pressure , mm hg , mean ± sd"
325,"diastolic blood pressure ( mm hg ) , mean ( sd )"
325,"systolic blood pressure , mm hg , mean ± sd"
325,"systolic blood pressure ( mm hg ) , mean ( sd )"
325,"systolic blood pressure , mm hg , mean ( sd )"
325,"diastolic blood pressure , mm hg , mean ( sd )"
326,length of stent > median
326,length of stent < median
327,£ median ( nmbr . nmbr )
327,< median ( nmbr . nmbr )
327,> median ( nmbr . nmbr )
328,with previous surgery
328,without previous surgery
329,corticosteroids
329,corticosteroid use
329,no corticosteroid
329,corticosteroidsa
329,corticosteroid
330,full population
330,full po pulatio n
331,no epa group n = nmbr
331,epa group n = nmbr
332,coronary artery disease — %
332,coronary artery disease ( % )
333,olodaterol nmbr m g
333,olodaterol nmbr mg
334,baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l
334,baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l
335,"digoxin , ( % )"
335,"digoxin , n ( % )"
336,vitamin k antagonists
336,vitamin k antagonist
337,off omt ( n = nmbr )
337,on omt ( n = nmbr )
338,ticlopidine
338,ticlopidin
339,"type nmbr diabetes , n ( % )"
339,"type nmbr diabetes , n ( % ) d"
340,"laba use at screening , n ( % )"
340,"lama use at screening , n ( % )"
341,dasnmbr - nmbr ( esr ) < nmbr . nmbr *
341,dasnmbr - nmbr ( esr ) < nmbr . nmbrt
342,modified acc / aha lesion class bnmbr / c
342,modified acc - aha lesion class bnmbr or c
342,modified acc / aha lesion class bnmbr or cj
342,modified acc or aha lesion class bnmbr or c
343,mtss ( nmbr - nmbr )
343,vas ( nmbr - nmbr )
344,oad only
344,diet only
344,past only
344,cabg only
344,dvt only
344,ptca only
344,ics only
345,< nmbr ml / min per nmbr - nmbr mnmbr
345,> nmbr ml / min per nmbr - nmbr mnmbr
346,gold stage
346,"gold stage , %"
346,gold stage ii
346,gold stage iv
346,gold stage iii
346,gold stage #
347,austrafca and new zealand
347,australia / new zealand
347,australia and new zealand
348,simvastatin
348,pravastatin
349,"subjects $ nmbr years of age , n ( % )"
349,"subjects , nmbr years of age , n ( % )"
350,"previous mi , n ( % )"
350,"previous ami , n ( % )"
350,"previous cabg , n ( % )"
350,"previous pci , n ( % )"
351,nmbr - nmbr vr — no . ( % )
351,nmbr - nmbr yr — no . ( % )
351,nmbr = nmbr yr — no . ( % )
352,"ldl cholesterol , mmol / l 丰"
352,"hdl cholesterol , mmol / 冲"
352,hdl cholesterol ( mmol / l )
352,ldl - cholesterol ( mmol / )
352,hdl cholesterol ( mmol / l ) :
352,"hdl cholesterol , mmol / l"
352,kdl cholesterol ( mmol / )
352,ldl - cholesterol ( mmol / l )
352,"hdl cholesterol , ( mmol / l )"
352,ldl cholesterol ( mmol / l ) :
352,"hdl cholesterol , mmol / l *"
352,ldl cholesterol ( mmol / l )
352,"ldl cholesterol , mmol / l"
352,"ldl cholesterol , mmol / l *"
352,hdl - cholesterol ( mmol / l )
353,no renal dysfunction
353,renal dysfunction
353,renal function
354,"prebronchodilator fevnmbr , % predicted"
354,"postbronchodilator fevnmbr , % predicted"
354,"post - bronchodilator fevnmbr , % predicted"
355,< qnmbr ( nmbr . nmbr ) — number / n ( % )
355,> qnmbr ( nmbr . nmbr ) — number / n ( % )
356,p valuenmbr
356,p value * nmbr
357,eze / simva - nmbryr km rale ( % )
357,pbo / simva - nmbryr km rale ( % )
358,"age , median ( iqr )"
358,"bmi , median ( iqr )"
359,inter .
359,intense
360,< nmbr . nmbr kg / mnmbr
360,nmbr - nmbr kg / mnmbr
360,> nmbr . nmbr kg / mnmbr
361,thiazide
361,thiazides
362,antiplatelet agents
362,antiplatelet agent
363,"hemoglobin , g / dl"
363,haemoglobin ( g / dl )
363,haemoglobin ( g / l )
363,hemoglobin ( g / dl )
363,hemoglobin ( gm / dl )
363,"hemoglobin , mg / dl"
363,"hemoglobin , g / l"
363,"haemoglobin , mg / dl"
363,hemoglobin — g / dl
363,"hemoglobin , g / dlf"
364,usual care ( n = nmbrla )
364,usual care ( n = nmbra )
364,usual care ( n = nmbr )
365,"ace - inhibitors , n ( % )"
365,"ace inhibitor , n ( % )"
366,total ho population ( n = nmbr )
366,total population ( n = nmbr )
367,"mean age , years"
367,mean age ( years )
367,"mean age , yrs"
367,mean age ( yrs )
367,mean age — yr
368,"waist - to - hip , female"
368,"waist - to - hip , male"
369,at index acs event
369,index acs event
370,chronic bronchitis !
370,chronic bronchitis
371,post - bronchodilation fevnmbr
371,pre - bronchodilation fevnmbr
371,pre - bronchodilator fevnmbr
372,lama use at screening
372,laba use at screening
373,exetimibe / simvastatin
373,ezetimibe / simvastatin
374,"cv death , ml , ischemic stroke"
374,"cv death , mi , ischemic stroke"
374,"cv death , mi , or ischemic stroke"
375,proton pump inhibitors
375,proton - pump inhibitors
375,proton - pump inhibitor
375,proton pump inhibitor use
376,duration of tnmbrdm ( years )
376,"duration of tnmbrdm , years"
376,duration of tnmbrd ( years )
377,anti platelet therapy
377,anti - platelet therapy
377,no antiplatelet therapy
377,antiplatelet therapy
377,antiplatelet therapy §
378,"diastolic blood pressurea , mmhg"
378,systolic blood pressure — mm hg
378,diastolic blood pressure ( mm hg )
378,"systolic blood pressure , mm hg"
378,systolic blood pressure ( mmhg )
378,diastolic blood pressure ( mm hg ) :
378,"systolic blood pressurea , mm hg"
378,"diastolic blood pressure , mm hg"
378,systolic blood pressure ( mm hg )
378,"diastolic blood pressure , mmhg"
378,diastolic blood pressure - mmhg
378,diastolic blood pressure ( mmhg )
378,systolic blood pressure - mmhg
378,"systolic blood pressure , mmhg"
378,diastolic blood pressure — mm hg
379,mineralocorticoid receptor antagonist
379,mineralocorticoid receptor antagonists
380,diet group ( n = nmbr )
380,stent group ( n = nmbr )
381,haq - di scoreff
381,haq - di scored
381,haq - di score
382,sirolimus
382,everolimus
383,ambulance
383,in ambulance
384,p value for heterogeneity
384,pvalue for heterogeneity
385,"race , while"
385,racea white
386,nmbr . nmbr - nmbr . nmbr mg / l
386,nmbr . nmbr - nmbr . nmbr mmol / l
387,"macroalbuminuria , n ( % )"
387,"microalbuminuria , n ( % )"
388,womac score
388,total score
389,lacunar
389,vascular
390,"dbp , mm hg , mean ± sdc"
390,"sbp , mm hg , mean ± sdc"
390,"sbp , mm hg , mean + sdc"
391,mean dlqi score ( nmbr % ci )
391,mean pasi score ( nmbr % ci )
392,"tc , mmol / l ( mg / dl )"
392,"fpg , mmol / l ( mg / dl )"
393,"body weight , mean ± sd , kg"
393,"body weight , mean = sd , kg"
394,race / ethnicity n ( % )
394,"race / ethnicity , n ( % )"
394,"race / ethnicity , no . ( % )"
394,"race or ethnicity , n ( % )"
395,arial flutter or fibrillation
395,atrial flutter / fibrillation
396,current smoker ( n z nmbr )
396,current smoker ( n = nmbr )
397,"waist circumference , mean ( sd ) , cm"
397,"waist circumference , mean ( sd ) , in"
398,empagliflozin
398,dapagliflozint
398,canagliflozin
399,coronary - artery bypass grafting
399,coronary artery bypass grafting
399,coronary artery bypass graft
400,sex : male
400,"sex , male"
400,"sex , % female"
400,sexa male
400,sex : female
400,"sex , female"
400,sex ( female )
401,"dbp , mean ( sd ) , mm hg"
401,"sbp , mean ( sd ) , mmhg"
401,"dbp , mean ( sd ) , mmhg"
401,"sbp , mean ( sd ) , mm hg"
401,"sbp , mean = sd , mmhg"
402,contrast volume ( ml )
402,"contrast volume , ml"
403,crp — mg / liter^
403,hscrp — mg / liter
404,omega - nmbr fa intake nmbrnd third
404,omega - nmbr fa intake nmbrst third
404,"omega - nmbr fa intake nmbr , d third"
405,mean ( sd ) pre - bronchodilator
405,mean ( sd ) post - bronchodilator
406,former smoking
406,former smoker
407,egfr > nmbr ml / min / nmbr . nmbr mnmbr
407,egfr > nmbr ml / min / nmbr - nmbr mnmbr
407,egfr < nmbr ml / min / nmbr . nmbr mnmbr
407,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr )
407,egfr < nmbr ml / min / nmbr - nmbr mnmbr
407,egfr > nmbr ml / min / nmbr . nmbrmnmbr
407,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr )
407,egfr < nmbr ml / min / nmbr . nmbr mnmbr *
407,egfr £ nmbr ml / min / nmbr . nmbrmnmbr
407,egfr < nmbr ml / min / nmbr . nmbr mnmbr §
407,egfr < nmbr ml / min / nmbr . nmbrmnmbr
408,primary outcomes
408,primary outcome !
408,primary outcome
409,nmbr vessel
409,nmbr vessels
410,non - st - segment elevation mi
410,non - st - segment elevation acs
411,rate ratio ( nmbr % ci )
411,rate ratio ( nmbr % cl )
412,extensive colitisy
412,extensive colitis
413,lipid - lowering therapy — no . ( % )
413,lipid - lowering therapy - no . ( % )
414,patients with at least one concomitant disease *
414,patients with at least one concomitant disease | |
415,hyperlipidemia ( % ) §
415,"hyperlipidemia , %"
415,hyperlipidaemia ( % )
415,hyperlipidemia ( % )
416,diagnosed diabetes ( n = nmbr )
416,undiagnosed diabetes ( n = nmbr )
417,salmeterol ( n[nmbr )
417,salmeterol ( n [nmbr )
418,physician ' s judgment that vka inappropriate]
418,physician ' s judgment that vka inappropriate
419,female simva
419,male simva
420,western europe ( n = nmbr )
420,eastern europe ( n = nmbr )
421,elevated creatine kinase - mb ( > nmbr u / l )
421,elevated creatine kinase mb ( > nmbr u / l )
422,current tobacco use
422,no current tobacco use
423,bare metal
423,bare - metal
424,corticosteroid or azathioprine / nmbr - mercaptopurine
424,corticosteroid - azathioprine / nmbr - mercaptopurine
425,dapagliflozin nmbr mg
425,dapagliflozin nmbrmg
425,empagliflozin nmbr mg
425,ertugliflozin nmbr mg
426,ics / lama
426,ics / laba
426,ics + laba
427,duration of disease — yr
427,duration of disease — mo
428,eze + statin
428,pbo + statin
428,ze + statin
429,coronary endpoint
429,coronary end point
430,patients with baseline crp concentration £ nmbr mg / l
430,patients with baseline crp concentration < nmbr mg / l
431,none 一 no . ( % )
431,"score , no . ( % )"
431,score 一 no . ( % )
432,female simva ( „ = nmbr }
432,male simva ( „ = nmbr }
433,aspirin — no . ( % )
433,aspirin 一 no . ( % )
434,adas — cog score
434,adas - cog score *
435,troponin nmbr at baseline *
435,troponin nmbr at baseline
436,lower limb fracture
436,upper limb fractures
436,upper limb fracture
436,lower limb fractures
437,"inflix , yes"
437,"inflix , no"
438,east europe
438,e . europe
438,western europe
438,w . europe
438,eastern europe
438,w est europe
438,eastern european
439,general health
439,mental health
440,canakinumab dose ( per mo )
440,canakinumab dose ( per month )
441,age ( years ) : < nmbr
441,age ( years ) : > nmbr
442,chd status §
442,chd status
443,rheumatoid factor positive
443,rheumatoid factor - positive
444,"priorheartfailure , %"
444,prior heart failure yes
444,"prior heart failure , %"
445,"gender , male"
445,gender male
446,metabolic syndrome * n = nmbr
446,metabolic syndrome ( n = nmbr )
446,nonmetabolic syndrome ( n = nmbr )
447,bmi ( kg / mnmbr )
447,"bmi , kg / mnmbr"
447,"bmi , kg / mnmbr , n"
447,bmi ( kg / mnmbr ) *
448,baseline bmi < nmbr kg / mnmbr
448,baseline bmi > nmbr kg / mnmbr
449,duration of assigned regimen before surgery post - randomisation characteristic *
449,duration of assigned regimen before surgery post - randomisation characteristic * *
450,asa use at baseline
450,no asa use at baseline
450,ics use at baseline
451,female eze / simva ( „ = nmbr }
451,male eze / simva ( „ = nmbr }
452,"body mass index , kg / mnmbr , mean + sd"
452,"body mass index , kg / mnmbr , mean ( sd )"
452,"body mass index , kg / mnmbr , mean ± sd"
453,abdominal obesity *
453,abdominal obesity
454,cohort nmbr ( n = nmbr )
454,cohort nmbr ( n = nmbr ) f
455,"age , median ( nmbrth - nmbrth percentiles ) , y"
455,"age , median ( nmbrth — nmbrth percentiles ) , y"
456,"baseline hbanmbrc , %"
456,baseline hbanmbrc ( % )
457,"no aminosalicylates , n"
457,aminosalicylates * *
457,"aminosalicylates , n"
458,vildagliptin nmbr mg qd
458,vildagliptin nmbr mg bid
459,< nmbr kg / mnmbr ( n — nmbr )
459,> nmbr kg / mnmbr ( n — nmbr )
460,baseline ldl - c > nmbr . nmbr to < nmbr . nmbr mmol / lc
460,baseline ldl - c nmbr . nmbr to < nmbr . nmbr mmol / lc
461,methotrexate use
461,methotrexate user
462,bare metal stent
462,bare - metal stent
463,other ( n = nmbr )
463,other ( n — nmbr )
464,amputationsa
464,amputation
465,p — value for interaction
465,p - value for interaction *
465,p value for interactiont
465,p value for interaction
465,p - value for interaction
465,p value for interaction^
465,p value fo interactio
466,waisthip ratio
466,waist - hip ratio
467,tnglycendes < median
467,tngtycerides a median
467,tngtycendes a median
467,tngtycerides < median
468,furosemide
468,torsemide
469,drinker ( % ) a
469,drinker ( % )
470,uncertain
470,uncerlain
471,"mean diastolic blood pressure , mm hg"
471,"mean systolic blood pressure , mm hg"
472,maximum cimt < median
472,maximum cimt a med an
473,at clinic diastolic pressure > nmbr mm hg
473,at clinic systolic pressure > nmbr mm hg
473,at clinic systolic pressure < nmbr mm hg
473,at clinic diastolic pressure < nmbr mm hg
474,thiazolidinediones
474,thiazolidinedioneb
474,thiazolidinedione no
474,thiazolidinedione
474,thiazolidinedione yes
475,crcl < nmbr ml / min
475,crcl > nmbr ml / min
475,ecrcl < nmbr ml / min
476,stroke or transient ischemic attack
476,stroke / transient ischemic attack
477,"hdl cholesterol , mmol / l , women , mean ± sd"
477,"hdl cholesterol , mmol / l , men , mean ± sd"
478,disease duration > nmbr years ( n = nmbr )
478,disease duration b nmbr years ( n = nmbr )
479,bmi ( kg / rrr )
479,bmi ( kg / m )
480,"anterior ( n , % )"
480,"inferior ( n , % )"
481,blood pressure — mm hg
481,"blood pressure , mm hg"
481,blood pressure — mmhg
481,"blood pressure , mm"
481,blood pressure ( mm hg )
481,blood pressure ( mmhg )
481,"blood pressure , mmhg"
482,non - st - elevation mi
482,non - st — elevation mi
482,non - st - elevation ml
483,nmbr - nmbr . nmbr : overweight
483,"nmbr - nmbr - nmbr , overweight"
484,intention - to - treat with st - segment - elevation myocardial infarction
484,intention - to - treat without st - segment - elevation myocardial infarction
485,no history of cancer
485,history of cancer
486,antidiabetic agent
486,antidiabetic agents
487,age > = nmbr years old
487,age < nmbr years old
488,ics use at baseline : no
488,ics use at baseline : yes
489,"crp $ nmbr mg / l , n"
489,"crp < nmbr mg / l , n"
490,stent thrombosis *
490,stent thrombosis
491,high - dosage ics plus laba with baseline blood eosinophils > nmbr cells per pl ( n = nmbr )
491,high - dosage ics plus laba with baseline blood eosinophils anmbr cells per pl ( n = nmbr )
491,high - dosage ics plus laba with baseline blood eosinophils < nmbr cells per pl ( n = nmbr )
492,not hispanic or latino ( n = nmbr )
492,not hispanic or latino ( n — nmbr )
493,< nmbr mg / dl simva
493,> nmbr mg / dl simva
494,cardiovasculardeath
494,cardiovascular death !
494,cardiovascular death
495,"mean body - mass index , kg / mnmbr"
495,"mean body mass index , kg / mnmbr"
495,mean body mass index ( kg / mnmbr ) *
495,mean body mass index ( kg / mnmbr )
496,anmbr + enmbr ( n = nmbr )
496,anmbr / nmbr ( n = nmbr )
496,nmbr - nmbr ( n = nmbr )
497,"mean sd nmbr - h asbp , mm hg"
497,"mean ± sd nmbr - h adbp , mm hg"
498,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr
498,egfr nmbr – nmbr ml / min / nmbr . nmbr mnmbr
498,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr
499,nmbr - nmbr / month
499,nmbr - nmbr months
500,with corticosteroid treatment < nmbr
500,with corticosteroid treatment > nmbr
501,"postmenopausal , no hrt"
501,postmenopausal and no ht
501,"poslmenopausal , no ht"
501,postmenopausal and no hrt
501,"poslmenopausal , ht"
502,depression
502,depression^
502,no depression
503,concomitant medications
503,concomitant medication
504,nmbr blocker
504,( nmbr - blockers
504,nmbr blockers
504,( nmbr blocker
504,/ nmbr - blockers
504,", nmbr - blockers"
505,no prior stroke / tia
505,prior stroke / tia
505,prior stroke or tia
506,cv entry criteria
506,entry criteria
507,"fevnmbr / fvc , % a"
507,"fevnmbr / fvc , % *"
508,"placebo , % > ( n / n )"
508,"placebo , % ( n / n )"
509,"mayo < nmbr , n"
509,"mayo $ nmbr , n"
510,"weight in kg , median ( iqr )"
510,"weight - kg , median ( iqr )"
510,"weight ( kg ) , median ( iqr )"
511,prior myocardial infarction — no . ( % )
511,prior myocardial infarction 一 no . ( % )
512,baseline ics use : no
512,baseline ics use : yes
513,"tg , median ( min , max )"
513,"mtss , median ( min , max )"
513,"jsn , median ( min , max )"
514,all - cause mortality or hf hospitalization
514,all - cause mortality or hf hospitalization^
515,fbs < nmbr mg / dl
515,fbs > = nmbr mg / dl
516,amlodipine / valsartan nmbr / nmbr mg
516,amlodipine / wlsartan inmbr / nmbr mg
517,all - cause mortality
517,all cause mortality
518,renal insufficiency / failure
518,renal insufficiency or failure
519,anticoagulants
519,anti - coagulants
519,anticoagulant
520,oral corticosteroids
520,oral corticosteroid
521,prior lower gi clinical event
521,prior upper gi clinical event
522,"complex anatomy ( n - nmbr , nmbr )"
522,"noncomplex anatomy ( n - nmbr , nmbr )"
523,all cana
523,all cancer
524,ace inhibitors / arb
524,ace inhibitor or arb
524,ace inhibitors and arb
524,ace inhibitors or arb
524,ace inhibitors or arbs
524,ace inhibitors / arbs
525,physician ' s global assessment
525,physician ' s global assessment !
526,previous or current im use : no
526,previous or current cs use : no
527,"nyha class , n ( % ) i"
527,"nyha class , n ( % )"
527,"nyha class , n ( % ) ii"
527,"nyha class , ( % )"
528,baseline heart rate ( beat / min )
528,baseline heart rate ( beats / min )
529,"concomitant medications , %"
529,concomitant medication | |
530,"metabolic syndrome , ! n ( % )"
530,"metabolic syndrome , n ( % )"
531,body weight ( kg )
531,"body weight , %"
531,"body weight , kg"
531,body weight — kg
531,bodyweight ( kg )
531,"body weighta , kg"
532,fev_ ( l ) :
532,"fvc , l"
532,fvc ( l ) ;
532,fvc ( l ) *
532,fvc ( l )
533,no fracture history
533,fracture history
534,nmbr to < nmbr ml / min
534,> nmbr to < nmbr ml / min
534,nmbr - < nmbr ml / min
534,nmbr - nmbr ml / min
535,met criterion at blt ( n [ % ] )
535,met criterion at bl ( n [ % ] )
536,( % ) ( nmbr . nmbr )
536,( % ) ( nmbr - nmbr )
537,"post - bronchodilator fevnmbr reversibility , % a"
537,"postbronchodilator fevnmbr reversibility , %"
537,"post - bronchodilator fevnmbr reversibility , %"
538,cigarette smoking
538,cigarette smoker
539,daily dose nmbr mg n = nmbr
539,daily dose > nmbr mg n = nmbr
540,"female ( n = nmbr , nmbr )"
540,"male ( n = nmbr , nmbr )"
541,hemoglobin ( g rnmbr )
541,hemoglobin ( g nmbr ! )
542,with lipid - lowering agents
542,without lipid - lowering agents
543,macroalbuminuria
543,macroalbuminuriaf
543,microalbuminuria
543,macro - albuminuria
543,micro - albuminuria
544,egfr ( ml / min per nmbr - nmbr mnmbr )
544,egfr ( ml / min per nmbr - nmbr mnmbr ) t
545,macroalbuminuria — no . / total no . ( % )
545,microalbuminuria — no . / total no . ( % )
546,chd simva
546,no chd simva
547,> nmbr . nmbr mu / l $ mmol / l
547,< nmbr . nmbr mu / l $ mmol / l
548,stage nmbra : > = nmbr and < nmbr
548,stage nmbrb : > = nmbr and < nmbr
549,"canakinumab , hscrp > nmbr - nmbr mg / l at nmbr months ( n = nmbr )"
549,"canakinumab , hscrp < nmbr - nmbr mg / l at nmbr months ( n = nmbr )"
550,post - bronchodilator screening fevnmbr ml
550,pre - bronchodilator screening fevnmbr ml
551,duration of hypercholesterolaemia ; mean ± sd ( year )
551,duration of hypercholesterolemia ; mean ± sd ( years )
552,< nmbr with no historical count > nmbr
552,< nmbr with historical count > nmbr
553,baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr
553,baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr
554,difference from placebo ( nmbr % ci )
554,difference from placebo * ( nmbr % ci )
555,central eosinophil count ( cells per pl )
555,central eosinophil count ( cells per pl ) t
556,other anti - platelet agents
556,other antiplatelet agents
557,other forms of atherosclerosis^
557,other forms of atherosclerosis ’
558,"race or ethnic group , no . ( % )"
558,race or ethnic group — no . ( % ) f
559,prior smoker
559,prior stroke
559,no prior stroke
560,"gender , n ( % )"
560,"gender , no . ( % )"
561,"coronary heart disease , n ( % ) b"
561,"coronary heart disease , n ( % ) t"
562,mean ± s . d . fpg
562,mean ( s . d . ) fpg
563,troponin i ( pg / ml )
563,troponin t ( pg / ml )
564,> nmbr ml / min / nmbr . nmbrmnmbr
564,≥ nmbr ml / min / nmbr . nmbr mnmbr
564,< nmbr ml / min / nmbr . nmbrmnmbr
564,< nmbr ml / min / nmbr . nmbr mnmbr
564,> nmbr ml / min / nmbr . nmbr mnmbr
565,ischemia - driven revascularization
565,ischemia driven revascularization
566,timi minor
566,timi major
567,"history of major microvascular disease , n ( % )"
567,"history of major macrovascular disease , n ( % )"
568,pre - bronchodilation fvc
568,post - bronchodilation fvc
569,nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr )
569,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr )
569,nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr )
570,history of macrovascular disease ( % )
570,history of microvascular disease ( % )
571,patient characteristics
571,patients ' characteristics
572,treatment with anti - platelet drugs
572,treatment with antiplatelet drugs
573,"concomitant medications , * n ( % )"
573,"concomitant medication , n ( % )"
573,"concomitant medications , n ( % )"
574,"fpg , mean ( sd ) , mg / dl"
574,"fpg , mean ( sd ) , mg / dlt"
575,one - vessel disease
575,two - vessel disease
576,ethnicity
576,"ethnicity ,"
577,ind / glyb n = nmbr
577,ind / gly n = nmbr
578,non - hispanic / latino
578,not hispanic or latino
578,not hispanic / latino
579,north american
579,north america
579,south africa
579,south american
579,sou ti africa
579,south america
579,northamerica
580,"bloodpressure , mean ( sd ) , m m hg"
580,"blood pressure , mean ( sd ) , mm hg"
581,tiotropium / olodaterol nmbr . nmbr / nmbr mg
581,tiotropium + olodaterol nmbr . nmbr / nmbr mg
581,tiotropium + olodaterol nmbr . nmbr / nmbr pg
582,"diastolic bp , mmhg ( sd )"
582,"systolic bp , mmhg ( sd )"
583,postamendment
583,preamendment
584,fasting glucose — mg / dl
584,fasting glucose ( mg / dl )
584,"fasting glucose ( mg / dl ) ,"
585,"mean systolic bp , mmhg , mean = sd"
585,"mean diastolic bp , mmhg , mean = sd"
586,"number of prior aeds , n ( % ) b"
586,"number of prior aeds , n ( % )"
587,mean ( sd ) sdai *
587,mean ( sd ) cdai *
588,age > nmbr yearsnmbr
588,age < nmbr yearsnmbr
589,baseline systolic blood pressure ( mm hg )
589,baseline diastolic blood pressure ( mm hg )
590,adp antagonist
590,tnf antagonist
591,comorbidities
591,co - morbidities
592,vildagliptin nmbr mg bid n = nmbr
592,vildagliptin nmbr mg qd n = nmbr
593,migraine with aura
593,migraine without aura
594,previous cancer
594,previous cancerc
595,lipid - lowering drugs
595,lipid - lowerinq druq
595,lipid - lowering drug
596,des type
596,acs type
597,"fevnmbr ( post - albuterol ) , l"
597,"fevnmbr , pre - albuterol , l"
597,"fevnmbr ( pre - albuterol ) , l"
597,"fevnmbr , post - albuterol , l"
598,p blockers ( % )
598,p - blocker ( % )
599,severe or very severe
599,severe / very severea
600,difference ( nmbr % cl )
600,difference ( nmbr % ci ) *
601,nmbr months
601,nmbr mentis
601,nmbr mortis
601,> nmbr months
601,< nmbr months
601,nmbr montlts
602,"seated sbp , mean ( sd ) , mmhg"
602,"seated dbp , mean ( sd ) , mmhg"
603,alcohol abuse
603,alcohol use
604,> nmbr microg / l
604,< nmbr microg / l
605,tobacco abuse
605,tobacco use
606,hospital stay ( days )
606,"hospital stay , days"
607,fevnmbr — % of predicted value
607,fevnmbr ( % of predicted value )
608,"maternal history , n ( % )"
608,"paternal history , n ( % )"
609,"plp - c , mean ( sd ) , mg / dl"
609,"ldl - c , mean ( sd ) , mg / dl"
609,"hdl - c , mean ( sd ) , mg / dl"
610,nmbr drinks / wk
610,> nmbr drinks / week
610,nmbr + drinks / wk
610,> nmbr drinks / wk
611,prior hypertension yes
611,prior hypertensiona yes
612,drug - related ae *
612,drug - related teaes *
613,subgroup p valuef
613,subgroup p value 本
614,white ethnic origin
614,while ethnic origin
615,> nmbr yr since menopause
615,< nmbr yr since menopause
616,ls mean difference ( nmbr % ci )
616,"( mean difference , nmbr % ci )"
616,"( mean % difference , nmbr % ci )"
617,reversibility : < nmbr %
617,reversibility : > nmbr %
618,male eze / simva
618,all ez / simva
618,female eze / simva
619,glycated hemoglobin - % ’
619,"glycated hemoglobin , %"
619,glycated hemoglobin ( % )
619,glycated hemoglobin — %
619,glycated haemoglobin ( % )
620,anmbrc ( mmol / mol )
620,"hbanmbrc , mmol / mol"
620,hbanmbrc ( mmol / mol )
621,arterial hypertension *
621,arterial hypertension
622,intervention
622,interruption
623,waist circumference ( cm )
623,waist circumference — cm
623,"waist circumference , ( cm )"
623,"waist circumference , cm"
624,"dbp ( mm hg ) , median ( iqr )"
624,"sbp ( mm hg ) , median ( iqr )"
625,"total cholesterol , mg / dl"
625,total cholesterol — mg / dl
625,total cholesterol ( mg / dl )
625,toial cholcsierol ( mg / dl )
625,"total cholesterol , mg / dl^"
626,no change
626,% change
627,> nmbr ml / min
627,£ nmbr ml / min
627,< nmbr ml / min
628,smoking history ( pack - years )
628,"smoking history , pack - years"
628,smoking history ( pack - yr )
629,dm + ( aliskiren vs . placebo )
629,dm - ( aliskiren vs . placebo )
630,without beta blocker
630,with beta blocker
631,timi risk score !
631,timi risk score
631,"timi risk score , %"
632,angiotensin - converting enzyme inhibitor
632,angiotensin - converting - enzyme inhibitor
633,total asthma symptom score
633,total asthma symptom score :
634,"diastolic bp , mmhg , mean ± sd"
634,"systolic bp , mmhg , mean ± sd"
635,uric acid fertile nmbr ( > nmbr . nmbr mg / dl )
635,uric acid tertile nmbr ( < nmbr . nmbr mg / dl )
635,uric acid tertile nmbr ( > nmbr . nmbr mg / dl )
636,> nmbr . nmbr mmol / liter
636,> nmbr . nmbr mg / liter
636,< nmbr . nmbr mg / liter
636,< nmbr . nmbr mmol / liter
636,< nmbr . nmbr pmol / liter
637,"age ( years ) - < median ( n = nmbr , nmbr )"
637,"age ( years ) - > = median ( n = nmbr , nmbr )"
638,"macrovascular disease , n ( % )"
638,"microvascular disease , n ( % )"
639,vorapaxar ( n = nmbr . nmbr )
639,vorapaxar ( n = nmbr nmbr )
639,"vorapaxar ( n = nmbr , nmbr )"
640,risk difference
640,lsm difference
641,"aspirin ( n = nmbr , nmbr )"
641,aspirin ( n = nmbr nmbr )
642,rosuvastatin
642,rosuvastatin +
643,metformin use
643,no metformin use
644,"copd severity , n ( % ) a"
644,"copd severity , n ( % )"
644,"copd severity , n ( % ) *"
645,prior revascularization
645,pci revascularization
646,ldl - c : hdl - c
646,ldl - c / hdl - c
646,ldl - c / hdl - cx
647,oral agents
647,two agents
647,ras agents
648,mean ( sd ) fevnmbr ( l ) pre - bronchodilator
648,mean ( sd ) fevnmbr ( l ) post - bronchodilator
649,< nmbr years simva ( n = nmbr }
649,> nmbr years simva ( „ = nmbr }
650,bmi > nmbr kg / mnmbr
650,bmi < nmbr kg / mnmbr
650,"bmi , xnmbr kg / mnmbr"
650,bmi < nmbrkg / mnmbr
650,bmi > = nmbrkg / mnmbr
651,"bmi , median ( sd ) , kg / mnmbr"
651,"bmi , mean ( sd ) , kg / mnmbr"
652,physical function
652,physical functioning
653,ldl - c ( mg / dl )
653,hdl - c ( mg / dl )
653,"hdl - c , mg / dl"
653,"ldl - c , mg / dl"
654,regular aspirin use
654,no regular aspirin use
655,> nmbr beats / min
655,< nmbr beats / min
656,antiplatelets
656,antiplatelet
657,characteristics
657,characteristic
658,hypokalemia
658,hvookalemia
658,hyperkalemiab
659,hungary
659,surgery
660,baseline uacr < nmbr mg / g
660,baseline uacr > nmbr mg / g
661,insulin plus nmbr oral agent
661,insulin plus > nmbr oral agent
662,long - acting nitrates
662,long acting nitratef
662,long - acting nitrate
663,ischaemic aetiology
663,ischemic aetiology
664,"systolic blood pressure , mean ( sd ) , mm hga"
664,"systolic blood pressure , mean ( sd ) , mm hg"
665,hscrp < nmbr . nmbr mg / l
665,hscrp > nmbr . nmbr mg / l
665,hscrp > nmbr . nmbr mga .
665,hs - crp > nmbr . nmbr mg / l
665,hs - crp < nmbr . nmbr mg / l
665,hs - crp < nmbr . nmbr g / l
666,"creatinine clearance , ml / min"
666,"creatine clearance , ml / min"
666,creatinine clearance ( ml / min )
667,total cholesterolnmbr < nmbr mg / dl
667,total cholesterolnmbr > nmbr mg / dl
668,"rosuvastatin , n ( rate )"
668,rosuvastatin n ( rate ) *
668,rosuvastatin n ( rate )
669,tiotropium / olodaterol nmbr / nmbr mg
669,tiotropium + olodaterol nmbr / nmbr mg
669,tiotropium + olodaterol nmbr / nmbr pg
670,diastolic blood pressure
670,"diastolic blood pressure ,"
670,systolic blood pressure
670,"systolic blood pressure ,"
671,cardiac failure *
671,cardiac failure §
671,cardiac failure
672,major cardiovascular event
672,major cardiovascular event *
672,major cardiovascular events
673,no concomitant immunosuppressive and / or prior anti - tnf use
673,concomitant immunosuppressive and / or prior anti - tnf use
674,triglycerides - mg / dl * *
674,triglycerides ( mg / dl ) * *
675,"nmbr - nmbr months , n ( % )"
675,"nmbr - < nmbr months , n ( % )"
676,"received nmbr prior biologic therapies , n"
676,"received nmbr prior biologic therapy , n"
677,immunosuppressants onlyff
677,immunosuppressants only
678,mtx > nmbr mg / week
678,mtx £ nmbr mg / week
679,active smoking
679,active smoker
680,"cardiovascular risk factors , no . ( % )"
680,"cardiovascular risk factors , n ( % )"
681,demographic
681,demographics
681,demography
682,no stroke ( n = nmbr )
682,any stroke ( n = nmbr )
683,left main
683,back pain
683,neck pain
683,rest pain
684,< nmbr mg / dl eze / simva
684,> nmbr mg / dl eze / simva
685,no st depression or elevation
685,st depression or elevation
686,"medication use at baseline , n ( % )"
686,"medications at baseline , n ( % )"
687,history of atrial fibrillation or fl utter
687,history of atrial fibrillation / flutter
688,statin without other llt
688,statin with other llt
689,< qnmbr ( nmbr ) — number / n ( % )
689,> qnmbr ( nmbr ) — number / n ( % )
690,"time from qualifying mi , %"
690,"time from qualifying mi , yrs"
691,prior history of ml or ischemic stroke
691,prior history of mi or ischaemic stroke
692,hazard ratio ( nmbr % confi dence interval )
692,hazard ratio ( nmbr % confidence interval )
692,hazard ratio ( nmbr % confidence interval ) *
693,with antiplatelets
693,without antiplatelets
694,"range , ( min , max )"
694,"range : min , max"
694,"range ( min , max )"
695,aml nmbr mg / hctz nmbr mg
695,om nmbr mg / hctz nmbr mg
696,insulin therapy
696,noninsulin therapy
697,"mean ± sd , n"
697,mean ± sd ( yr )
697,mean ± sd ( n )
698,stage nmbr : > nmbr ml / min / nmbr . nmbr mnmbr
698,stage nmbr : < nmbr ml / min / nmbr . nmbr mnmbr
699,"median ( qnmbr , qnmbr )"
699,median ( qnmbr : qnmbr )
700,bmi category ( % )
700,age category ( % )
701,supplementary oxygen
701,supplemental oxygen
702,fvc ( liters )
702,fvc — liters
703,> nmbr years of age
703,< nmbr years of age
704,$ nmbr exacerbations
704,nmbr exacerbation
704,> nmbr exacerbations
704,nmbr exacerbations
705,"history of mi ( n = nmbr , nmbr )"
705,"no history of mi ( n = nmbr , nmbr )"
706,vka therapy
706,dual therapy
707,"egfr , mean ( sd ) , ml / min / nmbr . nmbr mnmbr"
707,"egfr , mean = sd , ml / min / nmbr . nmbr mnmbr"
708,nt - probnp ， pmol / h
708,"nt - probnp , pmol / l^"
708,"nt - probnp , pmol / l"
709,antihypertensive
709,antihypertensives
710,"gender , n ( % ) male"
710,"gender , n [ % ] male"
711,"ldl - c ( mmol / l , mean )"
711,"hdl - c ( mmol / l , mean )"
712,all patients ( « = nmbr nmbr )
712,"all patients ( n = nmbr , nmbr )"
713,eastern europe ( % )
713,western europe ( % )
714,om nmbrmg / aml nmbr mg
714,om nmbr mg / aml nmbr mg
715,ischaemic heart disease
715,ischemic heart disease
716,"hbanmbrc , mean ( sd ) , %"
716,"hbanmbrc , mean = sd , %"
716,"hbanmbrc , median ( sd ) , %"
717,asia pacific
717,asia - pacific
717,asia / pacific
718,previous coronary revascularization
718,previous coronary revascularisation
719,corticosteroid use at baseline - no
719,corticosteroid use at baseline - yes
720,"fevnmbr reversibility , % *"
720,"fevnmbr reversibility , % b"
721,serum triglycerides — mmol / liter
721,serum triglycerides — pmol / liter
722,angina pectoris
722,angina pectoris 本
722,angina pectoris *
722,angina pectorisf
723,alc > = nmbr . nmbr %
723,alc < nmbr . nmbr %
724,major bleeding
724,minor bleeding
725,a from baselineb
725,a from baseline
726,bmi : < nmbr . nmbr kg / mnmbr
726,bmi : > nmbr . nmbr kg / mnmbr
727,"mayo score , mean ( sd )"
727,mayo score ( mean ± sd )
728,total ( n = nmbr nmbr )
728,"total , n = nmbr nmbr"
728,"total ( n = nmbr , nmbr )"
729,> median ( nmbr . nmbr years ) — number / n ( % )
729,< median ( nmbr . nmbr years ) — number / n ( % )
730,difference vs placebo * *
730,difference vs placebo '
730,difference vs . placebo
730,difference vs placebo
731,avm % △ ( se )
731,met % △ ( se )
732,chronic kidney diseased
732,chronic kidney disease
733,estimated difference %
733,estimated difference
734,u . s . site
734,u . s . sites
735,history of diabetes ( n = nmbr )
735,no history of diabetes ( n = nmbr )
736,"< nmbr months , median ( min , max )"
736,"> nmbr months , median ( min , max )"
737,posterior circulation
737,anterior circulation
738,insulin yes
738,insulin use
738,insulin based
739,non - black race and ss > nmbr ( n = nmbr vs nmbr )
739,non - black race and ss < nmbr ( n = nmbr vs nmbr )
740,family history of diabetes ( % ) *
740,family history of diabetes ( - )
740,family history of diabetes ( + )
741,"duration of diabetes , years"
741,duration ofdiabetes — yr
741,duration of diabetes ( years )
741,duration of diabetes — yr
741,"duration of diabetes , yrs"
741,duration of diabetes ( y )
741,duration of diabetes ( years ) t
741,duration diabetes ( years )
742,at index event
742,index event
743,moderate ckd
743,moderate ’
743,moderatey
743,no moderate ckd
743,moderate
744,"weight < nmbr . nmbr kg , n"
744,"weight $ nmbr . nmbr kg , n"
745,history of microvascular disease
745,history of macrovascular disease
746,"disease duration , years"
746,disease duration ( years )
746,disease duration ( yr )
747,"glycated hemoglobin , nonstandardized level — %"
747,"glycated hemoglobin , standardized level — %"
748,baseline characteristics
748,baseline characteristic
749,patients without chronic
749,patients with chronic
750,baseline egfr < nmbr ml / min / nmbr . nmbr mnmbr
750,baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc
750,baseline egfr > nmbr ml / min / nmbr . nmbr mnmbr
751,"ldl - c , mean ( sd )"
751,"tchdl - c , mean ( sd )"
751,"hdl - c , mean ( sd )"
752,symptomatic pad
752,symptomatic padt
753,statin during admission
753,no statin during admission
754,rosuvastatin events / patients ( % )
754,"rosuvastatin , events / patients ( % )"
755,average weekly mtx dose ( mg / week )
755,average weekly mtx dose ( mg / week ) t
756,all teaes *
756,all teaes
756,mild teaes
757,"sbp , mean ± sd ( mmhg )"
757,"dbp , mean ± sd ( mmhg )"
758,death ( all - cause )
758,death ( all cause )
759,qnmbr : > nmbr . nmbr kg ( n = nmbrvsnmbr )
759,qnmbr : < nmbr . nmbr kg ( n = nmbrvsnmbr )
760,"> = nmbr years ( placebo n = nmbr , nmbr ; saxagliptin n = nmbr , nmbr )"
760,"< nmbr years ( placebo n = nmbr , nmbr ; saxagliptin n = nmbr , nmbr )"
761,"without psoriasis ( zi = nmbr , nmbr )"
761,"without psoriasis ( n = nmbr , nmbr )"
762,heart rate > nmbr bpm
762,heart rate < nmbr bpm
763,inferior
763,non - anterior
763,nonanterior
763,not anterior
763,anterior
764,hyperlipidaemia
764,hyperlipidemia
764,hyperlipidemia^
765,left - sided colitisz
765,left sided colitis
765,left - sided colitis
766,nadroparin ( n = nmbr )
766,no nadroparin ( n = nmbr )
767,social functioning
767,social function
768,eze / simva
768,ez / simva
769,aniagonisi
769,antagonist
770,all - cause death n
770,all - cause death
771,family history of cancera
771,family history of cancerf
772,indacaterol nmbr mg
772,indacaterol nmbr pg
773,"p , regional difference"
773,"p , regional difference *"
774,"liraglutide nmbr . nmbr mg , n = nmbr"
774,liraglutide nmbr . nmbr mg n = nmbr
774,liraglutide nmbr - nmbr mg ( n = nmbr )
774,liraglutide nmbr . nmbr mg ( n = nmbr )
775,fevnmbr pre - bronchodilator
775,fevnmbr post - bronchodilator
776,"ace inhibitors / arbs , n ( % )"
776,"ace - inhibitors / arbs , n ( % )"
777,"increase creatinine , < nmbr . nmbr mg / dl"
777,"increase creatinine , > nmbr . nmbr mg / dl"
778,> nmbr . nmbr ( % )
778,< nmbr . nmbr ( % )
779,baseline lipid and lipoprotein values
779,baseline lipid / lipoprotem values
779,baseline lipid / lipoprotein values
780,previous stroke *
780,previous stroke
781,hypertension — no . ( % )
781,hypertension — no . ( % ) |
782,overall ( n = unmbr )
782,overall ( n = nmbr )
783,history of diabetes :
783,history of diabetes
784,"beta - blockers , n ( % )"
784,"beta - blockers , ( % )"
785,history of hypertension *
785,history of hypertension
786,"ischemic heart disease , ( % )"
786,"ischemic heart disease , n ( % )"
786,"ischaemic heart disease , n ( % )"
787,"patients receiving enl , no . ( % )"
787,"patients receiving lcz , no . ( % )"
788,urinary albumin : creatinine ratioa ( mg / g )
788,urinary albumin : creatinine ratio ( mg / g )
789,indian ( american ) or alaska native
789,indian ( american ) or alaskan native
790,saxagliptin nmbr mg
790,saxagliptin nmbrmg
791,mssbp < nmbrmmhg
791,mssbp > nmbrmmhg
792,infarct localisation
792,infarct localization
793,placebo group ( n = nmbr )
793,placebo group ( n = nmbr ) f
794,sjc ( nmbr joints )
794,sjc ( / nmbr joints )
794,tjc ( / nmbr joints )
794,tjc ( nmbr joints )
795,oral anticoagulants
795,oral anticoagulant
796,ischemia
796,ischaemic
797,disease characteristics
797,disease characteristics *
798,nyha functional class
798,ara functional class
799,teaes ( > nmbr % in any treatment group ) *
799,teaes ( > nmbr % in any treatment group )
800,history myocardial infarction
800,history of myocardial infarction
801,acq - nmbr score *
801,npi - nmbr score *
801,acq - nmbr scoret
802,nmbr - h ppg ( mmol / l )
802,nmbr - h ppg ( mmol / l ) *
802,nmbr - h pg ( mmol / l )
803,fvc post - bronchodilator
803,fvc pre - bronchodilator
804,baseline su dose < nmbr / nmbr maximal
804,baseline su dose > nmbr / nmbr maximal
805,"mean sd ldl - c , mg / dl"
805,"mean sd hdl - c , mg / dl"
806,laa closure
806,pfo closure
807,cdai < nmbr . nmbr *
807,sdai < nmbr . nmbr *
808,nyha class — no . ( % ) $
808,nyha class — no . ( % )
809,drug - eluting
809,drug eluting
810,homa - p
810,homa - ir
811,no . of patients with psa
811,no . of patients with ra
811,no . of patients with as
812,"ng ( n = nmbr , nmbr )"
812,"no ( n = nmbr , nmbr )"
812,"nmbr ( n = nmbr , nmbr )"
813,"sf - nmbrvnmbr mcs , mean [sd]"
813,"sf - nmbrvnmbr pcs , mean [sd]"
814,regular ppi use
814,no regular ppi use
815,hospitalization for acs
815,hospitalization for
815,hospitalization for hf
816,pbo + mtx to mtx
816,czp + mtx to mtx
817,"tg , mg / dl , mean ± sd"
817,"tc , mg / dl , mean ± sd"
817,"tc , mg / dl , mean + sd"
818,aiirocumab
818,alirocumab
819,hispanic or latino ethnic groupf
819,hispanic or latino ethnic group !
819,hispanic or latino ethnic groupb
819,hispanic or latino ethnic group *
820,prior aspirin
820,no prior aspirin
821,"medication , n ( % )"
821,"medications , n ( % )"
821,medication — no . ( % )
821,medications . no . ( % )
821,"medications , no . ( % )"
822,eze + statin n = nmbr
822,pbo + statin n = nmbr
823,incidence *
823,"incidence , %"
823,incidencea
824,"asia , pacific and other"
824,asia pacific or other
824,asia pacific and other
825,apo b : apo a - i ratio
825,apob : apoal ratio
825,apob : apoa - l ratio
826,saxa + met n = nmbr
826,dapa + met n = nmbr
827,patients with uncomplicated events
827,patients with complicated events
828,"sf - nmbr mcs , mean ± sd"
828,"sf - nmbr pcs , mean ± sd"
829,systolic blood pressure subgroups
829,diastolic blood pressure subgroups
830,"losartan , n / n ( % )"
830,"valsartan , n / n ( % )"
831,persistent
831,persistent af
832,ukpds nmbr - year risk score < nmbr %
832,ukpds nmbr - year risk score > nmbr %
833,sirolimus - eluting
833,everolimus - eluting
834,immunosuppressants
834,immunosuppressant^^
835,"hdl - c , mg / dl , mean ± sd"
835,"ldl - c , mg / dl , mean + sd"
835,"ldl - c , mg / dl , mean ± sd"
835,"hdl - c , mg / dl , mean + sd"
836,medication use
836,medication
836,education *
836,medications *
836,medications
837,sgrq total score * ( units )
837,"sgrq total score , units"
837,sgrq total score ( units )
838,"weight , median ( sd ) , kg"
838,"weight , mean ( sd ) kg"
838,"weight , median ( iqr ) , kg"
838,"weight , mean ( sd ) , kg"
839,"diclofenac nmbr mg ( n nmbr nmbr ) , . . . n . . ( . % . . ) . . . . . . . . . . . ."
839,"diclofenac nmbr mg ( n nmbr nmbr ) , . . . n . . ( . % . . ) . . . . . . . . . . ."
840,total no .
840,total body
841,ind / gly ( n = nmbr )
841,ind + pbo ( n = nmbr )
841,ind + gly ( n = nmbr )
842,"score of $ nmbr , no . ( % )"
842,"score of # nmbr , no . ( % )"
843,body - mass index ( kg / m ' )
843,body - mass index ( kg / m - ) !
843,body - mass index ( kg / m - )
844,time to treatment initiation ( min ;
844,time to treatment initiation ( min )
845,patients with microalbuminuria at baseline
845,patients with macroalbuminuria at baseline
846,atrial fibrillation !
846,"atrial fibrillation , %"
846,atrial fibrillation
846,atrial fibrillation ( % )
847,prior tnf antagonist treatment - no
847,prior tnf antagonist treatment - yes
848,pt baseline ( week nmbr )
848,db baseline ( week nmbr )
849,odds ratio ( nmbr % ci )
849,odds ratio ( nmbr % cl )
850,"ethnicity , n ( % )"
850,"ethnicity , no . ( % )"
850,ethnicity - no . ( % )
851,"pacemaker , n ( % )"
851,"pacemaker , ( % )"
852,physical examination
852,physical examinations
853,ileum and colon
853,ileum or colon
854,killip class > ii ( % )
854,"killip class , n ( % )"
855,qrs < nmbr msec
855,qrs > nmbr ms *
856,"hbanmbrc , % , mean ( sd ) b"
856,"hbanmbrc , % , mean ( sd )"
856,"hbanmbrc , % , mean ± sd"
857,< nmbr % blood eosinophils at baseline
857,> nmbr % blood eosinophils at baseline
858,czp nmbr mg ( n nmbr )
858,czp nmbr mg ( nnmbr )
859,"age ( median , iqr ) , y"
859,"age , median ( iqr ) , y"
860,atrial fibrillation / flutter
860,atrial fibrillation or flutter
861,metformin
861,no metformin
862,q wave
862,q wave mi
862,q - wave mi
863,hand fracture
863,hip fracture
864,canagliflozin ( n = nmbr )
864,empagliflozin ( n = nmbr )
865,smoking history
865,"smoking history ,"
866,"post - bronchodilator fevnmbr / fvc , %"
866,"postbronchodilator fevnmbr / fvc , %"
867,smoker ( % )
867,smoker ( % ) a
868,"ast , u / l"
868,"alt , u / l"
869,"non - hdl - c , mmol / l"
869,non - hdl - c ( mmol / l )
870,menopause and ht
870,menopause and hrt
871,minimum - maximum
871,minimum : maximum
872,patients < nmbr %
872,patients > nmbr %
873,women ( n = nmbr vs nmbr )
873,men ( n = nmbr vs nmbr )
873,men ( n = nmbr nmbr )
874,diastolic — mean ( sd ) ( mm hg )
874,systolic — mean ( sd ) ( mm hg )
875,active cancer
875,no active cancer
875,ac tve cancer
876,"physical activity , kcal / wk"
876,"physical activity , kcal / wk *"
877,loop or thiazide diuretic
877,loop or thiazide diuretic #
878,"alcohol use , drinks / wk"
878,"alcohol use , drinks / wk *"
879,total population
879,total population n
880,interruption ( n = nmbr )
880,intervention ( n = nmbr )
881,non - st - segment elevation myocardial infarction
881,non — st - segment — elevation myocardial infarction
882,% risk reduction ( nmbr % ci )
882,risk reduction ( nmbr % cl )
883,use of beta - blocker
883,use of beta - blockers
884,hf hospitalization
884,hf hospitalization n
884,hospitalization
885,r elative risk ( nmbr % ci )
885,relative risk ( nmbr % ci )
885,relative risk ( nmbr % cl )
886,> nmbr . nmbr ( n — nmbr )
886,< nmbr . nmbr ( n — nmbr )
887,mi > nmbr months *
887,mi < nmbr months *
888,> nmbr months — number / n ( % )
888,< nmbr months — number / n ( % )
889,"all n = nmbr , nmbr"
889,all n = nmbr nmbr
890,any clinical or lesion rf for st
890,no clinical or lesion rfs for st
891,neuropathy
891,nephropathy
892,hbanmbrc > nmbr % ( n nmbr nmbr )
892,hbanmbrc < = nmbr % ( n nmbr nmbr )
893,am △ 士 s . e .
893,ama 士 s . e .
894,im or cs use : no
894,im and cs use : no
895,hdlnmbr - c
895,ldlnmbr - c
896,at randomization
896,randomization
896,to randomization
897,> nmbr years simva
897,< nmbr years simva
898,simvastatin nmbr mg ( n = nmbr ) *
898,simvastatin nmbr mg ( n = nmbr )
899,hispanic or latino ( n — nmbr )
899,hispanic or latino ( n = nmbr )
900,copd exacerbation : yes
900,copd exacerbation : no
901,hdl cholesterol > nmbr - nmbr mmol / l
901,ldl cholesterol < nmbr - nmbr mmol / l
901,ldl cholesterol > nmbr - nmbr mmol / l
901,hdl cholesterol < nmbr - nmbr mmol / l
902,"sex , female , n ( % )"
902,"sex ( male ) , n ( % )"
902,"sex , male , n ( % )"
902,"sex , male , no . ( % )"
903,adjusted p - value for interaction
903,unadjusted p - value for interaction
904,no chd eze / simva
904,chd eze / simva
905,aspirin use ( p = nmbr - nmbrt )
905,aspirin use ( p = nmbr - nmbr 十 )
906,dapagliflozin nmbr mg ( n = nmbr )
906,ertugliflozin nmbr mg ( n = nmbr )
906,empagliflozin nmbr mg ( n = nmbr )
907,prior coronary artery bypass grafting
907,prior coronary artery bypass graft
908,cholesterol ( mmol / l )
908,"cholesterol , mmol / l"
909,"fevnmbr , litres ( pre ipratropium ) , mean ( sd )"
909,"fevnmbr , litres ( post ipratropium ) , mean ( sd )"
910,insulin ( pmol / l )
910,"insulin , pmol / l"
911,"proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr , nmbr )"
911,"proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr , nmbr )"
912,( mmol / l]
912,mmol / mol
912,mmol / l
913,wc ( cm )
913,rr ( cl )
914,patient ' s global assessment
914,patient ' s global assessment !
914,patient ' s global assessment of
915,no epa group no . of events ( % )
915,epa group no . of events ( % )
916,"nitrates , ( % )"
916,"nitrates , n ( % )"
917,cox hr ( nmbr % ci )
917,cmh rr ( nmbr % ci )
918,coronary revascularization
918,coronary revascularisation
919,n - nmbr pufa ( n = nmbr )
919,n - nmbr - pufa ( n = nmbr )
920,antihypertensive agents
920,antihypertensive agents *
921,"mean ( sd ) , y"
921,mean ( sd ) bmi
922,"non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr , nmbr )"
922,"non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr , nmbr )"
923,aldosterone blocker
923,aldosterone blockers
924,adjusted hr ( nmbr % ci )
924,adjusted hr ( nmbr % cl )
925,cohort nmbr ( uacr < nmbr . nmbr mg / g )
925,cohort nmbr ( uacr > nmbr . nmbr mg / g )
926,"no extensive colitis , n"
926,"extensive colitis , n"
927,prior migraine
927,prior migraine *
928,primary endpoint death / mi / idr / st
928,primary end point : death / mi / idr / st
929,difference from placebo
929,difference from placeboa
929,difference from placebo ¥
930,standing after nmbr minute change from baseline
930,standing after nmbr minutes change from baseline
931,american indian or alaskan native
931,american indian / alaska native
931,american indian or alaska native
932,multiracial
932,multi - racial
933,aqlq ( s ) + nmbr scored
933,aqlq ( s ) + nmbr scorets
934,antiarrhythmic
934,anti arrhythmic
935,ct findings
935,ecg findings
936,lipoprotein ( a ) ( nmol / l )
936,lipoprotein ( a ) ( mmol / l )
937,"baseline . mean _ sd , mg / dl"
937,baseline . mean _ sd . mg / mg
937,baseline . mean _ sd . mg / dl
938,≤ nmbr u / kg / day
938,> nmbr u / kg / day
939,valsartan
939,bosentan
939,losartan
940,history of stroke
940,history of stroke *
941,patients without syndesmophytes at baseline
941,patients with syndesmophytes at baseline
942,lipid - lowering
942,lipid lowering
943,stratum ii
943,stratum i
944,"aaponmbr at rest , mm hg"
944,"paonmbr at rest , mm hg"
945,"mean ( s . d . ) systolic blood pressure , mm hg"
945,"mean ( s . d . ) diastolic blood pressure , mm hg"
946,"> nmbr to < nmbr h , n ( % )"
946,"nmbr to < nmbr h , n ( % )"
947,coronary artery disease^
947,coronaiy artery disease
947,coronary artery disease
948,> o - nmbr - i - i
948,> o - nmbr - ii
949,"egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )"
949,"egfr , ml / min / nmbr . nmbr mnmbr , mean ± sd"
950,baseline fevnmbr
950,baseline fevnmbr #
951,nmbr ( n nmbr nmbr )
951,nmbr mg ( n nmbr nmbr )
952,"respiratory rate , breaths / min"
952,respiratory rate ( breaths / min )
953,karnofsky score < nmbr
953,karnofsky score 竺 nmbr
954,ldl - csmedian
954,ldl - c > median
955,non - hdl - c *
955,non - hdl - c
956,duration of pci — min
956,"duration of pci , min"
957,"mean ( s . d . ) bmi , kg / mnmbr"
957,"mean ± s . d . bmi , kg / mnmbr"
958,baselinec
958,( baseline )
958,baselineb
958,"baseline ,"
958,baseline
959,< nmbr . nmbr % ( nmbr mmol / mol )
959,≥ nmbr . nmbr % ( ≥ nmbr mmol / mol )
960,inferior ( % )
960,anterior { % )
961,"age group , no . ( % )"
961,"age group , n ( % )"
962,qualifying mi < nmbr yrs prior
962,qualifying mi $ nmbr yrs prior
963,hawaiian / pacific islander
963,hawaiian pacific islander
964,bl mean ( mmhg )
964,bl mean ( cm )
965,no or unknown
965,no / unknown
966,loop diuretic
966,loop diuretics
966,non diuretics
967,esam ( ng / ml )
967,ngal ( ng / ml )
968,fevnmbr / fvc
968,fevnmbr / fvc %
969,history of diabetes ( a )
969,history of diabetes ( % )
970,age : < nmbr years ( n = nmbr )
970,age < nmbr years ( n = nmbr )
971,"age , years , mean ( range )"
971,"age , years : median ( range )"
972,metabolic syndrome ( % ) b
972,metabolic syndrome ( % )
973,peripheral artery disease — no . ( % )
973,peripheral - artery disease — no . ( % )
974,aiorvasiaiin
974,atorvastatin
975,epa ( mol % )
975,"aa , mol %"
975,"epa , mol %"
976,cardiovasculardeath / myocardial infarction / stroke
976,cardiovascular death / myocardial infarction / stroke
977,m o nito ring treatment
977,monitoring treatment
978,"baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )"
978,"baseline focal seizure frequency / nmbr days , median ( qnmbr - qnmbr )"
979,thiazide diuretics
979,thiazide diuretic
980,diabetes present nmbr ( nmbr . nmbr )
980,diabetes absent nmbr ( nmbr . nmbr )
981,baseline medication
981,baseline cv medications
981,baseline medications
982,calcium aniagonisi
982,calcium antagonist
982,calcium antagonists
983,at qualifying event
983,qualifying event
984,nmbr - nmbr . nmbr : obese class ii
984,nmbr - nmbr . nmbr : obese class i
985,white race — no . ( % ) f
985,white race — no . ( % ) : t
985,white race — no . ( % ) :
986,ileocolon
986,lleocolon
987,tiotropium nmbrmg ( n = nmbr
987,tiotropium nmbr mg ( n = nmbr )
988,multi - vessel coronary artery disease
988,multivessel coronary artery disease
989,"mean ± sd msdbp , mm hg"
989,"mean sd mssbp , mm hg"
990,"mean age , y ( sd )"
990,mean age ( y ) ( sd )
991,age in nmbr classes
991,egfr in nmbr classes
992,"heart rate , bpm"
992,heart rate — bpm
992,heart rate ( bpm )
993,biguanide ( metformin )
993,biguanides ( metformin )
994,naive : no
994,naive : yes
995,no steroids ( n = nmbr vs nmbr )
995,steroids ( n = nmbr vs nmbr )
996,secondary ' outcomes
996,secondary outcomes
997,clopidogrel
997,clopiodogrel
998,antiplatelet - onl group ( n = nmbr )
998,antiplatelet - only group ( n = nmbr )
999,myopathyt
999,myopathy
1000,baseline hdl - c in nmbr classes
1000,baseline trl - c in nmbr classes
1001,with diabetes
1001,without diabetes
1002,treated vessel
1002,treated vessel !
1003,estimated glomerular filtration rate - ml / min / nmbr . nmbrmnmbrtt
1003,estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr )
1004,inferior or posterior
1004,inferior / posterior
1005,weight > nmbr kg
1005,weight < nmbr kg
1006,"systolic ( mean , sd )"
1006,"diastolic ( mean , sd )"
1007,tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr
1007,tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr
1008,patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr at baseline
1008,patients with egfr < nmbr ml / min / nmbr . nmbrmnmbr at baseline
1009,baseline hbanmbrc > nmbr . nmbr %
1009,baseline hbanmbrc < nmbr . nmbr %
1010,nmbr . nmbr - nmbr . nmbr % f
1010,nmbr . nmbr - nmbr . nmbr % t
1011,number of stents
1011,number of patients
1012,"tjc ( nmbr joints ) , mean ( sd )"
1012,"sjc ( nmbr joints ) , mean ( sd )"
1013,"body mass index , median ( iqr ) b"
1013,"body mass index , median ( iqr )"
1014,all other
1014,all others
1015,secondary *
1015,secondary pci
1016,"no . of prior aeds , n ( % )"
1016,"no . of prior aeds , c n ( % )"
1017,"( mean change , nmbr % ci )"
1017,"( mean % change , nmbr % ci )"
1018,hazard ratiof
1018,hazard ratio
1019,prior myocardial infarction yes
1019,"prior myocardial infarction , %"
1020,dpp - nmbr inhibitor
1020,dpp - nmbr inhibitors
1021,ldl - c / hdl - c ratio
1021,ldl - c : hdl - c ratio
1022,modified has - bled $ nmbr
1022,modified has - bled < nmbr
1023,subgroup
1023,subgroups
1024,old stroke *
1024,new stroke *
1025,low risk
1025,lower risk
1026,high - intensity statin
1026,high - intensity statin *
1026,no high - intensity statin
1027,"smoker , ! n ( % )"
1027,"smokers , n ( % )"
1028,"ics use yes / no , %"
1028,"ics use , yes / no %"
1028,"ics use , yes / no , %"
1029,present smokerc
1029,present smoker
1030,p - value ( int )
1030,p value ( int )
1031,alteplase
1031,reteplase
1032,western europe / australia
1032,western europe and australia
1033,geographical region
1033,geographic region
1034,tiotropium nmbr mg respimat ® ( n z nmbr )
1034,tiotropium nmbr mg respimat ® ( n = nmbr )
1035,"body - mass index > nmbr , n ( % )"
1035,"body mass index > nmbr , n ( % )"
1036,pbo + mtx n = nmbr
1036,czp + mtx n = nmbr
1037,"ef < nmbr % hfref ( n = nmbr , nmbr % )"
1037,"ef > nmbr % hfpef ( n = nmbr , nmbr % )"
1038,macroalbuminuria at baseline ( nmbr % of patients treated )
1038,microalbuminuria at baseline ( nmbr % of patients treated )
1039,any coronary artery disease
1039,only coronary artery disease
1040,estimated gfr < nmbr ml / min / nmbr . nmbr mnmbr
1040,estimated gfr > nmbr ml / min / nmbr . nmbr mnmbr
1041,"female patients , n ( % )"
1041,"male patients , n ( % )"
1042,"history , pack - years"
1042,history ( pack - years )
1043,duration of diabetes > nmbr years
1043,duration of diabetes < nmbr years
1044,structural heart disease §
1044,structural heart disease
1045,"no family history of chd ( n = nmbr , nmbr )"
1045,"family history of chd ( n = nmbr , nmbr )"
1046,"subcortical wml load diameter , mm , mean ( sd )"
1046,"subcortical wml load diameter , mm , , mean ( sd )"
1047,"etoricoxib nmbr mg ( n nmbr nmbr ) , . . . n . . . ( . % . . ) . . . . . . . . . . ."
1047,"etoricoxib nmbr mg ( n nmbr nmbr ) , . . . n . . ( . % . . ) . . . . . . . . . . ."
1048,glycoprotein iib / iiia inhibitor
1048,glycoprotein iib / iiia inhibitors
1049,with acei / arb
1049,without acei / arb
1050,corticosteroid or immunosuppressant
1050,corticosteroids and immunosuppressants
1050,corticosteroid and immunosuppressant
1051,egfr < nmbr ml / min
1051,egfr > nmbr ml / min
1052,st - segment — elevation myocardial infarction
1052,st - segment elevation myocardial infarction
1053,patients with psoriasis ( n = nmbr )
1053,patients without psoriasis ( n = nmbr )
1054,egfr < nmbr ml / min / nmbr . nmbr mz
1054,egfr > nmbr ml / min / nmbr . nmbr mz
1055,age > nmbr years ( median )
1055,age < nmbr years ( median )
1056,no . pts
1056,no . men
1057,nmbr mg qw nmbr . nmbr pt yrs
1057,nmbr mg biw nmbr . nmbr pt yrs
1058,fasting plasma glucose ( mg / dl )
1058,fasting plasma glucose — mg / dl
1059,antidiabetic medications
1059,antidiabetic medication
1060,"ldl - c ( median , iqr ) , mg / dl"
1060,"hdl - c ( median , iqr ) , mg / dl"
1061,nonischemic cardiomyopathy
1061,ischaemic cardiomyopathy
1061,ischemic cardiomyopathy
1062,no ilb / iiia inhibitors
1062,ilb / iiia inhibitors
1063,nontatal ml
1063,nonfatal ml
1064,no of events women men *
1064,no of events womenmen *
1065,demographic features
1065,demographic feature
1066,non - epa ( n = nmbr )
1066,non - us ( n = nmbr )
1067,heart failure *
1067,heart failure
1067,heart failurea
1068,acetylsalicylic acid
1068,acetyl - salicylic acid
1069,difference ( % )
1069,difference ( se )
1070,exercise > once weekly
1070,exercise > once weekly ?
1071,nmbr - nmbr days ( % )
1071,nmbr - nmbr yr ( % )
1072,number stent > nmbr
1072,"number ste "" t > nmbr"
1073,"most common concomitant aeds , d n ( % )"
1073,"most common concomitant aeds , n ( % )"
1074,> nmbr % to < nmbr % ( > nmbr to nmbr mmol / mol )
1074,> nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )
1075,baricitinib nmbr mg ( n = nmbr )
1075,baricitinib nmbr mg qd ( n = nmbr )
1076,alcohol consumption
1076,alcohol consumption !
1077,"sri response , %"
1077,"acr response , %"
1078,endpoint / baseline
1078,endpoint / baselinec
1079,ranozaline
1079,ranolazine
1080,left anterior descending coronary artery
1080,l eft anterior descending coronary artery
1081,renal subgroup
1081,female subgroup
1082,ss < nmbr ( n = nmbrvsnmbr )
1082,ss > nmbr ( n = nmbrvs nmbr )
1083,transient ischemic attack
1083,transient ischaemic attack
1084,nmbr mg ew n = nmbr
1084,nmbr mg eow n = nmbr
1085,phgada ( mm )
1085,ptgada ( mm )
1086,patient ' s assessment of pain !
1086,patient ' s assessment of pain
1087,lama ( only monotherapy )
1087,laba ( only monotherapy )
1088,insulin glargine ( n = nmbr )
1088,insulin glargine ( n = nmbrll )
1089,"secukinumab , nmbr mg ( n = nmbr )"
1089,secukinumab nmbr mg ( n = nmbr )
1090,paroxysmal
1090,paroxysmal af
1091,history of major microvascular disease — no . ( % )
1091,history of major macrovascular disease — no . ( % )
1092,non - hdl cholesterol
1092,non - hdl choleslerol
1093,insulin treated
1093,insulin - treated
1094,"msdbp , mmhg ( sd )"
1094,"mssbp , mmhg ( sd )"
1095,"no prior statin ( n = nmbr , nmbr )"
1095,"prior statin ( n = nmbr , nmbr )"
1096,fevnmbr ( liters )
1096,fevnmbr — liters
1097,systolic
1097,diastolic
1098,czp + mtx^mtx
1098,pbo + mtx^mtx
1099,history of paroxysmal af
1099,no history of paroxysmal af
1100,stage nmbr : > = nmbr
1100,stage nmbr : < nmbr
1101,ato nmbr mg and sim nmbr^nmbr mg ( n = nmbr )
1101,ato nmbr mg and sim nmbr - nmbr mg ( n = nmbr )
